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Abstract
In this thesis I present the magnetic haemoﬁlter - a novel medical device
designed to remove magnetic materials directly from a patient's bloodstream.
The haemoﬁlter is a high gradient magnetic separator incorporated into an
extra-corporeal loop. A patient's blood is constantly circulated through the
device, which magnetically captures and retains target agents while the rest of
the blood returns to the patient unharmed. Clinical versions of the device were
conceived, designed and modelled. Small scale versions, designed to mimic the
performance of the clinical designs, were manufactured using 3D printing and
tested in benchtop in vitro experiments.
Many potential applications for the device are envisioned, and justiﬁed with an
extensive literary review of magnetic labelling, the process of binding magnetic
particles to speciﬁc targets to enable their separation. The device has signiﬁ-
cant potential as a platform technology enabling these varied applications. In
this project, however, malaria was chosen as the primary application. Malaria
infected red blood cells are paramagnetic, so their separation does not require
magnetic labelling - the haemoﬁlter simply exploits their naturally occurring
magnetic properties.
The haemoﬁlter was tested using samples of malaria infected blood ﬁltered
at a variety of ﬂow rates, with a reduction in parasitaemia observed in every
experiment at throughputs orders of magnitude higher than any previously
reported clinical magnetic haemoﬁltration device. The results demonstrate
that even without further optimisation, the clinical version of the device could
halve a child's parasitaemia in less than 90 minutes. The ﬂow rates used in the
experiments, and those that could be used in the clinical versions, are orders of
magnitude higher than any previously reported clinical magnetic haemoﬁlter.
Experiments on samples donated by malaria patients demonstrated that no
other blood components are aﬀected by the process.
A commercial evaluation of the haemoﬁlter as a medical device to treat malaria
was conducted. The market analysis showed a large potential total address-
able market, segmented into three principal patient populations. The product
development and manufacturing costs were estimated and shown to be reason-
able, while a ﬁnancial analysis showed that a margin could be earned while still
saving customers money. A route-to-market and commercialisation strategy
is presented.
I conclude that the magnetic haemoﬁlter has the potential to deliver signiﬁcant
clinical beneﬁts to a wide variety of malaria patients, saving lives in serious
cases, providing a treatment option for currently untreatable patients, and
speeding up recovery in uncomplicated cases, while improving the eﬃcacy and
eliminating the side-eﬀects of pharmaceutical drugs.
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Chapter 1
Introduction and Background
1.1 Introduction
1.1.1 Aim
The aim during this PhD was to design and test a magnetic haemoﬁlter which could be
used to remove magnetic agents directly from a patient's bloodstream. The idea is that
the blood is circulated via an extra-corporeal loop through the device, which captures and
retains target agents; the rest of the blood components return to the patient unharmed.
Combined with magnetic tagging techniques, using magnetic nanoparticles for example,
the device could be used to treat a large number of diﬀerent medical problems. In these
applications, magnetic particles are bound to speciﬁc targets, either through the inclusion
of a mixing or tagging chamber in the system, or by injecting the magnetic particles
directly into the bloodstream prior to ﬁltration. However, the focus of this project has
been on the haemoﬁlter's potential use as a novel method for the treatment of malaria,
using only the device to exploit the naturally occuring magnetic properties of malaria
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infected red blood cells.
Malaria infected erythrocytes produce a paramagnetic waste product called haemo-
zoin, which is stored within the infected cell. The infected cells therefore exhibit para-
magnetic properties, enabling them to be magnetically separated from uninfected cells.
Passing a malaria patient's blood through a high gradient magnetic separator could there-
fore remove the infected cells from the bloodstream, reducing a patient's parasite burden
without the need for any pharmaceutical drugs, in a dialysis-like process. The blood is
ﬂowed continuously until the treatment has reduced a patient's parasite burden, known
as parasitaemia, below a target level.
Presented in this thesis are the design of such a device and experiments conducted
on a scaled-down version, demonstrating its potential eﬀectiveness. The potential clinical
applications and commercialisation plan for the device as a treatment for malaria are also
considered.
1.1.2 Summary of device
The device consists of two core parts: an assembly of permanent magnets creating a
strong magnetic ﬁeld, and a separation chamber which is placed within the magnetic
assembly and incorporated into a blood circuit connected to a patient. The permanent
magnets are `rare-earth', made from a neodymium iron boron alloy (NdFeB, chemical
formula: Ne2Fe14B), the strongest permanent magnetic material currently available. The
separation chamber contains a ﬁne ferromagnetic mesh which, when placed within the
magnetic ﬁeld generated by the assembly, generates strong magnetic forces which pull
magnetic agents onto the mesh. These are retained, or captured, as long as the magnetic
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force exceeds the drag force caused by the ﬂow of bood through the chamber. The
magnetic force on an object (discussed in more detail in section 1.3) is given by:
F¯m = µ0χV H¯∇H¯ (1.1)
where χ is the magnetic susceptibility of the object, V is the volume of magnetic material,
H is the magnetic ﬁeld (in A/m) and ∇H¯ is the magnetic gradient (in A/m2). The drag
force for a spherical object is given by Stokes' law:
¯Fd = 6piµRv (1.2)
where µ is the liquid viscosity, R is the object's radius, and v is the velocity of the liquid
relative to the object. These two equations underlie the functioning of the device, and
are the main drivers behind all the design considerations presented in this thesis.
The blood returns to the patient cleansed of targets, which may include cells, toxins,
bacteria, or indeed anything that has or can be given suﬃcient magnetic susceptibility
thanks to magnetic tagging; other blood components are unaﬀected. The separation
chamber is connected to the patient via a venous or central catheter, and the blood is
pumped continuously through the circuit at a controlled rate using a peristaltic pump.
Anticoagulant is added at the start of the process and, if necessary, saline is added at
the end, both at controlled rates. The separation chamber and all of the extra-corporeal
circuit - the consumables - are disposable, while the instrument - the magnetic assembly,
along with the pump and safety features, amongst others - can be reused throughout its
lifetime, which could be many years.
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1.1.2.1 A treatment for malaria
Magnetic haemoﬁltration could have a wide variety of clinical uses, particularly if com-
bined with magnetic nanoparticles (see section 2). Indeed, malaria can be considered as
just the primary indication of the device, with further treatments or uses which could
become available through future research. Malaria was selected as the initial application
and primary focus of this work for the following reasons:
 The clinical need and social impact is potentially huge: Malaria is one of humanity's
biggest scourges (see section 1.2.3). The continued emergence of drug resistance
and the high mortality rate of severe cases demonstrate the clinical need for an
innovative and diﬀerent treatment methodology that could complement conventional
techniques as well as ﬁll gaps that currently exist in malaria treatment strategies
(see section 5.2).
 Malaria infected cells are naturally magnetic (see section 1.2.8) This greatly simpli-
ﬁes testing of the device, since it is not necessary to source or fabricate functionalised
magnetic nanoparticles with speciﬁc targets. It also removes a variable - if testing
reveals that the device does not successfully remove malaria infected cells, it is be-
cause the magnetic forces are not overcoming the drag forces, and not, for example,
because the magnetic nanoparticles have not successfully bound to the target.
 Malaria infected cells are a baseline establishing target : As haemozoin is paramag-
netic, its magnetic susceptibility is positive but small, so magnetises less than a
superparamagnetic or ferromagnetic particle in the same magnetic ﬁeld (see section
1.3.3). As such, malaria infected cells will experience smaller magnetic forces com-
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pared to a cell or other component labelled with magnetic nanoparticles, unless the
total magnetic nanoparticle volume is very small. The advantage therefore in de-
veloping the device for the purpose of treating malaria is that if it captures malaria
infected cells, it will capture almost anything tagged with magnetic nanoparticles.
In other words, if it works for malaria, it will work for everything else.
1.1.2.2 Beneﬁts
Without using any biological or pharmaceutical products, the haemoﬁlter could achieve
similar results to the current frontline malaria treatments - elimination of infected cells
from the bloodstream - but more rapidly and without the side-eﬀects caused by the
circulating debris which results from drug treatments. It could provide a number of
clinical beneﬁts, whether utilised as a complement to existing therapies or as a stand-
alone treatment. A malaria patient's recovery time and chances of survival are linked to
the magnitude of their parasitaemia when they present at hospital: lower parasitaemias
mean improved prognosis and patient outcomes. There are also patients who cannot be
treated using pharmaceuticals, including pregnant women, the immune deﬃcient, and,
most famously, those with drug resistant cases. By removing gametocytes, the sexual
form of the parasite responsible for disease transmission, the haemoﬁlter could also help
reduce the spread of the disease.
1.1.2.3 Limitations and challenges
The haemoﬁlter does have limitations. Only parasites or infected cells currently circulat-
ing in the bloodstream can be passed through the ﬁlter, so any within the liver or adhered
to blood vessels could not be captured (see section 1.2.2). In addition, the quantity of
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magnetic material in an infected cell is dependent on the time since it was invaded by
a parasite. As such, only mature cells can be captured - in order to eliminate all of the
infected cells, the device will need to either be combined with drug treatments, repeated
within 24 hours, or performed continuously.
There are also challenges in terms of adoption. Haemoﬁltration is a much more com-
plex medical procedure than current malaria treatments, which are usually tablet based,
and at worst IV injections. Incorporation of haemoﬁltration into the current treatment
pathway would therefore be disruptive and challenging. It would also, at least initially,
require a hospital environment with the supplies and expertise to carry out the proced-
ure. Many malaria patients are in diﬃcult-to-access areas with very limited access to
healthcare - these patients could not be treated with the haemoﬁlter without a portable
version useable in rural clinics, which would be challenging to achieve. Furthermore, the
vast majority of malaria patients are from low income areas, and endemic countries are
mostly developing nations. The economics of introducing a new treatment are therefore a
signiﬁcant challenge, and creating a cheap device is essential - a high cost per treatment
would probably be a showstopper.
1.1.3 Structure of thesis
During this PhD, both the technical and the commercial feasibility of a magnetic haemo-
ﬁlter to treat malaria were assessed. The results of this research are:
 a design for a medical magnetic haemoﬁlter - Chapter 3
 computational proof-of-principle through magnetic modelling - Chapter 3
 a design and manufacturing process for a scaled down prototype - Chapter 3
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 results demonstrating that the device is capable of capturing a high percentage of
malaria infected cells from a blood sample - Chapter 4
 evaluation of the potential market for the device - Chapter 5
 a go-to-market strategy and the foundations of a business plan - Chapter 5
In addition, a literature review of high gradient magnetic separation (HGMS), presenting
the state of the art of research which relates to potential clinical applications of the
haemoﬁlter was completed, and is presented in Chapter 2. The background information
presented in section 1.2 details the fundamentals of malaria as a disease and its impact
on humanity. Section 1.3 provides the theoretical aspects of magnetism necessary to
understand this work. In Chapter 6, it is concluded that the device, as it is designed, is
technically feasibile of being used as a medical device to treat malaria. In addition, it is
concluded that its commercialisation would be both a worthwhile and viable venture.
1.2 Malaria
1.2.1 Introduction
Malaria is a mosquito-borne infectious disease caused by the protozoan parasite Plas-
modium. There are six species that aﬀect humans: Plasmodium falciparum, P. vivax,
P. malariae, two species of P. ovale, and the zoonotic species P. knowlesi which causes
malaria in monkeys[8]. P. falciparum and P. vivax account for the vast majority of
infections[2]. Malaria has been eradicated from most of the developed world and en-
demic countries are predominently in Africa, South America and South East Asia (Fig.
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Figure 1.1: Map of global malaria incidence, created using Global Malaria Mapper[1]
1.1). Tropical regions tend to have a high incidence due to favourable conditions for the
Anopheles mosquito, the females of which are the primary malaria vector.
While it is both preventable and curable, malaria continues to cause huge suﬀering
to hundreds of millions of people, signiﬁcantly impacting quality of life and economic
development (section 1.2.3). It is a disease that is inexorably linked to poverty. Firstly,
poverty causes malaria: not only are poorer patients less able to aﬀord treatment, but
they are also more likely to live in environments that favour mosquito reproduction (e.g.
hot and humid rural conditions, poorly drained land, etc.), and have lifestyles which
increase the likelihood of mosquito bites (e.g. rudimentary housing, no door screens or
mosquito nets, majority of time spent outside, etc.). Secondly, malaria causes poverty,
severely impacting economic growth for example by incapacitating workers during the
harvest season[9, 10].
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Figure 1.2: Life-cycle of malaria parasite. Note that the haemoﬁlter device is concerned with infected cells in the erythrocytic
stage, particularly targeting mature trohpzoites and schizonts. Note also the variations in the life-cycles between diﬀerent species,
notably the sequestration of schizonts to blood vessel walls in cases of P. falciparum (see section 1.2.4.3)[2, 3]
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1.2.2 Life cycle
The malaria parasite has three distinct stages: sporogonic (mosquito stage), exoerythro-
cytic (liver stage) and erythrocytic (blood stage) (Fig. 1.2). The exoerythrocytic stage
begins when a female anopheles mosquito carrying the malaria parasite bites a human,
injecting sporozoites from its salivary gland into the bloodstream. The sporozoites nav-
igate to the liver where they infect hepatocytes. In P. vivax and P. ovale, the parasites
can diﬀerentiate into hypnozoites and remain dormant in the liver for signiﬁcant periods
of time before resuming the life-cycle, causing patient relapses sometimes decades after
ﬁrst disease indication[2].
Infected hepatocytes diﬀerentiate into schizonts each containing from 10,000 to 30,000
merozoites, which are released into the bloodstream when the cells rupture, beginning
the erythrocytic stage[2]. Each merozoite infects an erythrocyte and begins to consume
the cell's haemoglobin, producing haemozoin which is stored in a food vacuole within
the cell (section 1.2.8). The parasite grows from ring-stage to mature trophozoite, ﬁnally
diﬀerentiating into a schizont, at which point it divides into several merozoites. When
the cell ruptures, the merozoites immediately each infect a new erythrocyte. According
to Warrell et al., there are on average 16 merozoites in each P. vivax and P. falciparum
erythrocytic schizont when it ruptures, 8-16 in P. ovale schizonts, and 10 in P. malariae
and P. knowlesi [2]. Furthermore, they state that the erythrocytic stage for P. vivax, P.
falciparum and P. ovale lasts 48 hours, while it lasts 72 hours for P. malariae and 24
hours for P. knowlesi.
During the erythrocytic stage, P. falciparum infected erythrocytes adhere to blood
vessel walls in a phenomena known as cytoadherence. One of the modiﬁcations to the cell
10
that the parasite causes, which include decreased deformability and the formation of a
tubovesicular membrane network which delivers nutrients to the parasite, is the formation
of `knobs' on the membrane of the infected erythrocyte. These knobs cause infected
erythrocytes to adhere to the endothelium of blood vessels and capillaries and accumulate
within organs, resulting in reduced circulation and causing some of the symptoms of severe
malaria (see section 1.2.4.3)[11, 12, 13, 14, 15].
While still at the ring-stage, the parasite can diﬀerentiate into a gametocyte, its sexual
form responsible for retransmission of the disease. These are ingested by female anopheles
mosquitoes upon taking a blood meal, beginning the sporogonic cycle. The gametocytes
ﬁrst diﬀerentiate into the male and female forms, the microgametes and macrogametes
respectively. While still in the stomach, the microgametes penetrate the macrogametes to
form a fertilised zygote. The zygote diﬀerentiates into a motile ookinete which navigates
through the stomach wall to the midgut and develops into an oocyst, which produces
about 1,000 sporozoites. These are then released and travel to the mosquito's salivary
gland, ready to reinfect a new human upon the next blood meal[2, 3].
1.2.3 Global impact
1.2.3.1 Human impact
With half the world's population at risk, malaria is one of the biggest healthcare challenges
facing humanity. According to the World Health Organization (WHO), in 2012 there were
207 million cases and 626,000 deaths (Table 1.1). 77% of global deaths, and 82% of deaths
in Africa, are children under 5 years old[4, 2]. Some believe that the WHO underestimates
the numbers, due to the unreliability of the data they use. This is generally provided by
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Table 1.1: The global burden of malaria[4]
Figure 1.3: Evolution of malaria cases and deaths and margin of error in WHO
estimates[4]
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governments who collect numbers from patients who present at clinics, ignoring those who
remain in rural villages. Furthermore, bias from those reporting the ﬁgures, bias from
governments wishing to show that their eﬀorts to tackle malaria are having an impact,
and non-inclusion of patients who remain undiagnosed, all suggest that the real burden
of malaria is even higher[16, 17, 18, 19].
While global incidence and mortality has decreased over the past decade (see Fig. 1.3),
climate change is forecast to cause an expansion in the size of endemic regions and increase
the population at risk[20, 21]. However, other factors such as drug resistance, migration
and net spending on treatment and prevention will probably play more signiﬁcant roles[22,
23].
The geographical spread of malaria is unequal (Fig. 1.1). Africa accounts for 80% of
the cases, and 90% of the deaths, while much of the developed world has eradicated malaria
completely. Outside of Africa, the majority of cases and deaths are in South East Asia,
which accounts for 13% of global cases, just under twice the remaining regions combined
(Fig. 1.4a). The distribution of malaria cases is primarily driven by environmental factors,
with tropical countries seeing high incidence due to conditions favourable to mosquitoes.
However, the economic situation of a country and its population also play a major role,
with wealthier countries more able to instigate control and treatment programmes. In
poorer regions, however, limited access to, aﬀordibility and the low quality of treatments
promotes transmission, while prevention programmes rely on international donations.
In terms of the number of deaths, the two main factors are poverty, with its resultant
eﬀect of limited access to and poor quality of treatment, and local parasite species, with
the predominant malaria species in the region being P. falciparum, which has signiﬁcantly
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(a) Global distribution of malaria cases
(b) Global distribution of malaria deaths
Figure 1.4: Global distribution of malaria burden[4]
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higher mortality rates than P. vivax. The eﬀect of P. falciparum on mortality can be seen
in Table 1.1: in the Americas, where P. vivax dominates, there is only one death per
thousand cases. In Africa and Western Paciﬁc however, where P. falciparum dominates,
there are respectively 3.4 and 3.5 deaths per thousand cases. The higher mortality rate
of P. falciparum is partly due to cytoadherence (which is discussed in sections 1.2 and
1.2.4).
1.2.3.2 Economic impact
Malaria is a disease indelibly linked to poverty, signiﬁcantly hindering the economic de-
velopment of the most severely aﬀected countries. The map in Fig. 1.1 highlights the
countries with the highest levels of malaria incidence, but could also be a map highlighting
the countries with lowest GDP. There has been some debate as to whether malaria is a
cause or consequence of poverty; in reality, it is both.
The environments which favour high mosquito populations - swamps and wetlands -
also hinder economic development by limiting the ability to grow crops or build infra-
structure. As with any disease which can aﬀect a high proportion of the population,
controlling and treating it requires signiﬁcant resources - richer countries have been able
to eradicate malaria, whereas poorer ones cannot (see section 1.2.6). So clearly, malaria
is to some degree a consequence of poverty, although it is important to note that is not a
direct result of poor living conditions or sanitation, like tuberculosis for example.
However, several studies have indicated that high malaria incidence is also a cause of
poverty, not least due to the loss of life and man hours - an aicted individual can be
bedridden for days, and is thus unable to perform his normal job or tend to crops. A
much cited study by Gallup and Sachs estimates that, after accounting for factors such
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as environment, colonial history and geographical location, countries with severe malaria
incidence had income levels in 1995 of only 33% of those free of malaria, regardless of
whether they were in Africa or elsewhere[10]. Another study estimated that in 2009,
the annual costs of treating childhood malaria in Ghana, Kenya and Tanzania were $38
million, $109 millon and $132 million respectively[24]. USA's Centers for Disease Control
and Prevention (CDC) estimates that the global direct costs of malaria (including for ex-
ample treatment and premature death) are $12 billion and that "the cost in lost economic
growth is many times more than that"[25].
1.2.3.3 Cost of ﬁghting malaria
Over the past decade, a drastic increase in the funding to ﬁght malaria has had a signiﬁcant
impact on malaria incidence and deaths. Indeed, seven endemic countries, including for
example Algeria, are categorised by the WHO as being in the elimination phase, and 12
in the pre-elimination phase. The number of both cases and deaths has been declining,
respectively by 13% and 22% between 2005 and 2012 (Fig. 1.3). Incidence reduction and
movements towards elimination are overwhelmingly due to total spending on control and
treatment, and therefore economic growth, although recent progress is largely due to the
impact of international aid from organisations such as the Global Fund to Fight AIDS,
Tuberculosis and Malaria, the Medicines for Malaria Venture (MMV) and the Bill and
Melinda Gates Foundation. Much of the money is spent on insecticide treated nets (ITN)
- the Global Fund has already distributed over 400 million nets worldwide - but global
investment also covers other prevention methods as well as research into new treatment
methods.
Global investment in malaria has increased from $100 million in 2000 to $2 billion in
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2013; the Global Fund accounts for 50% of this amount[4]. The investment comes largely
from governments - particularly USA and UK - as well as philanthropic foundations (such
as the Gates Foundation) and non-governmental organisations (such as the World Bank).
Despite the large increase in investment, global commitments remain less than half of the
estimated requirements. The Roll Back Malaria Partnership estimates that $5.1 billion
will be required every year to 2020[26].
1.2.4 Symptoms and complications
1.2.4.1 Uncomplicated malaria
Symptoms of malaria are driven by the body's immune response. The most common
symptoms are fevers and headaches - in a survey of 46 malaria patients conducted for this
PhD, the proportion of respondents who declared that they had a fever and headache was
98% and 74% respectively (see Appendix B). Other symptoms include exhaustion, vomit-
ing, joint pains, shortness of breath, chest pains, and feeling unusually cold. Symptoms
can vary widely from patient to patient, but most are bedridden and unable to operate
normally. Some describe malaria as "the worst I have ever felt".
Patients are typically unwell for about a week, but symptoms can persist for over
a month, particularly if the administered treatment is ineﬀective. In the survey, 83% of
respondants took time oﬀ work or school, with an average of 8.8 days missed (range 1-42).
The time between starting treatment and symptom elimination also varies signiﬁcantly,
from less than 24 hours to over a week.
The majority of patients exhibit some of the above symptoms before recovering either
due to successful tablet based treatments or thanks to the patient's immune system.
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Sporozoites induce an antibody response in patients, leading to the production of cir-
cumsporozoite proteins (CS). CS occur in a large proportion, perhaps over 90%, of the
adult population in endemic areas, and were shown to inhibit sporozoite development in
mice over 30 years ago[27, 28]. This natural immunity results in malaria being a much
more severe disease for children than adults in endemic regions, which is the main reason
why such a high proportion of the deaths are in children under ﬁve (section 1.2.3.1) -
those who survive their ﬁrst bout tend to have the natural defences required to overcome
subsequent cases.
1.2.4.2 Severe malaria
While uncomplicated cases undoubtedly cause signiﬁcant suﬀering (and economic dam-
age), they do not require hospitalisation, and are treated (if at all) with relatively simple
tablet courses. Survival rates are high. Severe, or complicated, malaria, however, carries
much greater risks and requires more serious interventions in the form of parenteral treat-
ments. The WHO classiﬁes a malaria case as severe when there is "clinical or laboratory
evidence of vital organ dysfunction". The criteria for deﬁning a case as severe are well
deﬁned and include imparied consciousness, prostration, convulsions, respiratory distress
and acute renal failure, amongst others[29].
Several of these symptoms can be exhibited simultaneously. Survival rates amongst
severe malaria patients are much lower than uncomplicated malaria, and can occur within
hours of complications developing. The causes of escalation from uncomplicated to
severe malaria vary, including amongst others old age, pregnancy, immune deﬃciency
and delayed treatment; patients who originate from non-endemic countries (and thus
have no immunity) are particularly strongly at risk[30, 31, 32, 33].
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1.2.4.3 Cytoadherence
Most, though not all, severe malaria cases are caused by P. falciparum. Some have sug-
gested that this is caused by the phenomenon of cytoadherence (or sequestration), in
which trophozoites and schizonts stick to blood vessel walls, which occurs exclusively
in P. falciparum. The cells no longer circulate in the bloodstream, and their accumu-
lation at adherence sites can cause blockages, which in turn cause complications. This
is particularly the case for cerebral malaria, in which patients lapse into a coma which
can last several days; mortality can be as high as 50%, although most survivors are free
of residual neurological problems[30, 34]. Cerebral malaria is frequently associated with
clumps of schizonts within the blood vessels of the brain. Indeed, these and other vascular
obstructions are a common clinical feature of severe malaria[34, 35].
The mechanisms of cytoadherence are not completely understood, and are not relevant
to this project, so will not be discussed. However, the phenomenon could have serious
implications for haemoﬁltration as a malaria treatment, since sequestered erythrocytes
do not circulate in the bloodstream and cannot be captured by the device. Peripheral
parasitaemia levels can be artiﬁcially low. However, in severe cases (where the haemoﬁlter
would be most useful - see section 5.2), schizonts and trophozoites can still be seen in the
bloodstream, and parasitaemia levels can still be high. Furthermore, a high mature stage
parasitaemia has been shown to be a strong indicator of fatality[36, 37].
Cytoadherence is likely to limit the haemoﬁlter's eﬀectiveness in treating patients with
P. falciparum. It is however probable that it could still provide patient beneﬁts, by re-
moving the erythrocytes containing haemozoin that are still circulating, as well as any
circulating haemozoin from infected cells that have recently ruptured, either naturally or
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as a result of pharmaceutical treatment. Furthermore, some research groups are working
on products that inhibit cytoadhesion - combining these with the haemoﬁlter could be
very eﬀective. In any case, in cases of P. falciparum, in order to be eﬀective, the haemo-
ﬁlter will likely need to be combined with some form of pharmaceutical injected into the
bloodstream[38, 39, 40].
1.2.5 Treatment
Malaria is typically treated with anti-malarial tablets, with the objective of eliminating
the infection in uncomplicated cases, and preventing death in severe cases. One of the
oldest traditional treatments used bark from South American cinchona trees, eﬀective
because of the naturally occuring quinine found in the bark. Quinine was extracted from
the bark as early as 1820 to become one of the ﬁrst pure chemical compounds used to
treat a disease. The anti-malarial qualities of quinine are renowned as being at the origin
of the popularity of gin and tonic, used by British colonialists to counteract the bitterness
of cinchona bark - originally, tonic was simply quinine mixed with soda water. Quinine
is still used to treat malaria, but is no longer recommended by the WHO[41, 42, 43].
Another traditional herbal remedy that has inspired modern treatments is the qing-
hao plant from China, the source of artemisinin, today's frontline malaria drug. Re-
cords of the plant's antimalarial properties date back 1,000 years - Shen Gua (also spelt
Shen Kuo) mentions the beneﬁts of Artemisia annua in his Dream Pool Essays of 1086.
Artemisinin was the frontline malaria treatment for many years, and still is for P. vivax.
However, because of emerging resistance by P. falciparum to artemisinin and its derivat-
ives (see section 1.2.7), the WHO now recommends that P. falciparum be treated with
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artemisinin combined with drugs of a diﬀerent class (such as meﬂoquine). These are
known as artemisinin combination therapies (ACT), and are currently considered the
best anti-malarial treatments[44, 42, 41, 45, 46].
Arguably the most successful antimalarial of modern times is the synthetic compound
chloroquine, which has been widely used since the 1940s. It functions by inhibiting the
production of haemozoin, preventing the parasite from avoiding the toxicity of free heme
groups (see section 1.2.8), and is still used widely today, particularly as a treatment for
P. vivax. Chloroquine was used to treat all malaria species until the 1980s, when P.
falciparum began developing widespread resistance; more recently, resistance has also
been observed in P. vivax (see section 1.2.7), and is likely to lead to a reduction in the
use of the drug[42, 41, 47].
The WHO recommends using chloroquine in combination with primaquine, a synthetic
drug that prevents relapse by eliminating hypnozoites (see section 1.2.2); primaquine is
currently the only licensed drug able to target hypnozoites and prevent relapse. It is
worth noting that primaquine should not be used on patients with glucose-6-phosphate
dehydrogenase (G6PD) deﬁciency, a genetic defect linked with natural malaria resistance,
as it can cause severe haemolysis[42, 48, 2, 49, 50].
1.2.6 Prevention
1.2.6.1 Historical vector control
Some prevention methods focus on mosquitoes rather than humans, with mixed results.
For example, the National Malaria Eradication Programme (NMEP) launched by the
USA in 1947 successfully eradicated malaria within four years, primarily with the ex-
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tensive use of the insecticide dichloro-diphenyl-trichloroethane (DDT). Inspired by the
NMEP's success, the Global Malaria Eradication Programme (GMEP) was launched by
the WHO in 1955. The methods were essentially the same, combining DDT with the de-
struction of mosquito breeding habitats, but the results were not. During the programme,
treatment with anti-malarials, emerging resistance to chloroquine and other methods of
malaria prevention were overlooked, as were the logistical challenges of implementing the
programme in remote, rural regions. While malaria was eliminated from some areas, oth-
ers, particularly in Africa, experienced severe resurgences in the 1960s, some of epidemic
proportions. While the GMEP succeeded in eliminating malaria from Europe, North
America, the Caribbean and parts of Asia and South-Central America, it failed to have a
signiﬁcant impact in sub-saharan Africa, and the programme was eventually dropped in
1969[51, 52, 53].
1.2.6.2 Mosquito nets
Most of the resources spent ﬁghting malaria go towards prevention, particularly the dis-
tribution of ITN in endemic regions. Unprotected individuals can be bitten on average
ca. 250 times in a single night - a signiﬁcant reduction in this number could clearly have
an impact on transmission rates[10]. Indeed, ITN have been estimated to reduce malaria
cases by up to 50% and save 5.5 lives per year for every 1,000 children protected[54].
ITN are currently the most popular malaria prevention measure, and arguably the most
cost-eﬀective method of saving lives, and can even provide additional economic beneﬁts
when manufactured in endemic countries - Tanzanian based A to Z Textile Mills Ltd.,
Africa's largest ITN manufacturer, produces 30 million ITN annually and employs over
7,000 people[55]. Globally, ITN are estimated to have saved the lives of 250,000 children
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between 2000 and 2008[56].
Their large-scale introduction has not been without controversies - some estimate that
fewer than 20% of the nets are regularly used. In her TED talk in 2013, investigative
journalist Sonia Shah compares giving African families ITN with distributing free face
masks to everyone in Europe and the USA during ﬂu season: lives would be saved, but
people simply wouldn't use them[57]. A further problem is that mosquitoes develop a
resistance to the insecticides - the WHO claims that resistance has been identiﬁed in
64 endemic countries and estimates that widespread resistance to pyrethroids, the most
common insecticide, would prevent 120,000 deaths from being averted every year[58, 59].
Other issues include the nets' fragility, toxicity, and eﬀect on the natural immunity of
populations in endemic countries to malaria[60]. Despite their indisputable beneﬁcial
impact, ITN can only ever be one part of a wider anti-malaria eﬀort, and some have
argued that there is a danger in over-focussing malaria control eﬀorts on ITN.
1.2.6.3 Vaccines
Eﬀorts to develop a malaria vaccine have been made for decades, but no candidate has
managed to successfully get to market. There is still a lot of research attempting to
develop a viable and eﬀective malaria vaccine, and a lot of the research funding for malaria
goes towards these eﬀorts. The Bill and Melinda Gates Foundation, for example, have
committed over $200 million to support their development[61, 62].
The most promising candidate to date is the RTS,S/AS01 vaccine developed by Glaxo-
SmithKline (GSK, Brentford, UK). Results from Phase 3 clinical trials showed that the
vaccine eﬃciency was 46% against clinical malaria and 34% against severe malaria. The
results were not as good for infants, with a vaccine eﬃciency of 27% against clinical
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malaria, and no eﬀect against severe malaria. The results from the trial, which en-
rolled over 15 thousand children in Africa, were slightly worse than had previously been
hoped[63, 64, 65, 66].
1.2.7 Drug resistance
The ability of malaria parasites to develop a resistance to pharmaceutical anti-malarials
has always been a problem - the WHO ﬁrst deﬁned drug resistance of malaria in 1967[67].
For decades chloroquine was the frontline drug against all malaria strains; it still is for
P. vivax. P. falciparum resistance to chloroquine emerged in the 1980s, causing signi-
ﬁcant increases in incidence and mortality[68]. In the Mlomp district of Senegal, for
example, mortality rates in children under 5 increased 14-fold in the ten years to 1995, as
resistance to chloroquine rose from 0% to 44%[69]. The WHO reports that chloroquine
resistance is high or extremely high in every endemic country except Honduras, Malawi
and Nicaragua[67].
P. vivax has also developed a resistance to chloroquine, although it is speading at a
much slower rate than P. falciparum resistance. A recent review by Price et al. found that
some level of chloroquine resistance is present in most endemic countries[70]. Indonesia
is particularly badly aﬀected - several trials have reported early treatment failure (para-
sitaemia above 0 less than three days after treatment) in over 20% of cases, and relapse
after a month in over 70% of cases. This has prompted some to call for chloroquine to be
replaced by ACT as the frontline P. vivax treatment; the WHO currently recommends
ACT combined with primaquine in resistant cases[42, 71, 70, 72, 50].
P. falciparum resistance to artemisinin has recently been observed in the Greater
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Mekong region, particularly along the Cambodia-Thailand border, and the number of
resistant parasite populations has been increasing[73, 68, 74, 75, 76]. New drug resistance
has often ﬁrst been observed in Cambodia before spreading to other areas of the world[77].
In order to combat the spread of resistance, the WHO recommends ACT, combining
several drugs in order to reduce the chances of resistance being developed to one of them.
However, their uptake remains insuﬃcient, not least due to their higher cost[44]. The Roll
Back Malaria partnership are putting a lot of eﬀort into ﬁghting this emerging resistance,
and have launched the Global Plan for Artemisinin Resistance Containment (GPARC)[78].
There are two main reasons for the high level of concern regarding resistance to
artemisinin and its derivatives: the destructive eﬀects of resistance to previous drugs,
and the lack of alternatives to artemisinin therapies in the pipeline[67, 78]. Currently, the
resistance has not spread to Africa, but it is likely to do so despite GPARC's eﬀorts[79].
While the haemoﬁlter presented in this thesis is envisaged to hold beneﬁts for patients
beyond those with drug resistant malaria, the recent re-emergence of resistance adds
urgency and relevancy to the device (see section 5.2.1).
1.2.8 Haemozoin and magnetic properties
During the erythrocytic stage of the life-cycle, the malaria parasite breaks down the
haemoglobin of the cell, consuming the released amino acids in order to reproduce asexu-
ally within the cell. During this process, toxic free haem is produced as a by-product, and
synthesised into haemozoin, also known as the malaria pigment, to avoid the destruction
of the cell and parasite by the free haem. Haemozoin, which is paramagnetic, is stored
in a food vacuole within the infected cell, giving malaria infected cells their magnetic
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Figure 1.5: Evolution of quantity of haemozoin in infected erythrocytes from moment
of infection with parasite[5]
properties[47, 80, 81, 82, 83, 84].
The quantity of haemozoin within an infected erythrocyte depends on the time since
infection by the parasite (see Fig. 1.5, reproduced with data from [5]). In the presence of
a magnetic ﬁeld, this haemozoin will magnetise with a linear dependence on the magnetic
ﬁeld (see section 1.3). Thus the magnetic moment of an infected cell within a magnetic
ﬁeld will depend on the quantity of haemozoin in a cell as well as the magnetic ﬁeld. Hae-
mozoin has the same crystal structure as β-haematin - indeed, the latter is frequently used
in experiments to demonstrate the eﬀectiveness of new drugs - with an iron environment
single spin of s = 5/2[85, 86, 87, 88, 89].
The molar magnetic susceptibility of haemozoin iron has been found to be χmol =
11×10−3ml/mol[90]. To convert this to the dimensionless magnetic susceptibility χ from
Eq. 1.1, the following relationship can be used:
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χmolNmol = χV (1.3)
where Nmol is the number of moles of haemozoin. So Eq. 1.1 for an infected erythrocyte
becomes:
F¯m = µ0χmolNmolH¯∇H (1.4)
Some groups have attempted to measure the volumetric magnetic susceptibility χ of
malaria infected erythrocytes, which were ﬁrst isolated using HGMS in 1981[91]. This is a
challenging task due to the small size of the cells and high variation in haemozoin content
(and hence susceptibility). χ in Eq. 1.4 is really the diﬀerence between the susceptibility of
an infected cell and its environment (i.e. whole blood), and several studies have reported
values ca. 1.5− 2× 10−6 for mature infected erythrocytes (i.e. schizonts)[5, 90, 92].
Recent research using HGMS to isolate malaria infected erythrocytes is discussed in
section 2.2.1.
1.3 Theory of magnetism
1.3.1 Origins of magnetism
The spin magnetic moment, µ¯s, of electrons within a material depend on the electrons'
spin angular momenta, ~s¯:
µ¯s = −gµB s¯ (1.5)
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where µB is the Bohr magneton, equal to 0.927× 10−20emu, and g, a constant known as
the g-value, is equal to 2.0023. Electrons are therefore magnetic dipoles[93].
In atoms, the angular momentum of electrons also creates a magnetic ﬁeld in the same
way a current ﬂowing through a wire does - this is known as orbital angular momentum.
For atoms, the total magnetic moment (ignoring contribution from the nucleus) therefore
depends on both the sum of the orbital angular momentum and the sum of the spin angular
momentum. In atoms with completely ﬁlled orbital shells, these angular momenta sum
to zero. In atoms with incomplete shells however, the two combine to give the atom a net
magnetic moment[93].
The magnetic moment of a material or object is equal to the vector sum of all the
atoms' individual magnetic dipole moments. In non-permanent magnetic materials, the
dipoles are randomly oriented, giving a net-zero magnetic moment. When exposed to a
magnetic ﬁeld, however, the internal dipoles align, magnetising the material. Magnetised
objects create their own magnetic ﬁelds, and can have magnetic forces exerted upon them.
1.3.2 Magnetic ﬁelds and susceptibility
Magnetic ﬁelds are expressed as either the H-ﬁeld, which has units of Am-1, or the B-ﬁeld,
more commonly known as magnetic induction, which is measured in teslas (T). They are
related by the permeability of free space: µ0 = 4pi × 10−7mkgs-2A-2 and magnetisation
of the space[94]:
B¯ = µ0(H¯ + M¯) (1.6)
In free space, M¯ = 0, so the two are linearly connected - any diﬀerence between them
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is purely in terms of units. However, within a magnetically responsive material, B¯ is
related to H¯ via the degree to which the material is magnetised by H¯. This is deﬁned
using the dimensionless magnetic susceptibility, χ, which determines its magnetisation,
or magnetic moment, M¯ in a given magnetic ﬁeld:
χ =
M¯
H¯
(1.7)
∴ B¯ = µ0H¯(1 + χ) (1.8)
B¯ = µrµ0H¯ (1.9)
where µr = (1 + χ) is known as the relative magnetic permeability of a material[94].
1.3.3 Forms of magnetism
The class of magnetism to which a material belongs is determined by its relative mag-
netic permeability (and therefore susceptibility), which is in essence a measure of how
favourably a magnetic ﬁeld passes through a material. Materials with susceptibility less
than or equal to 0 are diamagnetic. With the notable exception of superconductors,
which will not be discussed here, their susceptibilities are very small and their magnetic
responsiveness is almost imperceptible. As these materials do not apparently respond to
permanent magnets they are generally considered to be `non-magnetic'; in fact, they are
weakly repelled by magnets (see Eq. 1.10).
The way in which a material's internal dipoles respond to a magnetic ﬁeld determ-
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Figure 1.6: Magnetic dipole alignment for diﬀerent magnetic material classes
ines the magnetic class to which it belongs (Fig. 1.6). For diamagnetic materials, the
dipoles align in the opposite direction to the ﬁeld. For materials with positive magnetic
susceptibilities, the dipoles align in the same direction as the ﬁeld and the object mag-
netises. For non-ferromagnetic materials, when the magnetic ﬁeld is removed, the dipole
orientations randomise, and the object demagnetises. Ferromagnetic materials have the
ability to maintain their magnetisation while below their Curie temperature, the point
above which thermal energy causes the magnetic ordering to be lost.
Paramagnetic materials have small, positive magnetic susceptibilities. They are con-
sidered `weakly' magnetic, and their response can be diﬃcult to detect.
Ferromagnetic materials have large, positive susceptibilities. They are `strongly' mag-
netic, and comprise the materials most frequently labelled `magnetic', most of which are
iron based, such as steel.
Superparamagnetic materials are paramagnetic below certain temperatures
Other forms of magnetism, such as ferrimagnetism and antiferromagnetism, are not
relevant to this project and will not be discussed.
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1.3.4 Magnetic forces
As discussed in section 1.3.2, magnetic ﬁelds magnetise objects, giving them a magnetic
moment, M¯ . In the case of paramagnetic materials, such as haemozoin, the eﬀect of
this acquired magnetic moment is that, in the presence of an inhomogeneous magnetic
ﬁeld, the object will be attracted in the direction of the highest magnetic ﬁeld. This
phenomenon is the result of the magnetic force exerted on an object, which is given by
Eq. 1.1[95]. Combining Eq. 1.1 with Eq. 1.7 and Eq. 1.6 gives the equation in terms of
the B-ﬁeld:
F¯m = µ0χV H¯∇H¯
B¯ = µ0H¯
∴ F¯m =
χV
µ0
B∇B (1.10)
where V is the volume of magnetic material, and ∇B is the ﬁeld gradient.
So the magnetic force on an object depends on both its magnetic moment and the
local variance in the magnetic ﬁeld. The consequence of Eq. 1.10 is that to generate a
magnetic force on an object, the ﬁeld in which it is located must be inhomogenous, and
the object will move towards higher ﬁelds. When trying to generate high magnetic forces,
the objective should therefore be to maximise not only the magnitude of the ﬁeld, but
also the ﬁeld gradient in the direction of the desired force. Indeed, priority is typically
given to the generation of a high magnetic gradient, as higher magnetic ﬁelds cease to
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have an eﬀect on the force on an object once the object's saturation magnetisation has
been reached.
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Chapter 2
Clinical Applications of High Gradient
Magnetic Separation
2.1 Introduction
The focus of this thesis is the design and development of a magnetic haemoﬁlter for the
treatment of malaria. However, as mentioned in section 1.1.2, the device is theoretically
capable of removing any magnetic material from the bloodstream, giving rise to a host
of potential applications. In the case of malaria, the intrinsic magnetic properties of
the infected cells are exploited; any other agent in the blood with paramagnetic, super-
paramagnetic or ferromagnetic properties can also be captured as long as the magnetic
force on the agent is greater than the drag force it experiences within the separation
chamber.
Biological entities with positive magnetic susceptibilities, such as magnetotactic bac-
teria or the cells that give rise to magnetoreception, are uncommon and very rarely present
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in the bloodstream[96, 97, 98]. However, a large number of diﬀerent agents can be `mag-
netically labelled' using magnetic beads or nanoparticles[95, 99, 100]. The ability to func-
tionalise these magnetic carriers, for example by conjugating antibodies to their surface,
enables their binding to speciﬁc agents, which can then be magnetically actuated.
In these applications, functionalised magnetic particles are mixed with blood, either
through prior injection into the patient, or within the extra-corporeal loop. In the lat-
ter, the loop would include a mixing chamber in which a `swarm' of magnetic particles
is created, causing a high number of collisions between the particles and targets. The
particles bind speciﬁcally to the target agent that needs to be removed - this could be an
`undesirable' agent, such as a toxin, or a `desirable' agent, such as a stem cell that can
then be used in research or a treatment. These magnetic particles, which are usually iron
oxides, need to be biocompatible, able to survive in the bloodstream, exhibit high mag-
netic susceptibilities, and bind to their targets with high eﬃciency and speciﬁcity. The
speciﬁcity is particularly important to avoid false positive capture, while the biocompat-
ibility and non-toxicity are paramount: the magnetic particles must not cause any harm
to the patient.
Thus combined with magnetic labelling techniques, the magnetic haemoﬁlter could be
used to remove from the bloodstream any agent that can be labelled. This gives rise to
a large number of potential applications for the device presented in this thesis. Many
research groups are already working on magnetic nanoparticles (MNP) or beads which
target speciﬁc blood-borne agents in order to deliver clinical beneﬁts; some have designed
their own magnetic separators, including one group working on a malaria treatment similar
to the one in this thesis, albeit with a very diﬀerent haemoﬁlter design (see section 2.2.1).
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Others are working on magnetic particles for diagnostic or bench-top puriﬁcation purposes
(a well established ﬁeld), sometimes without considering their clinical applications.
This Chapter provides an overview of the state of the art of magnetic particle research
as it could be applied to the magnetic haemoﬁlter, outlining some of the many possible
future clinical applications of the device presented in this thesis. To facilitate this analysis,
the Chapter has been broken down into three main sections which constitute potential
applications of the haemoﬁlter:
1. Cells : The separation of undesirable cells from the bloodstream for treatment or
diagnosis of a disease, or the separation of desirable cells for re-use in treatment or
research.
2. Sepsis : Magnetic haemoﬁltration as a treatment for sepsis, through the removal of
bacteria, fungi and other sepsis-causing pathogens.
3. Detoxiﬁcation: The detoxiﬁcation of blood, for the treatment of kidney disease and
renal failure, drug overdoses or radiation exposure.
4. Viruses : The diagnosis, treatment or control of viral infections through direct mag-
netic extraction of circulating virions.
This Chapter should not be taken as a comprehensive review of the applications of mag-
netic particles, or of the potential biomedical applications of HGMS - these topics have
been written about in great detail in many reviews and books[95, 99, 100, 101, 102, 103,
104, 105]. One of the core strengths of the magnetic haemoﬁlter is that its applications
are limited only by what can be usefully magnetically labelled. MNP have been used to
target an incredible number of diﬀerent agents, including cells, DNA, viruses and bacteria,
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and hold great promise in terms of unlocking future therapeutic applications.
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Table 2.1: Summary of clinical applications of HGMS presented in chapter
Target Targeting moiety Applications Ref.
Malarial erythrocytes N/A (naturally magnetic)
Treatment for malaria
Puriﬁcation for diagnosis and research
[106, 92, 107, 108]
Malaria gametocytes N/A (naturally magnetic)
Reduce malaria transmission
Puriﬁcation for diagnosis and research
[107, 108, 109, 110,
111]
Colon CTC BER-EP4 Improved detection of CTC for diagnosis [112]
Prostate CTC BER-EP4 Improved detection of CTC for diagnosis [113, 114, 115]
Kidney CTC BER-EP4 Improved detection of CTC for diagnosis [113, 114]
Lung CTC
BER-EP4
EpCAM
Improved detection of CTC for diagnosis
Lab-on-a-chip diagnosis
[116, 117, 118]
Melanoma CTC Ig-G Improved detection of CTC for diagnosis [119]
Leukaemia CTC CD3 Improved detection of CTC for diagnosis [115]
Breast CTC EpCAM Lab-on-a-chip diagnosis [117, 120, 118]
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Target Targeting moiety Applications Ref.
Circulating epithelial cells EpCAM Improved detection of CTC for diagnosis [121]
Fetal cells
CD71
GPA
CD14 and CD45
(depletion)
Diagnose pre-natal diseases [122, 123, 124]
Hematopoietic stem cells
CD34
CD133
Stem cell transplantation [125, 126, 127]
Sepsis causing pathogens Mannose binding lectin Treatment [128, 129]
Sepsis related cytokines Cytokine antibodies Treatment [130, 131, 132]
Homocysteine
P-cresol
Bovine serum albumin Improve treatment of kidney disease [133, 134, 135]
Caesium-137 Prussian Blue Blood detoxiﬁcation (radioactive toxins) [136]
Horseradish peroxidase Streptavidin Blood detoxiﬁcation [137]
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Target Targeting moiety Applications Ref.
Uranyl ions Biophosphonate Blood detoxiﬁcation (radioactive toxins) [138]
Digoxin Digoxin antibodies Blood detoxiﬁcation (drugs) [139]
Thrombin DNA polymers Blood detoxiﬁcation (drugs) [140]
Doxorubicin DNA polymers Blood detoxiﬁcation (drugs) [140]
Lead ions Iminodiacetic acid Blood detoxiﬁcation (heavy metals) [139]
Cadmium ions
Phenylazanediyl diacetic
acid
Blood detoxiﬁcation (heavy metals) [141]
HIV virions CD44 Lab-on-a-chip diagnosis [142]
Avian ﬂu virus
Anionic polymer
Monoclonal viral
antibodies
Improved detection for diagnosis [143, 144, 145]
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Target Targeting moiety Applications Ref.
Hepatitis virus
Poly(ethylene imine)
Protamine hydrochloride
Hepatitis antibodies
Lectin
Improved detection for diagnosis [146, 147, 148, 149]
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2.2 Cells
2.2.1 Malaria
As was discussed in section 1.2.8, the magnetic properties of malaria infected cells have
been known since 1981, when Paul et al. ﬁrst performed magnetic separation of malarial
blood samples[91]. Since then, bench-top magnetic separation columns (for example the
MACS columns available from Miltenyi Biotec, Germany) have been used to purify mal-
aria infected cells for research[83, 84, 108]. A couple of research teams have taken this
further, suggesting exploiting the magnetic properties of haemozoin to improve existing
diagnosis techniques or as a potential treatment.
Gandini et al. have attempted to produce a device similar to the one presented in this
thesis: a magnetic haemoﬁlter for the treatment of malaria[92, 106]. Their device, like
many magnetic separators presented in this section, functions in a very diﬀerent manner
to the haemoﬁlter presented in Chapter 3, relying on separation by fractionation within
microﬂuidic channels. They have performed computational simulations of infected cells
passing through the device.
The group's device consists of a 200µm diameter microﬂuidic channel across which a
magnetic ﬁeld gradient is created using a permanent magnet and series of ferromagnetic
wires, placed adjacent to the channel. The infected cells are pulled to one side of the
channel and, thanks to laminar ﬂow, separated into a capture chamber. In their simula-
tions, only the infected cells entering the channel on the side of the permanent magnet
were captured within a channel length of 80mm. This could be resolved by increasing
channel length or magnetic force, or by having ferromagnetic elements on both sides of
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the channel, rather than on one side only. Their simulations were conducted at ﬂow rates
of 1ml/min and 5ml/min in a Newtonian ﬂuid (note they do not specify the viscosity used
in their simulations).
Gandini's group has not published any further work. The patent is assigned to Ac-
celDX, a recent start-up that does not appear to be working on the malaria device. CEO
and lead author Gandini, was quoted in a blog in 2012 as saying "I developed a blood
puriﬁcation device, however the project was too costly and we couldn't get funding"[150].
In August 2012, AccelDX was awarded a $350k grant from the US National Institutes of
Health for a project titled "Blood Filtration System for the Treatment of Severe Malaria
Patients"[151]. However, the project was due to ﬁnish on 28 February 2013, and no results
were published, and AccelDX have not mentioned the project on their website.
Karl et al. have used magnetic separation in order to purify both malaria infected
erythrocytes and gametocytes, the sexual form of the malaria parasite (see section 1.2.2),
from a blood sample[109, 110, 111, 107]. They compared their in vitro magnetic separa-
tion method with the established methods of light microscopy and reverse transcription-
polymerase chain reaction (RT-PCR), which have detection thresholds of 16 and 0.13 per
µL of blood respectively; the magnetic separation method was expected to have a detec-
tion threshold of 0.05 per µL. They found that the magnetic separation method was as
eﬀective as RT-PCR in detecting gametocyte positivity and quantitative density, and was
also easier to carry out in-the-ﬁeld, requiring less specialised equipment and training[109].
The magnetic separator used by Karl et al. is similar to the MACS column sold by
Miltenyi Biotec, but with signiﬁcantly lower costs. It consists of a modiﬁed plastic pipette
ﬁlled with 420µm diameter S110 steel shot spheres which is placed between two NdFeB
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magnets. These are connected with an iron yoke, creating a maximum ﬁeld of 1T in the
area in which the column was placed. Using this arrangement, the group extracted nearly
100% of gametocytes at a ﬂow rate of 0.28mL/min[111].
Other suggestions for exploiting the magnetic properties of haemozoin for malaria dia-
gnosis include improving the detection of parasites through magnetic rotation of the hae-
mozoin crystal[152, 153], a magneto-optic ﬁnger probe for non-invasive in-vivo diagnosis[154],
and improving sensitivity of detection using MNP[155].
The existing research demonstrates the potential of exploiting the magnetic properties
of haemozoin in several areas of malaria, from basic research through diagnosis to poten-
tial treatments. However, no group has successfully developed a magnetic haemoﬁlter
appropriate for the treatment of patients, due to the diﬃculty of achieving high separ-
ation eﬃciencies at low cost. The literature not only supports the idea of the magnetic
haemoﬁlter presented in this thesis being valuable as a novel treatment, but also suggests
that it could form part of a cheaper and more eﬀective diagnosis technique. Furthermore,
the work of Karl et al. indicates that the magnetic haemoﬁlter may have an eﬀect on
malaria transmission rates through the removal of gametocytes, which should be easier
to magnetically capture than infected cells.
2.2.2 Circulating tumour cells
Cancer spreads from its primary site to other areas of the body through metastasis, during
which circulating tumour cells (CTC) can be found in the bloodstream. These settle in
other areas of the body, forming new cancers and leading to extreme complications. Many
groups have demonstrated the possibility of magnetically labelling CTC using magnetic
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particles. One of the ﬁrst was Enis et al. in 1997. They used MNP functionalised with
monoclonal antibodies to purify CTC from colon cancer cell lines, facilitating detection
with RT-PCR[112].
Zigeuner et al. performed a similar study with prostate and kidney cancer cells,
using commercial magnetic beads (Dynabeads®, Dynal AS, Norway) with a diameter
of 2.8µm. These were functionalised with antibodies speciﬁc to endothelial cells (BER-
EP4) for positive selection of the cancer cells from mononuclear cells isolated from healthy
volunteers. For samples with only one CTC per million mononuclear cells (an accepted
CTC concentration for early-stage patients), the group increased positive detection of
CTC from 23% to 93% of cases[113, 114]. Kularatne et al. used the same antibody to
magnetically target lung cancer cells[116]. Georgieva et al. used a similar method but
diﬀerent antibodies to purify melanoma cells, using immunoglobulin-G coated magnetic
beads[119].
More recently, Song et al. developed MNP able to target several diﬀerent cancer
cell types, functionalising Fe2O3 MNP with anti-CD3 monoclonal antibodies to target
leukaemia cells, and prostate speciﬁc membrane antigen antibodies to target prostate
cells. The combined cocktail of MNP were able to magnetically label up to 96% of cancer
cells after a 15 minute incubation time. The group was able to detect the presence of
CTC at a minimum concentration of one cancer cell per 10,000 (0.01%) healthy cells[115].
Other groups have focussed on the use of microﬂuidics in combination with these MNP
technologies in an attempt to provide `lab on a chip' cancer diagnostic tests. Ingber et
al. used 2.8µm microbeads conjugated with epithelial cell adhesion molecule (EpCAM)
antibodies to extract breast cancer cells from whole blood ﬂowed through their device.
44
They were able to isolate nearly 90% of cancer cells from an initial concentration as low
as 2 cells per ml of blood. The group also successfully used their method to extract CTC
from blood samples of mice with breast cancer, with high speciﬁcity (only 0.4% of the
captured cells were leukocytes)[120]. Kim et al. have reported a very similar system, also
using EpCAM functionalised magnetic nanobeads and a microﬂuidic magnetic separator
to isolate CTC from blood taken from patients with lung and breast cancer[117].
Neither Ingber et al. nor Kim et al. suggest incorporating their device into an extra-
corporeal loop as a potential treatment for cancer or method to prevent its spread through
the body. Indeed, with ﬂow rates of 1.6ml/hour and 5ml/hour respectively, their devices
would not be appropriate for such an application. Chang et al. have reported a similar
device capable of signiﬁcantly higher ﬂow rates (up to 4.3ml/min), also using EpCAM
antibodies to capture breast and lung cancer cells, but like the other groups, propose a
benchtop device to purify samples taken from patients, not incorporated into an extra-
corporeal loop[118].
The rarity of CTC, which can be as low as 1-10 CTC per ml of blood, which would
also contain 106 leukocytes and 109 erythrocytes, makes their detection (and thus the
detection of metastasis) very challenging, so the focus on their puriﬁcation from samples
of blood from cancer patients in understandable[156]. This section barely scratches the
surface of the research going into new methods for the puriﬁcation of CTC from whole
blood - the subject has recently been the subject of entire theses - but serves to give an
idea of the volume and type of research being carried out and demonstrate the state of
the art of the selective magnetic labelling of CTC[156, 157, 158, 159, 160].
The question remains whether extra-corporeal magnetic haemoﬁltration using MNP
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speciﬁc to CTC could provide any clinical or diagnostic beneﬁt. One could imagine that
continuous ﬁltration 24 hours a day, using a discreet wearable magnetic ﬁlter, could reduce
the risk of cancer spreading. It could also have the additional advantage of facilitating
the detection of metastasis through analysis of the captured cells when the `separation
cartridge' is changed. However, it is doubtful that such a method could prevent cancer
spreading - only one cell is required to settle at a new site for a new tumour to form.
That being said, the huge human and economic toll exerted by cancer, and the signiﬁcant
worsening of patient prognosis caused by metastasis, could justify investigation into such
a device, which could be valuable even if it only slows, rather than prevents, the spread
of the disease[161, 162, 163].
2.2.3 Other rare cells
CTC are one of a class of `rare cells' that it could be beneﬁcial to isolate from whole
blood. Others include circulating endothelial cells, fetal cells, viral or parasitic cells,
progenitor cells and stem cells[157, 160, 164]. Circulating endothelial cells, similarly
to CTC, are used for disease prognosis and personalised cancer treatment. They can
be isolated using similar methods, for example using EpCAM antibodies conjugated to
magnetic particles[121]. Fetal cells are used to diagnose prenatal diseases such as sickle
cell anaemia or to perform genetic analyses[122]. Their benchtop magnetic separation has
been possible for two decades - initial techniques required the depletion of other cells to
ensure speciﬁcity, but `one-step' techniques have also been reported[123, 124].
While CTC and fetal cells are extracted from peripheral blood for diagnostic purposes,
progenitor cells and hematopoietic stem cells (HSC) are used in various treatments. HSC,
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for example, are extracted for the purposes of stem cell transplantation (SCT), principally
as a treatment for leukaemia. This may include autologous SCT, wherein the patient's
own stem cells are used. These can be extracted from the bone marrow or from peripheral
blood, but are extremely rare in both cases[164].
Magnetic separation of HSC sometimes involves the depletion of other cells, but
markers such as CD34 and CD133 have been used to positively extract them; negat-
ive depletion is not a feasible option within an extra-corporeal loop. MNP functionalised
with anti-CD34 antibodies could be used to extract HSC directly from donors with high
purity[164, 157, 165, 125, 126, 127]. Similar methods have been used to isolate more
diﬀerentiated progenitor cells, which also have valuable clinical applications[166, 167].
Mesenchymal stem cells also have signiﬁcant clinical potential, and can be isolated
with the use of MNP[168, 169]. However, recent research suggests that they are not
found within the bloodstream[170]. The same is true of embryonic stem cells, particularly
valuable as they can diﬀerentiate into any cell type. While they can be magnetically
labelled, their magnetic separation will always remain a benchtop technique and is not
appropriate for extra-corporeal magnetic haemoﬁltration[126, 171].
2.3 Sepsis
Sepsis is caused by the body's immune response to pathogens in the bloodstream[172].
It is one of the most common deadly diseases and one of the leading causes of death in
the developed world, exerting a huge human and economic toll. The mortality rate is
36%. In the UK, there are over 100,000 cases and 37,000 deaths annually; in the US,
there are over a million cases and approximately 250,000 deaths. With an annual cost
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of $20.3 billion in 2011 (up from $4.4 billion in 1997), it is the most expensive condition
in the US, making up 5.2% of total healthcare spending. Direct costs to the NHS in the
UK are over ¿2.5 billion. Sepsis incidence has been increasing rapidly, by about 10% in
the decade to 2013. Incidence is 50% greater than myocardial infarction (heart attacks)
and 33% greater than stroke. Severity and mortality is strongly linked to the number of
pathogens in the bloodstream[161, 162, 173, 174, 175, 176].
2.3.1 Haemoﬁltration for the treatment of sepsis
Recently, Ingber et al., the same group mentioned in section 2.2.2, presented a micro-
ﬂuidic magnetic separation device designed to remove pathogens and toxins directly from
the bloodstream using functionalised MNP[128, 129]. They used genetically engineered
mannose-binding-lectin (MBL) as a targeting agent, binding it to the surface of 128nm
diameter MNP via immunoglobulin-G and streptavidin. MBL is able to bind a wide range
of pathogens and bacteria, so is ideal for MNP functionalisation[177]. They have designed
a microﬂuidic extra-corporeal magnetic separator so that the MNP mix with the blood
within the blood loop and do not need to be injected into the bloodstream.
In their early study, the group used functionalised magnetic microbeads to extract
80% of Candida albicans fungi, a prominent sepsis pathogen. In a more recent in vitro
study, they group simutaneously removed from whole blood 98% of anaerobic and 80%
of aerobic bacteria in a single pass through the device, and over 90% of Staphylococcus
aureus, Candida albicans and Escherichia coli after ﬁve passes. Initially, their separation
device only removed 80% of the MNP, but this was increased to nearly 100% by adding
1µm diameter magnetic microbeads to capture the MNP. In these experiments, the MNP
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were added to the blood in a constant ﬂow, so binding took place during the process. The
experiments were conducted at a ﬂow rate of only 10ml/hour, but it should be noted that
the factor limiting the ﬂow rate is the binding of the MNP to the targets, rather than
the magnetic extraction of the pathogen-bound MNP. 90-99% separation eﬃciencies were
achieved at 535ml/hour for `pre-bound' MNP[128].
The group then tested their device on septic rats, achieving similar results to their in
vitro experiments: 90% of S. aureus and E. coli were removed from the rat's bloodstream
in one hour. Furthermore, signiﬁcant reductions of pathogens and CD45+ inﬂammatory
cells in the lung, spleen and kidney were achieved. After injection with a lethal dose
of lipopolysaccharide, rats being treated with the device had signiﬁcantly less of the
endotoxin in those organs, and saw improved survivability when compared to untreated
rats. The device appears to alleviate or prevent the symptoms of sepsis - the treated rats
not exhibiting any signs of clinical distress while untreated rats did[128].
The separation device used by Ingber et al. consists of 16 microﬂuidic channels with
a height of 16µm. Each channel has two sections - the blood containing pathogens bound
to MNP ﬂows through the bottom channel, while saline is ﬂowed through the top channel.
NdFeB magnets placed above the device pull the MNP through small holes out of the
blood ﬂow and into the top channel, which is then discarded. In terms of magnetic
separation eﬃciency, their device is quite eﬀective, able to capture 90% of MNP from
blood at a ﬂow rate of 9ml/min, and 60% at 17ml/min. However, its potential ﬂow rate
is severely limited by the binding of the MNP to the target pathogens, which required
a ﬂow rate of 10ml/hour. In order to ﬁlter the total blood volume of a typical adult
at this ﬂow rate, 500 hours would be required. While the group could use several of
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their devices in series, it would still take a long time to eﬀectively clear the patient of
pathogens (especially because ﬁltering only total blood volume is insuﬃcient - see section
3.1.2). Even if the MNP were injected into the patient so that the device could run at
9ml/min, 10 hours would still be required to ﬁlter an adult's total blood volume, and 40
hours would be required to achieve a 90% pathogen reduction.
2.3.2 Bacteria and cytokines
While Ingber et al. are the only group to have attempted the development of a magnetic
haemoﬁlter combined with MNP for the treatment of sepsis, other groups have used
functionalised MNP to target bacteria or cytokines responsible for sepsis, which can be
caused by a wide variety of pathogens. Weber and Falkenhagen, for example, used iron
oxide MNP functionalised with appropriate antibodies to target interleukin 1β and tumor
necrosis factor α, two major sepsis causing cytokines[178, 179]. They successfully removed
80-90% of the pathogens from blood plasma[130]. Herrmann et al., another research
group developing an extra-corporeal magnetic separator (see section 2.4.3), also used
antibody functionalised MNP to target interleukin-6β, another inﬂammatory mediator
linked to sepsis, reducing concentation in blood by 38% in a single pass through their
device[131, 132, 180].
Other research groups have focussed on the puriﬁcation of bacteria to increase detec-
tion sensitivity with mass spectrometers. This could lead to applications in food quality
control or water treatment[181, 182]. Bacteria targeted with functionalised MNP include
Salmonella, Bacillus, Staphylococcus, E. coli, Biﬁdobacterium longum, Listeria monocyt-
ogenes and many others[183, 184]. Others have used non-magnetic functionalise nano-
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particles such as immunoglobulin coated platinum to target various bacteria[185]. Others
target bacterial nucleic acids such as DNA and RNA[186, 187].
In conclusion, the extensive use of functionalised MNP to target a wide range of
bacteria and other pathogens responsible for sepsis indicate that the treatment of sepsis
could be a very promising application for magnetic haemoﬁltration. The work of Ingber
et al. has created the link between magnetic labelling and sepsis therapy, and their in
vivo results are particularly promising; their magnetic separation device however needs
improvement before becoming a feasible medical device, particularly in terms of ﬂow rate.
One signiﬁcant challenge will be the development of MNP able to target an extremely
wide range of sepsis-causing pathogens while remaining unharmful to other blood com-
ponents. As sepsis can be caused by almost any infection with bacteria or fungi, one
solution may be to produce a `cocktail' of diﬀerent MNP, each targeting a diﬀerent com-
mon pathogen known to cause sepsis. Together, the MNP could be designed to target over
99% of pathogens commonly associated with sepsis. This cocktail, along with an appro-
priate magnetic haemoﬁlter, could then be administered to any patient that succombs to
an infection in a hospital intensive care unit (ICU), even before the cause of the infection
is identiﬁed. It is feasible that such a method, if it were cost-eﬀective (particularly in
terms of the MNP cost) could become common-place in ICU throughout the developed
world, helping to reduce deaths caused by one of the developed world's biggest killers.
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2.4 Detoxiﬁcation
2.4.1 Kidney disease
Stamopoulos et al. have used MNP alongside dialysis in a technique they call magnet-
ically assisted haemodialysis (MAHD). Their intention is to deliver clinical beneﬁts to
late stage chronic kidney disease and end stage renal disease patients by injecting func-
tionalised MNP into the patient in order to target toxic substances circulating in the
bloodstream. The MNP and targets are removed by adding a magnetic ﬁlter to tradi-
tional dialysis circuits, removing toxins with higher eﬃciency and speciﬁcity than existing
dialysis membranes, which rely on diﬀusion and convection through micro- or nano-sized
pores[188, 133, 134, 135].
The group advocates the use of iron oxides (Fe2O3 and Fe3O4) as the MNP, princip-
ally because of their biocompatibility. The group studied the eﬀect that unfunctionalised
Fe3O4 MNP and Fe3O4 functionalised with bovine serum albumin (BSA) conjugates had
on blood cells. They did not ﬁnd any interference between the MNP and white or red
blood cells, even when concentrations were high or when the cells were matured in the pres-
ence of MNP[188, 189]. The group used homocysteine and p-cresol as simulant targets in
vitro, both of which occur in humans and are known to cause clinical symptoms. Elevated
homocysteine levels in the bloodstream can cause cadiovascular disease and arteriosclero-
sis, while p-cresol has an impact on the metabolism. Binding eﬃciencies of approximately
40% and 20% were reported for homocysteine and p-cresol respectively[135]. The group
claims that their method increases removal of homocysteine by 60% when compared to
normal dialysis[134].
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Interestingly, the group talks of the possibility of producing MNP functionalised to
bind with multiple targets: "creatinine, urea, homocysteine, β-2-microglobulin etc."[135].
The separation of β-2-microglobulin could be particularly valuable - its ineﬃcient removal
is a cause of hemodialysis-associated amyloidosis, which causes joint problems ranging
from carpal tunnel syndrome to paraplgeia, and can be fatal[190, 191, 192]. Indeed,
other groups have investigated novel, non-magnetic methods to remove it and prevent
amyloidosis[193]. Stamopoulos et al. target β-2-microglobulin with MNP functionalised
with BSA, reporting rapid and eﬃcient adsorption[133].
The magnetic separator used by Stamopoulos et al. was simply a disc NdFeB magnet
placed below the tubing of the dialyser. The MNP are retained on the walls of the tubing.
With this design, the group were able to capture 80% of unfunctionalised MNP from saline
in a single pass. However, 15-20 passes of the BSA functionalised MNP were required to
achieve a similar separation eﬃciency[135]. The ﬂow rates used by the group varied from
80ml/min to 250ml/min. Separation ceased to be eﬃcient above about 150ml/min[133].
The group's work demonstrates that their MNP technology has signiﬁcant potential in
terms of binding toxins and delivering clinical beneﬁts to patients with kidney disease,
but their current magnetic separator is inadequate. The group has only analysed the
separation in saline, and previous research has demonstrated the diﬃculty in achieving
magnetic separations at higher viscosities (i.e. blood rather than saline)[194].
2.4.2 Radionuclides
MNP have been functionalised in order to treat nuclear waste by tageting radionuclides
or actinides[195, 196, 197, 198]. Kaminski, who has worked on magnetic microspheres
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to target actinides since 1996, has for over ten years been collaborating with Rosengart,
Chen and other colleagues on projects looking at using these MNP in the domain of blood
detoxiﬁcation, with a focus on radionuclides and blood-borne toxins. Their objective is to
develop "a magnetically based detoxiﬁcation system as a therapeutic tool for the selective
and rapid removal of biohazards, i.e. chemicals and radioactive substances, from human
blood"[194]. Their research has been partly funded by the Defense Advanced Research
Program Agency (DARPA), the research arm of the US military, as the researchers believe
that a portable version of their device could provide a convenient `in-the-ﬁeld' treatment
to troops exposed to biological or chemical weapons.
Most of the group's work has focussed on the magnetic separator, which consists of
several narrow tubes or capillaries placed between two ferromagnetic wires. A strong
external magnetic ﬁeld is applied, creating local ﬁeld gradients close to the wires, pulling
magnetic materials onto the surface of the tubes, where they are isolated. This design has
been modelled extensively, showing a potential 90% MNP capture eﬃciency (although
the design needs to be improved to be as eﬀective for viscous ﬂuids)[199].
The group has suggested some MNP which could be used, including MNP to separate
caesium-137, a radioactive isotope of casesium. These are magnetite nanoparticles encap-
sulated in a poly(ethylene)glycolic acid matrix, coated in long-chain poly(ethylene)glycol
(PEG), which is known to prolong lifetime in the blood by preventing clearance by the
spleen, and ﬁnally the surface functionalised with Prussian Blue, a chelating agent that
binds strongly to caesium[136]. They have also functionalised commercial magnetic latex
particles with streptavidin, demonstrating a binding aﬃnity to horseradish peroxidase
conjugated with biotin which was used as a model toxin. Successful binding was demon-
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strated via magnetic separation, although not under constant ﬂow conditions using the
magnetic separator described above[137].
One research group looked at the parameters which aﬀected the separation of com-
mercial 1.7µm magnetic spheres, consisting of magnetite within a polystyrene matrix
(Micromod, Germany). The main variables were viscosity, ﬂow rate and tubing thick-
ness. The group concluded that it was possible to remove 90% of spheres from blood
only if they had 3,000 individual tubes of polyetheretherketone tubing with an inner dia-
meter of 0.5mm and length of 15mm. They suggest this could be improved by optimising
their design, increasing the magnetic ﬁeld and magnetic, and using particles with higher
magnetic content[194].
Kaminski and Rosengart are clearly hopeful about the potential of magnetic haemo-
ﬁltration as a detoxiﬁcation technology and, similarly to this thesis, have focussed largely
on the magnetic separator. Indeed, in 2006, they published a patent proposing using
magnetic particles to remove any "deleterious substance" and detailing their magnetic
separator[200]. The potential applications mentioned in their research are wide-ranging:
"for selective and rapid decorporation of biological, chemical, and radioactive biohazards
from humans"[201], or simply "decorporation of blood-borne toxins from humans"[136].
They have not developed any novel MNP, and have not yet successfully extracted a clin-
ically relevant target from blood using their haemoﬁlter. There have been no publications
related to this research since 2010.
Wang et al. have also removed radionuclides from blood, targeting uranyl ions, sug-
gesting that the same method could be used to remove a number of other radioactive
metal toxins from blood[138]. The group used Fe3O4 MNP functionalised with a novel
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conjugate of dopamine and bisphosphonate. Using a simple in vitro process, in which they
spiked water and blood with uranyl ions and their MNP, they removed 99% of the uranyl
from water and 69% from blood by dipping a bar magnet into the solutions. The lower
eﬃciency on blood is almost certainly due to their basic magnetic separation technique,
as the 99% removal from water indicates that the binding eﬃciency of the MNP to the
uranyl is high[138].
One limitation of Kaminski and Rosengart's device may be the need to have a large
series of essentially microﬂuidic channels (500-750µm). This could make each separation
chamber very expensive to manufacture. The group have been trying to design a port-
able magnetic separator, that can be strapped to the arm, and ﬁlters 6L of blood in 30
minutes. This creates extreme engineering challenges, requiring a ﬂow rate of 200ml/min
through microﬂuidic channels without removing too much blood from the body at any
one time. Their 2007 design used channels 15cm long and with inner diameters of 0.5mm,
but required 3,000 channels to achieve their desired separation eﬃciency of 90%[194]. Fur-
thermore, it is questionable whether a 90% separation eﬃciency of the magnetic particles
would be suﬃcient.
In conclusion, the magnetic haemoﬁlter design of Kaminski, Rosengart et al. will
need signiﬁcant improvement before it is able to deliver the potential beneﬁts, which the
researchers clearly believe are broad and signiﬁcant. The group's work over ﬁve years
demonstrates not only the potential value of such a device, should an appropriate one
ever be produced, but also the diﬃculty in designing one which can achieve the required
ﬂow rates and separation eﬃciencies. Their work, combined with that of Wang et al. and
those who have tageting radionuclides with MNP for the purposes of water puriﬁcation,
56
show that this could be a very promising technique for removing such particles from
exposed humans.
2.4.3 Digoxin and other drugs
Herrmann and colleagues have worked on a magnetic separator in which, similarly to
Ingber et al., the MNP are never introduced to the system - they are introduced within
the extra-corporeal loop, binding with the targets before entering the magnetic separation
chamber[128, 131, 132, 139, 202]. Their ambition is for this technique to be used to
remove any targetable blood-borne toxin. They use several model toxins to demonstrate
the potential of their method, one of which is digoxin. Digoxin is a natural glycoside
extracted from foxglove plants; it is the active ingredient for many drugs used in the
treatment of several heart conditions[203]. Digoxin is toxic, and the accumulation of high
levels in the bloodstream can be lethal[204].
Herrmann and colleagues used carbon-encapsulated platinum-spiked iron carbide MNP,
20-40nm in diameter. For the removal of digoxin, antibodies were conjugated to their sur-
face via cross-linking with polyethylene-glycol (PEG) to render them speciﬁc to digoxin
molecules. In their most recent study, published in 2013, they successfully reduced digoxin
concentrations in rats by 50% in 10 minutes and 75% in 40 minutes. MNP concentrations
were reduced from 0.5mg/ml to below the detection limit of 1µg/ml[139].
The magnetic separator used by Herrmann et al. was built according to the design by
Bockenfeld et al. (a group including Kaminski and Rosengart from section 2.4.2), in which
the tubing is placed between four ferromagnetic wires magnetised by external permanent
magnets[199]. The group does not specify if their design varied for each of their studies.
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Magnetic materials are retained on or close to the walls of the tubing, which was 3mm in
diameter. The blood is passed through the separator four times in order to achivee the
required separation. The ﬂow rate through the magnetic separator was 1.5ml/min during
the rat experiments[131, 139].
The work of Herrmann and colleagues is particularly promising in that it avoids the
problems associated with introducing MNP into the patient and could lower treatment
costs due to eﬃcient use of MNP. Whether this system will work for diﬀerent target agents,
such as cancer cells or bacteria, as claimed by the authors, remains to be seen. The lower
contact time between the MNP and the target agents may limit capture eﬃciency and
ﬂow rates, causing unacceptably long treatment times.
Their magnetic separator has limitations in terms of ﬂow rates - a 1.5ml/min ﬂow rate
would need 55 hours to address the typical total blood volume of an adult - and the fact
that the blood needs to be circulated throught the device four times. However, the group
may yet detail a scaled-up design more appropriate for human use, and their current
method certainly seems successful in terms of removing MNP (although MNP are much
easier to separate than, for example, a mangetically labelled cell). In any case, their work,
which focusses on the MNP rather than on the separator, clearly demonstrates the po-
tential of magnetic haemoﬁltration to remove disease causing toxins from the blood. The
extra-corporeal magnetic labelling that they advocate is particularly interesting, avoiding
the need to inject MNP into a patient.
Several other groups have demonstrated the binding of nanoparticles to speciﬁc drugs
for which overdoses are common[205]. Wang et al., for example, have functionalised MNP
with DNA polymers in order to target thrombin and doxorubicin, used as models of
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large and small molecules respectively. They successfully bound 70% of thrombin and
93% of doxorubicin[140]. In his review, Leroux details a number of nanocarriers being
investigated to target diﬀerent drugs, although most are not MNP based[206]. However,
the volume of research indicates that many diﬀerent drugs could be targeted with MNP,
using many diﬀerent binding methods.
2.4.4 Heavy metal ions
Herrmann et al. also used their device to remove lead ions (Pb2+). Using the same plat-
inum iron carbide MNP as in section 2.4.3, they functionalised the MNP with physisorbed
poly(ethylene imine) (PEI) and iminodiacetic acid to target Pb2+, reducing concentations
in rats by 50% in 10 minutes and 75% in 40 minutes, the same results as they achieved
with digoxin. This demonstrates that if a given MNP can extract a certain percentage
of one toxin, it can probably extract the same percentage of another toxin that it binds
to[139].
Jin et al. have similarly used PEI coated MNP to target cadmium ions. They synthes-
ise their own iron oxide MNP, with a diameter of about 50nm, and use them to remove
98% of cadmium ions from water, as well as 50% of copper ions, demonstrating a high
binding eﬃciency. After 10 minutes of incubation in cadmium ion spiked blood, the re-
moval rate was 80%. These were achieved by simply placing a NdFeB magnet next to
the sample. They also demonstrate that their particles do not cause any haemolysis in
blood, even at very high concentations. The group also coat the MNP with 2,20-(phenyl
azanediyl) diacetic acid and PEG to both improve dispersion and reduce uptake by the
reticuloendothelial system[141].
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2.5 Viruses
2.5.1 Human immunodeﬁciency virus
HIV type 1 virions have successfully been puriﬁed in vitro using MNP[142]. The purpose
of the method was to provide a novel diagnostic tool as a replacement for centrifugation
or RT-PCR, purifying the virus from samples of whole blood. The idea is to use `lab-on-
a-chip' magnetic separation to enable easy and cheap HIV diagnosis even from samples
with very low viral concentrations. However, if the MNP are biocompatible and can
survive within the bloodstream for a suﬃcient length of time, they could be used with
the magnetic haemoﬁlter described in this thesis to extract HIV directly from a patient's
bloodstream.
It is not clear whether this would provide any clinical beneﬁts, or what those would
be, but it is feasible that such a method could be used to clear the virus from the body.
HIV infection severity is linked to the viral load, or the concentration of virions in the
blood[207]. Targeting these circulating virions could prevent further spread of the in-
fection, and over time possibly help clear the virus from the body suﬃciently to trigger
remission. However, it would likely require very long treatment times, not least because
only viruses that have not infected a cell would be separable, and achieving the required
speciﬁcity may be a signiﬁcant challenge.
Chen et al. used commercial anti-CD44 superparamagnetic particles with 50nm dia-
meter (purchased from Miltenyi Biotech, USA). Their magnetic separator was a micro-
ﬂuidic device which ﬁrst mixed a sample of blood spiked with HIV, and was then followed
by a magnet placed above a 5x4x0.12mm separation chamber. The maximum viral sep-
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atation eﬃciency achieved was 78%, achieved at a ﬂow rate of 50µL/min and when the
MNP and viruses were mixed in advance and not within the mixing device. While they
report that 100% binding between viruses and MNP is possible within a test tube (albeit
with a one hour incubation time), the mixing eﬃciency within their microﬂuidic device
is only 79%. Thus the separation eﬃciency when mixing within the device dropped to
approximately 50%[142].
The research by Chen et al. shows that magnetic capture of HIV virions is possible
using functionalised MNP. Combining these or similar MNP with the magnetic haemoﬁlter
in this thesis could theoretically reduce a patient's viral load. However, the group's
diﬃculty in achieving high binding between the MNP and the virus (1 hour incubation in
one experiment, and 250 passes through their microﬂuidic mixer in another) demonstrates
that this will be a signiﬁcant challenge in an extra-corporeal loop device.
It is therefore likely that the MNP would need to be injected into the bloodstream
in order to have suﬃcient time to magnetically label the viruses. They would thus have
to survive within the bloodstream for that period. Furthermore, investigations into the
consequences of a tagged virus infecting a T-cell would have to be investigated. The cell
may become magnetically labelled and also be captured, or the MNP could prevent the
cell from being infected, both of which would be positive results. However, it is also
possible that the infection would leave the MNP bound to neither the virus nor the cell,
and that as a result neither would be captured.
In conclusion, there does appear to be a potential clinical application for the magnetic
haemoﬁlter in terms of treatment of HIV. However, it is a particularly complicated area
with questionable clinical beneﬁts. Furthermore, the MNP required for such a treatment
61
are likely to incur a signiﬁcant cost (particularly if they are conjugated with antibodies
such as anti-CD44). As most of the regions in which the HIV/AIDS burden is highest are
also poor[208], the economic viability of such a treatment would be a signiﬁcant challenge.
2.5.2 Inﬂuenza
Inﬂuenza can be a highly dangerous virus, as demonstrated recently by the global concern
at the bird ﬂu and swine ﬂu outbreaks in 2004 and 2009 respectively, and historically by
the Spanish ﬂu pandemic which caused the death of 27 million people[209]. Furthermore,
the ﬂu is estimated by the WHO to kill 250,000-500,000 people worldwide every year, out
of 3-5 million severe cases[210].
Various groups have successfully functionalised MNP with inﬂuenza viral antibodies,
for the purpose of diagnosis by viral enrichment from blood samples - a sample is taken
from the patient, incubated with functionalised MNP, and enriched through bench-top
magnetic separation. Current diagnosis techniques, which include RT-PCR and antibody-
based assays, are insuﬃciently sensitive, unable to diﬀerentiate between particular strains
and cumbersome.
Sakudo et al. used 300nm diameter ferrite MNP functionalised with the anionic poly-
mer poly(methyl vinyl ether-maleic anhydride) to magnetically label the avian ﬂu viruses
H5N1 and H5N2[143]. Chou et al. used ca. 100nm diameter Fe3O4 MNP functional-
ised with subtype speciﬁc monoclonal antibodies, which successfully conjugated to H5N2
(but not H5N1). The group further suggests that hemagglutinin and nuraminidase, both
abundant glycoproteins on the surface of inﬂuenza viruses, could be used as general in-
ﬂuenza targets[144]. More recently, Hung et al. used 100nm manganese ferrite MNP
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functionalised with anti-inﬂuenza A nucleoprotein monoclonal antibodies to sucessfully
label H1N1[145].
This research conclusively demonstrates that antibody functionalised MNP can be
used to target the inﬂuenza virus, and it's removal from a patient should result in signi-
ﬁcant clinical beneﬁts, particularly if combined with antiviral pharmaceutical treatments.
Speciﬁc subtypes can be targeted, but for the purposes of virus removal from the blood-
stream, a general MNP which targets all subtypes, for example by binding to hemagglu-
tinin, would be preferable. In conclusion, the magnetic removal of inﬂuenza viruses from
the bloodstream could be a very promising application of the haemoﬁlter.
2.5.3 Hepatitis
Hepatitis (Hep) viral infections are responsible for over a million annual deaths from liver
disease cause by the virus; there are hundreds of millions of chronic hepatitis infections
globally[211]. Seveal research groups have investigated the use of functionalised MNP to
target the virus, usually to provide a new highly sensitive diagnostic tool.
One of the main studies, by Uchida et al., targets Hep A, B and C with MNP func-
tionalised with polyethyleneimine (PEI)[146]. PEI conjugated MNP have in fact been
reported to bind to several viruses (see section 2.5.4)[212]. Uchida's group demonstrated
that the PEI-MNP successfully bound to and concentrated Hep A and Hep C viruses,
but was less eﬀective against Hep B; concentration was however successfully achieved
by adding an anti-Hep B immunoglobulin-M antibody. Meanwhile, Yassin et al. have
successfully targeted Hep C using MNP coated with protamine hydrochloride, claiming
a 100% binding eﬃciency[147]. Arkhis et al. achieved similar results on Hep B and G
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using magnetic latex microparticles[213]. Leary et al. have used magnetic microparticles
functionalised with speciﬁc monoclonal antibodies to target and purify Hep C[148], while
Ko et al. avoided the use of expensive antibodies by using lectin bound MNP to target
Hep A[149]. Several other groups have successfully targeted hepatitis DNA and RNA
using MNP functionalised with speciﬁc antibodies or streptavidin[214, 215, 216].
The possibility of targeting hepatitis viruses with functionalised MNP has been con-
clusively demonstrated for the purposes of puriﬁcation. It should be feasible to use some
of these methods to extract viruses directly from the bloodstream. It should be noted
that PEI-MNP may not be suitable for this application due to the lack of speciﬁcity and
PEI's toxicity[217], but several groups have demonstrated that the method works just as
well using antibodies (although it is likely more expensive).
No group has suggested that hepatitis patients could be treated by extra-corporeal
removal of viruses. In order to be eﬀective, the technique would face similar challenges
to the magnetic separation of HIV from the bloodstream (see section 2.5.1). However,
if it could be both clinically and economically viable, it is one of the applications with
the highest potential human impact, treating millions and saving the lives of hundreds of
thousands.
2.5.4 Other viruses
In addition to HIV and inﬂuenza, a large number of other viruses have been targeted
using MNP, including yellow fever, dengue and herpes[215, 218, 219]. Indeed, thanks to
the ability to conjugate speciﬁc antibodies to MNP as well as the possibility of binding
speciﬁc DNA or RNA, almost any virus could be targeted using MNP. It may even be
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possible to synthesise generic MNP which target many diﬀerent viruses, although its lack
of speciﬁcity could cause problems due to the unwanted separation of non-viral bodies
from the bloodstream.
These techniques raise the possibility of using magnetic haemoﬁltration as a method
to treat all viral infections, possibly using the haemoﬁlter in combination with anti-viral
medication. The advantages of this technique are the same as in other applications: a
drug-free treatment prevents the evolution of drug resistance, and avoids or minimises
unwanted side-eﬀects. There is also the possibility of treating patients whose virus can
be targeted, but against which there is no drug treatment.
There would be signiﬁcant challenges in developing such a treatment, and many un-
answered questions:
 How many virions are circulating freely in the bloodstream, available for separation?
 How many of them would need to be removed to achieve a clinical beneﬁt?
 Considering that it would be impossible to remove 100% of the infection, would the
disease always relapse?
 Bearing in mind the signiﬁcant cost of MNP and antibodies, could any of these
methods ever be cost-eﬀective?
Despite the signiﬁcant diﬃculties that need to be overcome, the treatment of viral infec-
tions through MNP haemoﬁltraion could be a valuable new therapeutic tool in the long
term. The chaos caused by the recent re-emergence of viruses such as SARS, bird ﬂu,
swine ﬂu and ebola underlines the potential need for radical new methods of ﬁghting vir-
uses. Generic MNP could be developed, approved and appropriate for functionalisation
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with any antibody. This would enable the very rapid development of novel treatments as
a response to a new viral outbreak.
2.6 Conclusions
This Chapter provides a small snapshot of the wealth of research that is going into the
magnetic labelling of agents using MNP or magnetic beads. Magnetic separation is already
an invaluable clinical technique, used principally for the benchtop puriﬁcation of agents
to improve the sensitivity of detection methods and improve diagnoses. However, there is
clearly also a much wider future for magnetic separation for novel treatment and diagnostic
techniques.
In some areas, such as rare cells and viruses, the research is focussed almost exclus-
ively on diagnosis. However, several research groups have already proposed speciﬁc and
general therapeutic applications for magnetic haemoﬁltration within an extra-corporeal
loop, namely in the areas of malaria, kidney disease, blood detoxiﬁcation and sepsis. All
of these applications, should they be realised, could save a huge number of lives through-
out the world. In most cases, haemoﬁltration is proposed as a complement to existing
therapies: antimalarials, dialysis or antibacterials. However, all also promise something
new, such as the ability to treat drug resistance or remove radioactive particles.
The most promising application is arguably as a treatment for sepsis. It is a disease
which aﬀects millions and kills hundreds of thousands throughout the world. It's impact
in the developed world is high and growing, demonstrating not only the need for new
treatments, but also the commercial potential of those treatments should they be viable.
Magnetic haemoﬁltration holds a number of potential advantages over antibacterials, as
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it does not require diagnosis of the sepsis-causing pathogen, and is immune to the res-
istance that can plague antibacterials. It is no understatement to say that a cocktail of
biocompatible MNP able to target 99% of sepsis-causing pathogens, combined with an
eﬀective and eﬃcient magnetic haemoﬁlter, could revolutionise healthcare.
Despite this potential, there is no extra-corporeal HGMS currently in use or com-
mercially available. This could be due to a number of factors, not least the diﬃculty
in developing the MNP or beads appropriate for extra-corporeal use: these need to be
eﬀective, approved by the relevant bodies (e.g. FDA), and aﬀordable; each is a signiﬁcant
challenge. Those who have proposed extra-corporeal magnetic haemoﬁlters have focussed
on microﬂuidic devices, which have their own complications. While they can be eﬀective
separators, they can be very expensive to manufacture and diﬃcult to scale up. Flow
rates are particularly challenging - these applications will have to be capapble of ﬁltering
many litres of blood within an acceptable time-frame.
Magnetic haemoﬁltration is clearly a technology with a lot of potential far beyond
malaria. It is impossible to predict which, if any, of the potential applications presented
in this Chapter will be clinically successful, or what new applications may be developed
in the future. There is still a lot of work to be done, most of which will focus on the
development and approval of appropriate magnetic particles, but some of which must
focus on the development of the haemoﬁlter technology. The development of speciﬁc
haemoﬁtlers for each application would be an ineﬃcient expenditure of time and resources.
Ideally, there will be a single, ﬂexible haemoﬁlter appropriate for use with any magnetic
particles and in any application, enabling these and other new clinical techniques to reach
the bedside as quickly as possible. The aim of this project is to create that haemoﬁlter.
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Chapter 3
Design and Construction of Haemoﬁlter
3.1 Introduction
This section describes the process and results of designing and manufacturing the pro-
totypes that were used to establish whether a magnetic haemoﬁlter for the treatment of
malaria was feasible. The objective was to design a prototype which could be manu-
factured in-house and used on a variety of diﬀerent malaria infected blood samples. The
experiments (described in section 4) required an apparatus that was able to ﬁlter a variety
of diﬀerent sample volumes at controllable ﬂow rates.
From the start of the project, the intention was to design a device that was usable and
eﬀective in a clinical environment. Any experiments that were conducted therefore needed
to be representative of a clinical scale version of the device, avoiding a scenario in which
a scaled-down version functioned correctly but was impossible to scale up. Furthermore,
a clinical scale version has requirements beyond simply `able to remove malaria infected
red blood cells'. While it must be eﬃcient and ﬁt for use, it must also be easy to use and
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function quickly and safely. As the device will be used in malaria endemic countries, its
design must also be simpliﬁed as much as possible so that it is cheap to manufacture and
use.
In order to ensure that any testing or experiments were conducted on a prototype
representative of a clinical scale version, the latter was designed ﬁrst, and then scaled
down to enable benchtop testing. The scale down was necessary due to the challenges in
obtaining large volumes of malaria infected blood - a clinical scale version may have a total
volume of 100ml, which would have been logistically, economically and ethically unsuitable
for a benchtop version - there is no reason to ask malaria patients for donations of several
hundred ml of blood, when much smaller sample sizes are suﬃcient to investigate whether
the device works. The benchtop experiments were to be conducted using samples of 10ml
and above, so the scaled down prototype needed to be small enough for the sample to be
passed through the separation chamber to enable a measurement of the ﬁnal parasitaemia
to be made.
For simplicity, this section presents the design of the separation chambers and magnetic
assembly as if the chambers were designed ﬁrst, and the magnetic assembly designed to
ﬁt around them. In reality, both were designed simultaneously in order to integrate well
together. At the start of the design process, some features had already been decided on:
 The separation chambers would be manufactured in plastic, to enable the 3D print-
ing of prototypes for experiments.
 The ferromagnetic mesh within the chambers would be SS430 stainless steel, with
wire diameter of 50µm and aperture size 250µm. This was the ﬁnest ferromagnetic
mesh that could be aﬀordably sourced within the UK in small volumes.
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 The magnetic assembly would consist of an arrangement of block neodymium iron
boron (NdFeB) magnets. This was considered ideal because permanent magnets
generate very strong magnetic ﬁelds without using any power. Furthermore, block
magnets are generally cheaper than other shapes since they are easier to manufac-
ture.
 The separation chamber would be placed as close as possible to the surface of the
magnets in order to be in the area of highest ﬁeld strength.
 The magnetic assembly constructed in order to test the device would be as close as
possible a representation of the ﬁnal clinical version, but the separation chambers
would be scaled down to allow testing on small volumes.
Finally, it was accepted that it was probably not possible to ﬁnd the optimal separation
chamber dimensions. These were therefore designed to be easily modiﬁable, so that it
would be easy to tweak the dimensions and design while maintaining the overall idea.
For applications beyond malaria (such as those mentioned in section 2), a magnetic
haemoﬁlter would need to include a magnetic particle mixing chamber as well as a HGMS.
In this chamber, a high number of collision events between the magnetic particles and the
targets would be achieved through the actuation of the particles, for example by creating
a `magnetic swarm', wherein the particles are agitated in all directions using an external
magnetic ﬁeld, or causing the formation of rapidly rotating chains of magnetic particles.
One way of achieving this would be through a rotating array of permanent magnets, or
a series of electromagnets activated in turn similarly to a motor. Since the focus of this
thesis is on malaria, which does not require a mixing chamber, potential designs for these
are not included in this chapter.
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3.1.1 Required speciﬁcations
The haemoﬁlter needs to be eﬀective, safe, and usable if it is to be a viable medical device.
It must be as simple to manufacture and use as possible, and the design should therefore
avoid any unnecessary complexities. The identiﬁed key speciﬁcations were:
 High eﬃciency (>90%), capturing the maximum number of haemozoin containing
infected cells that pass through the separation chamber.
 High speciﬁcity (>90%), ensuring that only infected cells are captured while healthy
cells and other blood components pass through unaﬀected.
 High throughput, so that total time to reduce the parasitaemia to the target value
is as short as possible.
 Able to incorporate diﬀerent chamber types into the instrument (e.g. small, medium,
large), to allow consumables intended for infants, children or adults to be used on
any instrument.
 Controlled, consistent ﬂow rates that can be varied for diﬀerent patients or chamber
sizes.
 No harm caused to other blood components and risks to patient minimised to con-
form with regulatory requirements.
 Intuitive and easy-to-use user interface (UI) with an automatic mode, in which only
the chamber type and patient weight needs to be inputted, and a manual mode,
in which the clinician can control parameters such as the ﬂow and total volume
addressed.
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 Consumables cheap to manufacture, keeping the cost per treatment to a minimum.
Many of these speciﬁcations are required for a ﬁnal product, but not for a proof-of-concept
prototype. Therefore, the design of the separation chamber is much more important than
the design of the instrument. In short, the separation chamber provides the performance,
whereas the instrument provides the functionality. The separation chamber, combined
with the magnetic assembly, determines whether infected cells are captured, the eﬃ-
ciency, and the throughput. It will also be responsible for any negative eﬀects on other
blood components. The design process therefore focussed on the separation chamber
and magnetic assembly, with the intention of including features such as the UI once a
proof-of-concept had been produced.
3.1.2 Volumes and ﬂow rates
One critical requirement of the device is its ability to treat a patient within an acceptable
time-frame (i.e. a few hours). The total treatment time depends on three key factors:
1. The ﬂow rate
2. The separation eﬃciency
3. The desired total reduction in parasitaemia
It is important to remember that if the separation eﬃciency of the device is 90%, more
than the total blood volume (TBV) of the patient needs to be ﬁltered in order to achieve a
total parasitaemia reduction of 90%. This is because as the treatment progresses and the
patient's parasitaemia decreases, the device is removing fewer infected cells per minute.
This eﬀect is illustrated in Fig. 3.1, which shows that for two adults with a TBV of 5l,
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Figure 3.1: Parasitaemia reduction by device assuming a separation eﬃciency of 90%
in a single pass, 2% initial parasitaemia, and 5l TBV
with initial (removable) parasitaemias of 2% and 8%, and treated with a device with a
separation eﬃciency of 90%, 12.8l of blood need to be ﬁltered to reduce their parasitaemia
by 90%. Note that the percentage reduction in parasitaemia occurs at the same rate for
both patients, regardless of initial parasitaemia (although naturally the patient with a
higher initial parasitaemia will need to have more blood ﬁltered in order to reach the
same ﬁnal parasitaemia). To reach a parasitaemia reduction of 99%, 25l of blood need
to be ﬁltered. If the device's eﬃciency is 99%, 11.6l need to be ﬁltered to get a 90%
reduction in parasitaemia, and 23.2l need to be ﬁltered to get a 99% reduction.
It should be noted that the model for Fig. 3.1 is simpliﬁed - it calculates the reduc-
tion in steps of 25ml, assuming a constant separation eﬃciency and assuming that the
parasitaemia reduction is immediately spread throughout the body (i.e. each incremental
step has a slightly lower parasitaemia). In reality, the reduction may be faster, or in-
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deed slower, if the separation eﬃciency has a strong dependence on initial parasitaemia.
However, it serves to communicate two important messages:
1. Much more than TBV needs to be ﬁltered for the total parasitaemia to be reduced
by the same percentage as the separation eﬃciency.
2. The separation eﬃciency of the device has a limited eﬀect on total treatment time.
If the target parasitaemia reduction is 90%, increasing the separation eﬃciency from
90% to 99% only reduces the treatment time by 6% (11.6l ﬁltered vs. 12.8l).
This underlines the importance of the ﬂow rate in terms of achieving results within an
acceptable time-frame. It is expected that a higher ﬂow rate will lower the separation
eﬃciency by increasing the drag force (see Eq. 1.2), so the right balance between the two
will need to be found. However, priority should be given to the ﬂow rate, and this can
easily be illustrated with the model used in Fig. 3.1.
Fig. 3.2 shows the rate of parasitaemia reduction from an adult (initial parasitaemia
2%) for two theoretical ﬁlters: one with a ﬂow rate of 120ml/min and separation eﬃciency
of 80%, and one with a ﬂow rate of 60ml/min and a separation eﬃciency of 99%. The
model assumes that the device captures 80% or 99% of the infected cells that pass through
device and subtracts the captured cells from the total number of infected cells, moving
in steps of 25ml. So in the case of the the ﬁrst ﬁlter, 80% of the infected cells in 25ml
of blood are removed from the patient in each step, with each step corresponding to 12.5
seconds. For the second ﬁlter, 99% of the infected cells in 25ml of blood are removed per
step, with each step corresponding to 25 seconds.
The ﬁrst ﬁlter is superior, achieving a 90% reduction in overall parasitaemia within two
hours. Fig. 3.2 underlines why the low ﬂow rates from the studies discussed in Chapter 2
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Figure 3.2: Reduction in parasitaemia for two theoretical ﬁlters: one operating at
60ml/min with a separation eﬃciency of 99%, and one operating at 120ml/min with a
separation eﬃciency of 80%
are crucial to increase in order to create a viable medical device. A core design objective
of the haemoﬁlter is therefore to achieve acceptable separation eﬃciencies at high ﬂow
rates, prioritising the latter over the former.
3.1.3 Design process
The process followed or order to produce the prototypes was the following:
1. Establish the maximum total volume that a clinical scale device could have, by
looking at existing dialysis circuits and other extra-corporeal loops.
2. Create a separation chamber design with a large surface area, enabling maximum
ﬂow rates with low drag forces.
3. Ensure the design could achieve reasonably homogeneous ﬂow across its cross-
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section.
4. Design an assembly of permanent magnets to create the maximum possible magnetic
ﬁeld throughout the device, while ensuring that it is cheap and easy to build by
avoiding complex magnet arrangements.
5. Model the magnetic ﬁeld and forces within the device, to provide an estimate of the
ﬂow rates that could be utilised.
6. Source a ﬁne ferromagnetic mesh appropriate for use within the separation chamber.
7. Scale down the clinical design to a smaller volume, while maintaining the magnetic
forces and chamber length (i.e. on average a cell travels the same distance in the
small scale chamber as in the larger scale).
8. Construct the magnetic assembly at clinical scale, so that the magnetic ﬁeld that is
used in the experiments is the same as would be used in a clinical device.
9. Devise a cost-eﬀective manufacturing process using 3D printing, to give the capab-
ility to make the number of chambers required for the experiments.
The result of this process was an apparatus suitable for bench-top testing. The magnetic
forces in the small scale prototypes would be the same as in the clinical scale design, while
the ﬂow rates could be controlled so that the drag forces would also be the same as in the
clinical version. The theory is that the separation eﬃciency depends overwhelmingly on
these two forces (see section 1.1.2) so the results using the small scale prototypes should
be representative of what could be achieved using the clinical scale design. The prototypes
are essentially `cut-outs' of the clinical version, with the volumetric ﬂow rate adjusted to
achieve the same linear ﬂow rate (i.e. drag force) as the clinical scale version.
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3.1.4 Magnetic modelling
In order to assess the quality of the designs, the magnetic modelling software Opera
Vector Fields V16 (Cobham Technical Services, Oxford, UK) was used. This software
is able to calculate the magnitude of magnetic ﬁelds across a 3D space. A CAD model
is ﬁrst built and meshed in the modeller; this includes all objects and their magnetic
properties, provided through BH curves (see section 1.3 for information on BH curves).
The model is then processed using the TOSCA analysis for static models, which calculates
the ﬁelds generated by any permanent magnets and any distortions caused by magnetic
material within the model. The magnetic ﬁeld data can then be visualised within the
post-processor.
Opera Vector Fields was used to model the magnetic ﬁelds generated by diﬀerent
arrangements of permanent magnets in order to design the magnetic array. This enabled
not only the best magnetic arrangement, but also an analysis of any weak areas in the
ﬁeld generated, and the degree to which the ﬁeld varied within the assembly. The software
can also be used to model the eﬀect that the ferromagnetic mesh has on the ﬁeld.
One complication is that the mesh is orders of magnitudes smaller than the magnetic
array - the diﬀerent array designs had dimensions of tens of millimetres, whereas the area
of interest with respect to the mesh is of the order of microns. The software was unable
to manage such a degree of complexity and variance in size within a single model. The
data from the magnetic array was therefore inputted into a second model as a constant
background ﬁeld, so that the eﬀect of the mesh could be investigated. The results could
then be used to estimate the magnitude of the magnetic force on an infected cell using
Eq. 1.10.
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Figure 3.3: Approximate maximum blood volume in extra-corporeal loop for diﬀerent
weights and ages[6, 7]
3.2 Design of the consumables
3.2.1 Volume
The primary design constraint for the separation chamber is the volume of blood that can
be taken out of a patient without causing any harm or discomfort. This is well established
in the ﬁeld of nephrology at 8% total blood volume[6]. Total bood volume is typically
taken to be 80ml/kg, so the average adult (65kg) will have about 5 litres of blood. This
gives a maximum volume within the blood circuit of 400ml. However, a more sensible
limit is probably not more than 200ml, particularly considering the fact that malaria
patients frequently suﬀer from anaemia. In any case, 200ml is likely to be easily suﬃcient
to achieve the aims of the haemoﬁlter.
For children, who in the case of malaria are likely to make up the majority of patients,
the situation is more complicated. Fig. 3.3 shows a graph of approximate maximum
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blood volumes that can be taken out of a patient with diﬀerent total blood volumes and
ages. This shows that for an infant under 12 months of age, the total extra-corporeal loop
volume may need to be as low as 30ml. This increases to 45ml for a one year old, 70ml
for a three year old, and 115ml for a ﬁve year old.
As a result, several diﬀerent separation chamber volumes will be required in the ﬁnal
product. Assuming the tubing occupies a total volume of 10ml, the separation chambers
will need to range from `infant' (20ml), through `small' (60ml) and `medium' (100ml), to
`adult' (180ml). Occasionally, several of these chambers could be used in parallel to aﬀord
further ﬂexibility to clinicians. As the chambers will be ﬁlled with stainless steel mesh, a
certain proportion of the volume will be occupied by the mesh - up to approximately one
third. As such, a chamber designed for 60ml of blood may actually have a total volume
of 90ml.
3.2.2 Surface area
It is desirable for the ﬂow rate achievable through the device to be as high as possible,
in order to achieve rapid parasitaemia reduction and to minimise the treatment time.
The ﬂow rate is dictated primarily by the drag force described in Eq. 1.2, since it is not
possible to control the magnetic force. Higher ﬂow rates can therefore be increased by
maximising the surface area across which the blood ﬂows - a higher ﬂow rate across a
higher surface area corresponds to the same drag force.
As such, given a rectangular chamber, for example, the direction of ﬂow will determine
the linear ﬂow rate and thus the drag force. Consider, for example, the 20x10x5cm box
shown in Fig. 3.4. It has a volume of 1 litre, so if we ﬂow 1 litre of liquid through it
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Figure 3.4: Example box to demonstrate eﬀect of ﬂow direction on drag force
at 100ml/min, it will take 10 minutes for the liquid to pass through, regardless of the
direction of ﬂow. If the liquid is ﬂowed through from the front, the linear ﬂow rate will
be:
flinear =
fvolume
A
flinear =
100
50
= 2cm/min
However, if the liquid is ﬂowed from the bottom up through the top, the area A is
four times larger, so the linear ﬂow rate (and hence the drag force) is four time lower.
Hence despite ﬁxed chamber dimensions and volumetric ﬂow rates, the drag force can be
minimised by changing the direction of ﬂow. A consequence of this is that if one was to
design a chamber with a volume of 125ml, for example, the optimal dimensions would
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not be 50x50x50mm, but rather something like 125x10x10mm, with the direction of ﬂow
through the 125x100mm surface.
One caveat to this is that this method reduces the `ﬂow path length', or in other words
the number of layers of ferromagnetic mesh through which a cell travels. In our example,
it is reduced from 50mm to 10mm. When designing the chambers, the intention was
thus to minimise the drag force while maintaining a suﬃcient ﬂow path length. This was
chosen to be at least 100 layers of mesh, corresponding to approximately 30mm.
3.2.3 Orientation of mesh
The orientation of the mesh within the separation chamber is an important consideration
for two reasons:
1. Ferromagnetic wires magnetise diﬀerently depending on their angle with respect
to the magnetic ﬁeld. If the wire is aligned in the same direction as the ﬁeld, it
will become magnetised along its length, and not generate the desired local ﬁeld
gradient. However, if it is at 90º to the ﬁeld direction, it magnetises across its axis,
creating the strong local ﬁeld. This is demonstrated in Fig. 3.5, which shows how
a 50µm wire aﬀects a background magnetic ﬁeld of 250,000A/m (equal to 0.31T,
using Eq. 1.6). The force generated when the ﬁeld is parallel to the wire (Fig. 3.5b)
is essentially zero as there is no gradient. However, when the ﬁeld is perpendicular
to the wire (Fig. 3.5a), the ﬁeld is accentuated close to the wire, increasing to nearly
0.6T on the wire's surface (Fig. 3.6).
2. It is desirable for the blood to ﬂow through the apertures as much as possible. This
ensures that each cell is forced to pass close to the magnetised wires at every single
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(a) Field perpendicular to wire (b) Field parallel to wire
Figure 3.5: Eﬀect of 50µm SS430 stainless steel wire on a 0.3T background magnetic
ﬁeld (note that the magnetic ﬁeld within the wire has been hidden for clarity; it has no
eﬀect on the magnetic force on an object near the wire)
mesh layer, increasing the likelihood of capture. If the direction of ﬂow tends to be
between the layers of mesh, rather than through them, escape channels are more
likely to form.
The conclusion from these points is that the mesh should be layered perpendicular
to both the magnetic ﬁeld and the direction of ﬂow, which should therefore be in the
direction of the magnetic ﬁeld. The ﬁeld created by such an arrangement is shown in Fig.
3.7. If the ﬁeld was parallel to the mesh, one set of wires would still be perpendicular,
but the other half would behave as in Fig. 3.5b, thus reducing the capture area by half.
One ﬁnal option is to have the ﬁeld parallel to the mesh, but diagonal to both sets of
wires. However, as shown in Fig. 3.8, the wires do not magnetise diagonally but along
their length, due to magnetic anisotropy: the wires prefer to be magnetised along their
length due to the favourable interaction of the internal magnetic dipoles. This eﬀect is
demonstrated by the vectors displayed along the wires.
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Figure 3.6: Magnetic ﬁeld from the surface of one of the wires of the ferromagnetic
mesh, in the direction of the magnetic ﬁeld (i.e. perpendicular to the wire)
(a) Field variation above and below constituent
wires
(b) Field 10µm above mesh
Figure 3.7: Magnetic ﬁeld perpendicular to stainless steel mesh, with background ﬁeld
of 0.3T
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Figure 3.8: Magnetisation and magnetic ﬁeld generated with background ﬁeld at 45º
to mesh
Thus the arrangement in Fig. 3.7 generates the largest overall `capture areas' as well
as the highest magnetic force. Eq. 1.10 shows that for a given magnetic agent, the force
depends on the ﬁeld times the ﬁeld gradient. A simple calculation using the data in Fig.
3.6 gives:
B∇B = 0.516 (Tesla) ∗ 1.43× 104 (Tesla/m)
= 7.38× 103 (T 2/m)
for B∇B 5µm from the wire in the case of a perpendicular ﬁeld. As a comparison, the
ﬁeld generated by a a single 50x25x10mm NdFeB block magnet, capable of holding 32.2kg
of steel (according to the supplier, First4Magnets, Tuxford, UK) is shown later in Fig.
3.19. B∇B 1mm from the magnet in this case is:
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B∇B = 0.215 (T ) ∗ 11.11 (Tesla/m)
= 2.39
(
T 2/m
)
In other words, the magnetic force on a given malaria infected cell at a distance of
5µm from one of the wires in Fig. 3.7 is 3,088 times greater than at a distance of 1mm
from what would be considered a very powerful permanent magnet.
As a ﬁnal point, having the mesh stacked at a right angle to the ﬁeld creates `vertical'
capture areas above and below the wires. These areas, as they ﬁll up with captured cells,
avoid the higher drag forces that are present within the aperture.
3.2.4 Design of chamber
The instinct when designing a ﬂow chamber is to design a cylindrical shape. The main
reason for this is that corners have a tendency to form dead zones in which there is no ﬂow.
However, in this case, it was decided that a rectangular box shape was more appropriate
for one primary reason: the ferromagnetic mesh needed to be cut to size. Not only is
the cutting of the mesh laboursome - over 100 are required for each chamber - but the
resulting pieces need to be consistently the correct size. This is particularly challenging
when cutting circles. A hole punch was designed and fabricated for this purpose, but was
not successful in cutting through the stainless steel. However, the mesh could relatively
easily be cut into rectangles using scissors or a paper guillotine.
Furthermore, the choice of having the direction of ﬂow and magnetic ﬁeld in the same
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Figure 3.9: Basic chamber design (dimensions variable depending on patient's TBV)
direction, both perpendicular to the layers of mesh, presents a design problem when
considering the inlet and exit. Assuming the chamber will be placed between two or
more magnets, the direction of ﬂow will be from one magnet towards the other. But the
inlet and exit cannot be `through' the magnets for a variety of reasons, not least that
one cannot drill holes through block magnets. The inlet and exit therefore need to be
on opposite sides of the chamber, at the top and bottom respectively, encouraging the
desired `bottom to top' ﬂow. This solution has the advantage of simplicity, enabling the
chamber to be easily inserted between magnets, and should provide approximately the
desired ﬂow proﬁle. However, it is inevitable that there is a sacriﬁce in terms of ﬂow
homogeneity throughout the chamber. This design is illustrated in Fig. 3.9.
With this basic design in place, the dimensions were worked out based on the diﬀerent
chamber volumes from section 3.2.1. The height was set at 30mm, which should allow
for over 100 layers of mesh to be be stacked - four layers of mesh were measured to
be approximately one mm in height. The walls were 3mm thick, giving a total height
of 36mm. For the `adult' version, a total volume of 180ml was deemed appropriate;
incorporating the fact that one third of the volume inside the separation chambers is
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(a) External (b) Internal (walls invisible)
Figure 3.10: Design of adult (180ml) separation chamber
taken up by the mesh, a total chamber volume of 240ml was required. With a height of
30mm, that leaves an area of 80cm2. The depth and width were chosen to be 50mm and
160mm respectively (Fig. 3.10).
Fig. 3.10a shows the chamber as it would appear, whereas Fig. 3.10b shows the shape
of the internal chamber (i.e. without the walls). The most signiﬁcant diﬀerence is that
the inlet and outlet are circular on the outside of the device, but long thin slits with a
height of 2.5mm on the inside. The idea is that, between the inlet and the slit, the ﬂow
is spread homogeneously across the whole width of the chamber (as described in section
3.2.5)
The dimensions of the design in Fig. 3.10 can easily be changed to change the chamber
volume. Using the chamber volumes from section 3.2.1, the following chamber dimensions
(width x depth x height) were used:
 `Medium' chamber (blood volume 100ml): 100x50x30mm (volume before mesh: 150ml)
 `Small' chamber (blood volume 60ml): 75x40x30mm (volume before mesh: 90ml)
 `Infant' chamber (blood volume 20ml): 40x25x30mm (volume before mesh: 30ml)
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Figure 3.11: Cross-sections of four chamber designs
All of these designs use the same height, and their respective cross-sections (across
which the blood ﬂows) are shown in Fig. 3.11. The areas of the cross-sections are 10cm2,
30cm2, 50cm2 and 80cm2 respectively. This means that, in order for the drag force to be
the same in all the chambers (and assuming that the ﬂow is homogeneous throughout all
the chambers), the volumetric ﬂow rate will need to be eight times slower in the infant
version than in the adult version, and three time slower than in the small version (and so
on). This should not have signiﬁcant implications in terms of treatment times - a patient
using the adult chamber is projected to have about 20 times the total blood volume of an
infant. Indeed, despite the lower ﬂow rates, a child will likely be cleared of their infection
much faster than an adult.
3.2.5 Homogenising ﬂow
The biggest challenge of the designs based on Fig. 3.10 is to achieve a homogeneous ﬂow
across both the width and the depth of the chamber, particularly for the adult version.
To investigate this, ﬂow dynamics experts from The Fluid Group were consulted, and
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Figure 3.12: Design of ﬂow homogeniser (produced by The Fluid Group)
(a) Cross-section showing ﬂow proﬁle (b) Linear ﬂow rate at exit
Figure 3.13: Flow of liquid through ﬂow homogeniser (produced by The Fluid Group)
suggested that a ﬂow homogeniser could be used to split the ﬂow evenly from a tube to
the 2.5mm slit. Jim Wicks from The Fluid Group (Oxford, UK) proposed the design
shown in Fig. 3.12, which he has graciously donated to this project and is reproduced
with their permission. Their computational ﬂow dynamics (CFD) modelling shows that
the ﬂuid is evenly distributed across the width of the slit upon exit (Fig. 3.13).
In terms of homogenising ﬂow across the depth of the chamber, this is achieved in
large part thanks to the mesh. Upon entry into the chamber, there is a 2-3mm space in
which there is no mesh. The pressure required to travel through the mesh encourages the
liquid to ﬂow deeper into the chamber before ﬂowing upwards. In addition to this, having
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Figure 3.14: Probable dead zones in chambers
the outlet on the opposite side of the chamber encourages a more even ﬂow across the
width.
Despite these steps, some dead zones within the chamber are inevitable, and complete
ﬂow homogeneity will probably be impossible to achieve, particularly across the depth
of the chamber (Fig. 3.14). The important consideration concerning these dead zones is
the increased likelihood of blood clotting in these areas, and the diﬃculty in successfully
priming the chambers to ensure there is no air within them.
3.2.6 Scaled-down version
In order to test the design, small scale prototypes were designed, able to process volumes
as small as 10ml. This design followed the same principle as those in section 3.2.4, main-
taining the same height and simply scaling down the width and depth. The dimensions of
the scaled down version were 21x18x30mm, giving a total volume of 11.34ml, with inlet
and outlet internal diameters of 4mm and outer diameter of 8mm. The walls were 3mm
thick. They were designed in two parts, a chamber and a cap - the chamber could then be
loaded with the mesh and sealed with the cap. The design is shown in Fig. 3.15. Because
of the small size of the chamber, there are unlikely to be many problems in terms of ﬂow
inhomogeneity. Despite this, gradual smoothing of the tube into a slit `letterbox' shape
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Figure 3.15: Scaled-down chamber for use in experiments
(a) Inlet, with some walls of the model hidden to
illustrate structure
(b) Outlet in cap
Figure 3.16: Homogenising ﬂow in scaled-down chamber
was designed to even out the ﬂow across the width, as shown in Fig. 3.16.
The scaled-down chambers were designed to be 3D printed, so that a new one could
easily be manufactured for each experiment. Their manufacture is described in section
3.5.
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Figure 3.17: Magnetic ﬁeld on surface of
50x25x10mm NdFeB magnet
Figure 3.18: Magnetic ﬁeld generated by
50x25x10mm NdFeB magnet
3.3 Magnetic assembly
3.3.1 Design
In order to create a strong magnetic ﬁeld at an aﬀordable price, large commercial NdFeB
magnets were sourced from a commercial supplier (First4Magnets, Tuxfod, UK). The
objective was to ﬁnd magnets that could achieve a high magnetic ﬁeld over a large area,
with the highest possible strength to price ratio. The magnets that were chosen were N42
50x25x10mm rectangular blocks, magnetised in the direction of the 10mm axis, with a
pull of 32.2kg, costing ¿12.50 each.
Before they were purchased, the ﬁeld generated by the magnets was modelled in order
to ﬁnd the most eﬀective magnetic arrangement, generating a strong localised magnetic
ﬁeld that could accommodate the separation chamber. The magnetic ﬁeld generated by
a single block magnet is shown in Fig. 3.17 and 3.18. It generates a magnetic ﬁeld of
225mT close to its surface, with the ﬁeld strength dropping to 22mT 30mm away (Fig.
3.19).
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Figure 3.19: Magnetic ﬁeld generated by 50x25x10mm NdFeB magnet
Figure 3.20: Magnetic ﬁeld generated by two 50x25x10mm NdFeB magnets
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Placing two magnets side by side, 5mm apart and with opposing polar orientations
(Fig. 3.20) naturally increases the overall ﬁeld strength, particularly close to and between
the magnets where it is above 400mT. However, this arrangement is not suitable for the
magnetic assembly for two reasons:
1. The arrangement is not stable: the magnets attract each other very strongly, and
would need to be tightly held in position.
2. Stray ﬁelds : the magnetic ﬁeld is just as strong both sides of the magnets. For
safety reasons, it is desirable to `focus' the magnetic ﬁeld only within the working
area (i.e. the area in which the magnetic separation chamber is placed)
To overcome these problems, the magnets were placed on a steel back plate. Not only
does this hold the magnets in position by nature of their stronger attraction to the plate
than each other, but the plate also acts as a `magnetic conductor', as shown in Fig. 3.21,
due to the high magnetic permeability of steel. The magnetic ﬁeld behind the plate is
eliminated, while the ﬁeld in front of the magnets remains the same, or is even slightly
increased (Fig. 3.22).
Fig. 3.23 shows the magnetic ﬁeld in a circle around two blocks both with and without
a steel back plate. The circle on which the ﬁeld is measured is centred between the blocks
and has a radius of 35mm. 0◦ is therefore `behind' the magnets, 30mm from their surface,
while 180◦ is 30mm `in front' of the magnets (Fig. 3.23a and 3.23c). Fig. 3.23b shows
that the ﬁeld of 25mT is the same at the front of the magnets as it is at the back, as would
be expected. Fig. 3.23d however shows that adding a steel plate causes the ﬁeld to drop
to close to 0T at the back. Meanwhile, it is increased by 15mT to 40mT at the front. The
steel plate `focusses' the magnetic ﬁeld to the front, removing it from the back, an ideal
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Figure 3.21: Magnetic ﬁeld ﬂow through
steel back plate
Figure 3.22: Magnetic ﬁeld generated by
two magnets with steel back plate
result for the magnetic assembly where strong ﬁelds are required where the chambers will
be, with as few stray ﬁelds as possible (Fig. 3.24).
Putting two of these pairs of magnets with steel backs opposite each other so that
they are attracting each other, as shown in Fig. 3.25 and 3.26 further increases the
magnetic ﬁeld while keeping it conﬁned largely to the space between the two pairs of
magnets. The spacing between them can be varied to increase or decrease the magnetic
ﬁeld, with a minimum ﬁeld value at the halfway point. When 30mm apart, the magnetic
ﬁeld half-way between the two pairs was calculated to be 220mT at its peak, but 0T at its
minimum (Fig. 3.28). This compares to a maximum and minimum of 126mT and 57mT
respectively for a single pair (Fig. 3.27).
The four magnet arrangement thus has a magnetic ﬁeld with higher peaks, but much
lower troughs where the ﬁeld is close to or at 0T. However, closer to the surface of the
magnets, the magnetic ﬁeld becomes high throughout. Indeed, the central area with very
low ﬁeld halfway between the two pairs (i.e. 15mm from the surface of both) is actually the
area with the strongest ﬁeld 4mm from the surface in the same arrangement (Fig. 3.29).
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(a) Line on which ﬁeld was calculated (b) Without steel back plate
(c) Line on which ﬁeld was calculated (d) With 5mm thick steel back plate
Figure 3.23: Magnetic ﬁeld around two NdFeB block magnets
Figure 3.24: Stray magnetic ﬁelds generated by two pairs of magnets with steel back
plates
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Figure 3.25: Magnetic vector
orientations of two pairs of magnets with
steel back plates
Figure 3.26: Perpendicular magnetic
ﬁeld generated by two pairs of magnets
30mm apart
Figure 3.27: Magnetic ﬁeld 15mm from
and parallel to the surface of two block
magnets with a steel back plate
Figure 3.28: Magnetic ﬁeld parallel to
and halfway between two pairs of block
magnets with steel plates
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This ensures that, while there is an area of weak capture force in the centre of a chamber
placed between the pairs, there are no paths through the chamber with consistently low
magnetic ﬁeld.
This arrangement of four magnets with steel back plates is simple, easy and cheap to
assemble, generates strong magnetic capture forces, avoids escape channels, and is modi-
ﬁable. Not only can the distance between the two pairs be varied to either increase the
magnetic ﬁeld strength or allow for separation chambers with varying heights, but it can
also easily be expanded to increase the space available for the separation chambers. The
assemblies of four magnets can be placed in series alongside one another, accommodating
either several chambers or one larger chamber, as shown in Fig. 3.30. This magnetic
assembly, where each magnetic pair is separated from its neighbour by 5mm, is the one
that was built and used in the experiments described in Chapter 4. The magnetic ﬁeld
throughout this assembly when the two sides are separated by 30mm is shown in Fig.
3.31. Note that due to symmetry, the ﬁeld at 3mm is equal to the ﬁeld at 27mm, the ﬁeld
at 6mm is the same as at 24mm, and so on.
3.3.2 Frame and construction
Once the magnetic arrangement had been determined, the assembly was designed so
that the distance between the two sides of the assembly could be varied while ensuring
that they could not snap together. The frame holding the magnets was constructed out
of aluminium to ensure solidity (a ﬁrst plastic prototype quickly snapped) and avoid
modiﬁcation of the magnetic ﬁeld. Aluminium has a very low magnetic permeability so
any magnetisation is negligible.
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(a) Magnetic ﬁeld parallel to magnets
(b) Magnetic ﬁeld along line shown adjacent
Figure 3.29: Magnetic ﬁeld 4mm from surface of one pair of magnets
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(a) Vector orientation of magnets within assembly
(b) Magnetic ﬁeld 7mm from surface of magnets at bottom of assembly
Figure 3.30: Complete magnetic assembly, consisting of six pairs of 50x25x10mm
NdFeB magnets with steel backs
100
Figure 3.31: Magnetic ﬁeld within magnetic assembly, at diﬀerent distances from
magnet surfaces
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Figure 3.32: Constituent parts of each side of the magnetic assembly: aluminium
frame and three magnet pairs
Each side of the frame consisted of two parts designed to hold the magnets in position
and prevent any one pair with steel back plate from snapping to the opposite side of the
assembly. Indeed, it is of paramount importance that the magnets are all securely held
in position and there is no risk of them snapping together. Strong NdFeB magnets such
as the ones used in the assembly can crush ﬁngers caught between them. Once placed on
the steel plates, the magnetic attraction to the plate prevents any magnet from jumping
oﬀ said plate - using Opera Vector Fields, the force holding each magnet onto the steel
plate was calculated to be 119N. When two pairs were separated by 30mm, the force on
a single pair was calculated to be 45N; at 10mm however, it is 200N.
The parts which constitute each side of the assembly are shown in Fig. 3.32. To
prevent the pairs snapping together, the steel back plates were cut to a size of 65x50mm,
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Figure 3.33: Top and bottom of one side of the magnetic assembly after being
assembled
Figure 3.34: Completed magnetic assembly
providing a 5mm `lip' on each side which serves to hold the pairs within the frame.
Each pair was assembled individually, with the magnets carefully placed on them with
the correct positions and orientations. These were then placed in the ﬁrst part of the
aluminium frame, before the second part was placed on top (Fig. 3.33). The total size of
the frame was 210x75mm. This design enabled the surfaces of the magnets to be exposed,
so that the separation chambers could be placed within the area of highest magnetic ﬁeld.
The four holes of one side of the assembly were threaded to allow four threaded bars
to be inserted, which constitute the assembly's support structure. Nuts were then used
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to control the separation between the two sides of the assembly. The ﬁnal result is shown
in Fig. 3.34.
3.4 Forces within chamber
The magnetic modelling data can be used to calculate the magnetic force on a malaria
infected erythrocyte near a wire of the mesh. As per Eq. 1.4, the required variables are:
 χmol, the molar magnetic susceptibility of haemozoin. This taken to be 11 ×
10−3ml/mol = 11× 10−9m3, according to Moore et al. [5].
 Nmol, the quantity of haemozoin in an infected cell. This was taken from the data
shown in Fig. 1.5, also from Moore et al. [5].
 B and ∇B, the magnetic ﬁeld and gradient respectively. These were taken from
the modelling data in Fig. 3.6. 10µm from the wire, these are B = 0.455T and
∇B = 11.4× 103T/m.
These data are combined to give the magnetic force on infected cells at diﬀerent times after
parasite infection of the cell. It should be noted that these values correspond essentially
to the `trapping force' holding a cell onto a wire. The force further away from the wires of
the mesh is much lower, decreasing to almost zero due to the lack of a ﬁeld gradient (see
Fig. 3.7). Taken as it is at 10µm from directly above or below a wire, a cell essentially
needs to collide with a wire to feel these forces, which are among the strongest within the
separation chamber.
Using Eq. 1.2, the magentic forces felt by infected erythrocytes can then be compared
with the drag force for diﬀerent ﬂow rates through the benchtop version. The variables
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used in these calculations were:
 R, the radius of an erythrocyte. This value is an approximation - the Stokes drag
force applies to spherical objects, while red blood cells are more disc-like. How-
ever, the formula is an acceptable approximation, and the radius was taken to be
4µm[220].
 µ, the viscosity. The viscosity of blood can vary widely and is particularly susecptible
to variations in haematocrit. Here, a typical normal value of 3.5 × 10−3 kg
m·s2 was
chosen[221, 222].
 The mesh was assumed to occupy 30% of the area of the cross-section of a chamber,
decreasing the area through which the blood could ﬂow and thus increasing the ﬂow
rate.
The results of these two calculations can be seen in Fig. 3.35, demonstrating that at
this position the magnetic force exceeds the drag force by a factor of 1,000. It is worth
noting that this is the strongest magnetic strength within the chamber, and it deceases
rapidly with increase distance from the wires of the mesh - by moving from 10µm distance
from the wire to 25µm, for example, the force decreases ﬁve-fold. The drag force, however,
remains constant throughout. This analysis demonstrates that most infected cells should
be magnetically retained within the separation chamber if they collide with a wire, even
those with very small haemozoin content.
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(a) Magnetic force on an infected cell 10µm from a wire within a separation chamber at diﬀerent times
after infection with a malaria parasite
(b) Drag force on a red blood cell at diﬀerent ﬂow rates in the separation chamber
Figure 3.35: Comparison of magnetic and drag forces felt by malaria infected red
blood cells within the scaled-down separation chamber. Note the diﬀerent force scales
between 3.35a and 3.35b
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Figure 3.36: Method utilised to 3D print prototype separation chambers
3.5 Manufacture of small scale prototypes
3.5.1 3D printing
The ﬁrst manufacturing step was to produce the chambers described in section 3.2.6. The
two parts - the chamber and cap - were 3D printed in acrylonitrile butadiene styrene
(ABS). The steps that were taken in order to manufacture an object using a 3D printer
can be seen in Fig. 3.36 and are described in more detail below.
The model is ﬁrst built using computer aided design (CAD) software as described in
section 3.2.6. The SketchUp STL extension was used to export the design in the .stl
ﬁle format, which contains information relating to the surface geometry of a 3D object
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Figure 3.37: Chamber and cap at completion of printing process
(i.e. excluding colour, texture, material or other features). It renders the model into a
triangulated mesh that can be read by a vast array of diﬀerent software. The .stl ﬁle is
checked for errors (holes in the mesh, for example) using NetFabb Studio Basic (netfabb,
Germany, http://www.netfabb.com/) and repaired if necessary.
The repaired .stl ﬁle is then imported into a `slicing' program. The opensource software
Slic3r (chief author: Alessandro Ranellucci, Italy, http://slic3r.org/) was used for
this project. The purpose of slicing software is to translate the 3D model into a series
of instructions for the 3D printer. .stl ﬁles are sliced into the .gcode format, essentially
a list of commands fed to the 3D printer in the form of x, y and z coordinates. .gcode
ﬁles can also include temperature commands telling the printer what temperature to heat
the material to before beginning the print. This is achieved by dividing the model into
layers of a given height, each layer with a set of coordinates telling the 3D printer where
to deposit material. There are a large number of diﬀerent settings that can be changed,
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including layer height, print speed, percentage inﬁll and inﬁll pattern - in order to save
material, the objects can be made partially hollow. Typically, the settings need to be
optimised for each print in order to get a reliable and reproducible print.
The .gcode is loaded onto the 3D printer. The method of doing this depends on the
printer in use, but many use SD cards plugged directly into the printer. The printer itself
is controlled either by a UI directly on the printer or using a computer connected via
USB. Before launching the print, the correct temperatures need to be set. The extruder
temperature will depend on the print material being used - typically it is around 180C for
PLA and 250C for ABS, but optimal settings can vary with material supplier and colour.
Some printers have heated beds on which the object is printed, or enclosed chambers in
which the temperature can be controlled. The bed needs to be cleaned and prepared
before the print is launched.
For this project, the opensource Mendel 90 (nophead, UK, http://hydraraptor.
blogspot.co.uk/2011/12/mendel90.html) was used with a heated carbon ﬁbre print
bed. Before printing, the bed is coated with an ABS/acetone solution, made by melting
ABS in acetone until the solution is saturated - visible because of the presence of solid
plastic bits at the bottom of the solution. A thin coat of `ABS juice' dried onto the surface
of the heated bed helps the ﬁrst layer of the print to adhere well to the print bed and
helps avoid failed prints and the problem of the edges of printed objects curling upwards,
a common undesirable feature of ABS prints.
In order to communicate with the printer, the opensource 3D printer controller soft-
ware Pronterface (chief author: kliment, https://github.com/kliment/Printrun) was
used to set the temperatures and, once they were reached, launch the print. The settings
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used to produce the chambers are detailed in 3.1. Each chamber and cap pair took about
one hour to print, and up to eight were produced at a time; Fig. 3.37 shows a chamber
and cap still on the printer bed at the end of a print.
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Table 3.1: 3D printing settings used in Slic3r
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Figure 3.38: Prototype chambers curing after application of hydrophobic coating
3.5.2 Hydrophobic coating
Once printed, the internal faces of the chambers and caps were coated with the silicone
elastomer Sylgard® 184 (Dow Corning, USA), a silicone based polymer known as polydi-
methylsiloxane (PDMS). The kit supplied consisted of a base and curing agent, which are
mixed at a ratio of 10:1. The mixture was applied manually using gloves, ensuring the
coating covered all areas. The coated chambers were then cured at 80ºC for at least 12
hours. For eﬃciency, this process was carried out on several chambers at the same time
(Fig. 3.38).
The purpose of the coating was to render the chamber's internal surfaces hydrophobic.
The edges of the chambers are the areas most likely to provide `escape channels' for cells.
Their ridged proﬁle which results from the 3D printing process, could also cause localised
dead zones and encourage clotting. Finally, the biocompatibility of the ABS utilised in
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Figure 3.39: Mesh stacked horizontally in chamber
the fabrication process was uncertain, so the PDMS coating served to protect the sample
and eliminate a variable that could potentially aﬀect the results.
3.5.3 Inserting ferromagnetic mesh
Once coated, the chambers were ﬁlled with SS430 stainless steel mesh (The Mesh Com-
pany, Warrington, UK). The mesh had a wire diameter of 50µm and an aperture size of
250µm and was purchased in large sheets which needed to be cut to size. The ﬁneness
of the mesh enabled it to be cut using scissors and a guillotine paper cutter. Each piece
was inserted into the chamber manually, with both horizontally and vertically stacked
versions made, in order to investigate if one or the other was more eﬀective (Fig. 3.39).
The mesh was packed tightly, with as few non-ﬁlled areas as possible. Once the chamber
was ﬁlled, the cap was placed and sealed in position using acetone, melting the ABS at
the interface between the chamber and the cap. The ﬁnal result can be seen in Fig. 3.40.
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Figure 3.40: Completed and sealed
prototype separation chambers (lines
represent direction of mesh stacking)
Figure 3.41: Separation chamber in
magnetic assembly
Figure 3.42: Disposable Blood circuit used for each treatment with the magnetic
haemoﬁlter. The pumps, air detector and pressure sensor are part of the instrument to
which the consumables are connected, and the separation chamber is placed within the
magnetic assembly
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3.6 The medical device
The medical device will comprise an instrument which drives functionality. It includes
the magnetic assembly presented in section 3.3, pumps, UI and safety mechanisms such
as the air bubble detector and pressure monitors. The consumables, blood circuits which
include the separation chambers presented in section 3.2.4, are simply connected to the
instrument and the patient. An example blood circuit including its interface with parts
of the instrument is shown in Fig. 3.42.
The inlet and outlet pressure sensors allow for monitoring of the patient's blood pres-
sure as well as the pressure within the separation chamber for safety reasons. In the case
of an unexpected variation in the patient's blood pressure to abnormal levels, the sys-
tem would shut oﬀ automatically. An increase in pressure within the separation chamber
would be indicative of saturation within the ﬁlter - the captured cells having caused a
blockage due to their gradual build up on the ferromagnetic mesh. Alternatively, high
pressure within the chamber could be caused by clotting.
The air detector will monitor for the presence of any signiﬁcant air bubbles, an import-
ant safety feature - air bubbles circulating within the bloodstream can cause pulmonary
embolisms. If any bubbles are detected, the device will automatically stop pumping. The
presence of some microbubbles may be inevitable, so the circuit will also include a system
for removing them. An eﬀective method would be the use of gas permeable plastic for all
or part of the tubing.
As with any extra-corporeal treatment, anti-coagulant will be required to ensure that
the blood does not coagulate within the device. This is essential for both safety reasons
and functional reasons. Firstly, blot clots can cause serious clinical side-eﬀects such as
115
embolisms and strokes, so it is essential to ensure that no clots are returning to the
patient's circulatory system. Secondly, clotting within the separation chamber could cause
blockages and inhibit the device's ability to capture target cells, reducing the eﬃcacy of
the treatment. In the case of malaria, the most sensible anticoagulant to use would be
heparin, since the hospital or clinic would need to provide the anticoagulant, and heparin
is the most aﬀordable and widely available anticoagulant.
In its normal mode, the instrument will automate the treatment, with only a few
essential inputs required by the user. The instrument then automatically calculates ﬂow
rates, total volume to be processed etc. An `expert' mode will also be provided, giving
more control to the user. The user inputs will be:
 Required:
 Patient weight
 Separation chamber version
 Central or peripheral cathetar
 Optional:
 Initial parasitaemia
 Flow rate
 Total treatment time or volume to process
 Target ﬁnal parasitaemia
The device will provide a number of outputs throughout the procedure to inform the user
of the current status of the treatment. These will include:
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 Current status (e.g. ﬁltering)
 Flow rate (for both blood and anti-coagulant)
 Current pressures - in loop and patient blood pressure
 Total volume ﬁltered
 Total treatment time and estimated remaining time
 Estimated current parasitaemia
The protocol for using the device will be as simple as possible, with much of it automated.
The protocol will be as follows:
1. Prepare device, consumables, patient and working area:
 Patient comfortable and ready (not neccessarily in a bed).
 User inputs provided when instrument asks for them.
 Saline and heparin ready.
2. Insert central or peripheral cathetar into patient.
3. Remove consumables from packaging and connect to device:
 Chamber locked within magnetic assembly.
 Heparin syringe loaded into syringe pump and connected to circuit.
 Saline bag connected to circuit.
 Tubes placed within persitaltic pump.
 Circuit connected to pressure monitor and air bubble monitor.
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4. Priming of the circuit (automated).
5. Connect circuit to cathetar.
6. Start treatment
At the end of the treatment, the circuit is disconnected from the patient and disposed in
a controlled manner. If necessary, the circuit may be cleared with saline at a controlled
rate to return all the blood in the circuit to the patient, preventing any unnecessary blood
loss.
3.7 Conclusion
In this section, the design of the magnetic haemoﬁlter has been presenting, outlining
the process that was employed to produce a design which meets the required speciﬁca-
tions from section 3.1.1. The main results of that process are the separation chambers and
magnetic assembly, which integrate together to create a system which generates high mag-
netic forces, allowing throughputs orders of magnitude higher than any of the magnetic
separators from the literature (see Chapter 2).
The haemoﬁlter has been designed to be cheap to manufacture and easy to modify,
allowing for easy optimisation for diﬀerent volumes or applications. Clinical-scale separ-
ation chambers appropriate for patients of any age have been designed so that the two
determiners of performance - linear ﬂow rate and magnetic force - are constant. A small-
scale chamber for benchtop proof-of-concept experiments was designed and manufactured
in-house using 3D printing, signiﬁcantly reducing product development costs[223].
The magnetic assembly is modular - two sets of a pair of NdFeB magnets with steel
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back plates can easily be added or removed. The distance between the magnets can be
changed at will, increasing or decreasing the magnetic ﬁeld in the separation chamber
area. The simple magnetic arrangement used results in low-cost, easy manufacturing
while ensuring a strong, focussed magnetic ﬁeld with near zero stray ﬁelds. A prototype
version was manufactured to enable benchtop testing.
In conclusion, the designs presented in this Chapter are simple, yet should be eﬀect-
ive. The main objective was to produce a magnetic haemoﬁlter which generates strong
magnetic forces and allowed high throughput with low drag forces. The designs not only
achieve that, but are also cheap to manufacture and easy to optimise. The magnetic
assembly and separation chamber designs presented in this Chapter are the underlying
foundations of the magnetic haemoﬁlter as a medical device.
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Chapter 4
Evaluation of Haemoﬁlter
4.1 Aims and methods
4.1.1 Aims
This Chapter presents the experiments that were conducted in order to evaluate whether
the designed haemoﬁlter from Chapter 3 could be eﬀective at capturing malaria infected
cells from a ﬂowing sample. In order to test the device, samples containing malaria infected
erythrocytes were passed at controlled ﬂow rates through the scaled-down version of the
device detailed in section 3.2.6. The parasitaemia of the initial sample was compared with
the ﬁnal sample's parasitaemia in order to investigate the degree to which the infected
cells were captured. The aims of these experiments were to:
1. Establish the maximum separation eﬃciency (percentage reduction in parasitaemia)
that can be achieved
2. Investigate how the ﬂow rate aﬀects the separation eﬃciency
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3. Investigate other variables that aﬀect the separation eﬃciency
4. Demonstrate that human samples show the same results as mouse samples, thus
validating the bench-top animal model, as well as demonstrating that the device
works on both P. vivax and P. falciparum
5. Quantify the infection stages (i.e. time since parasite has infected RBC) that are
successfully removed
6. Check for any adverse eﬀects on other components of the blood that might be caused
by the ﬁltration process
7. Investigate degree of false positive capture
4.1.2 Giemsa staining
The parasitaemia was quantiﬁed using Giemsa staining and optical microscopy, the cur-
rent gold standard for malaria diagnosis[224]. Giemsa stains DNA - as erythrocytes do
not naturally contain any DNA, Giemsa clearly highlights any parasites within the cells
so that they can be identiﬁed using optical microscopy. The diﬀerent stages of infection
(ring, trophozoite, schizont) are also visually distinguishable, enabling the parasitaemia to
be broken down into the individual contributions of each infected stage. This enables an
investigation into the stage at which infected cells are successfully captured (i.e. contain
suﬃcient haemozoin), as well as the quantiﬁcation of the separation eﬃciency for each
stage.
The quantiﬁcation of the parasitaemia was carried out with the generous assistance of
malaria microscopist experts from the London School of Hygiene and Tropical Medicine
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Figure 4.1: Thin ﬁlm blood smears: unstained (top) and stained (bottom)
(LSHTM) and the Universidad de Antioquia in Medellín, Colombia. Their independence
and expertise in diﬀerentiating between both diﬀerent infection stages and false positives
serve to increase the credibility of the results.
4.1.2.1 Protocol
To stain the samples, a thin ﬁlm blood smear is created by placing a drop of sample of
about 100µm onto a glass microscope slide, and smearing it using the edge of a second
slide (Fig. 4.1). Once the sample has dried, it is ﬁxed by dropping methanol onto the
slide. The slides are then covered with a solution of Giemsa diluted 4:1 in water (Fig.
4.2). After 25 minutes, the slides are delicately rinsed with water and are ready to be
counted using an optical microscope using oil immersion 100x magniﬁcation.
The microscopist ﬁrst locates an area with a good distribution of cells, packed close
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Figure 4.2: Giemsa staining of microscope slides
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together but not overlapping each other - the purpose of the thin ﬁlm blood smear is to
ensure that such an area can be found on the slide. They then count the number of rings,
trophozoites and schizonts visible in the current ﬁeld of view. This is repeated for 11 total
ﬁelds per slide. The parasitaemia of each stage (and of the total) is calculated using:
P% =
3 
∑
c
100
(4.1)
where P is the parasitaemia as a percentage, and c is the number of infected cells. This
formula assumes that there are on average 303 cells in every ﬁeld of view:
P% =
∑
c
RBCtotal
× 100 = 3 
∑
c
100
RBCtotal = RBCfield × 11
∴ RBCfield × 11 = 10
4
3
∴ RBCfield =
104
33
= 303 (4.2)
4.1.3 Apparatus
All of the experiments looking at the device's ability to remove malaria infected eryth-
rocytes used the same apparatus (Fig. 4.4). Samples containing malarial erythrocytes
were ﬂowed through the scaled-down separation chamber detailed in section 3.2.6, placed
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into the magnetic assembly detailed in section 3.3. Magnetic forces pull the chamber into
the position of highest magnetic ﬁeld within the assembly, ensuring that the chambers
are always placed in the same, optimal position. The separation chambers were mass
produced using 3D printing (see section 3.5.1 for 3D printing details and method) so that
a new separation chamber could be used in each experiment (Fig. 4.5). Their internal
surfaces were rendered hydrophobic by coating them with PDMS, before they were ﬁlled
with ferromagnetic mesh as described in section 3.5.2. The lines on the chambers repres-
ent the direction in which the mesh was stacked - a horizontal line represents horizontal
stacking (Fig. 4.5e), and a vertical line vertical stacking.
The initial blood samples were loaded into a 20ml Chromacol® syringe (Essex Sci-
entiﬁc Laboratory Supplies, UK), which was connected to the separation chamber via
Versilic® silicone tubing (Scientiﬁc Laboratory Supplies, UK). The samples entered at
the bottom of the chamber, in order to ensure that the experiment was not aﬀected by
gravitational forces, particularly as the chambers are initially empty and were not primed
before the start of the experiments. The samples exited at the top and opposite side of the
chamber, ﬂowing via silicone tubing into a BD Biosciences FalconTM tube (Farnell, UK).
The ﬂow rates were controlled by an Aladdin-220 programmable syringe pump (World
Precision Instruments, Hitchin, UK).
4.1.4 Cultured P. falciparum
The experiments detailed in this section were carried out in the research labs of the Grupo
Malaria, in the SIU of the Universidad de Antioquia, Medellín, Colombia. We are very
grateful to the research group for providing this opportunity.
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Figure 4.3: Constituent parts of apparatus
Figure 4.4: Assembled apparatus with experiment running
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(a) Chamber and cap 3D
printed
(b) 3D printed chambers
(c) 3D printed lids for chambers (d) Chambers curing at 70ºC
(e) Ferromagnetic mesh stacked horizontally
in chamber
(f) Chambers sealed and ready for use
Figure 4.5: Production of separation chambers
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4.1.4.1 Cultures
The ﬁrst experiments were conducted on samples of cultured P. falciparum. These were
human red blood cells infected with parasites which had previously been isolated from
a patient and cryopreserved. Small samples can be taken from this isolate and cultured
at 37ºC in medium, in this case Roswell Park Memorial Institute (RPMI). The sample
progresses through the diﬀerent erythrocytic stages of the malaria life-cycle (see Fig. 1.2
and section 1.2.2), and the parasitaemia increases approximately every 48 hours when the
schizonts rupture, releasing merozoites which infect new erythrocytes in the culture.
In order to control the parasitaemia of the samples used in the experiments, the
cultures were allowed to progress to high parasitaemia and then diluted with healthy
erythrocytes. The cultures were then centrifuged and the cell pellet re-suspended in
RPMI. The haematocrit was kept constant for all experiments, by using 1ml RPMI for
every 7µl of cell pellet. A typical sample consisted of a 700µl pellet suspended in 40ml
RPMI. This was then divided into two 20ml samples in order to conduct two experiments.
The cell cultures and sample preparations for this project were carried out by Alex-
andra Marcela, from the Grupo Malaria.
4.1.4.2 Filtration
Before each experiment, the area was cleaned and cleared of clutter. Appropriate protect-
ive equipment (gloves, lab coat, goggles) were worn. The apparatus was set up as shown
in Fig. 4.4, with 20ml of sample loaded into the syringe which was connected to a clean
separation chamber. The syringe pump was programmed to the desired ﬂow rate, and the
experiment started. Once the syringe was empty, the experiment was paused while it was
128
carefully removed from the syringe pump and loaded with air. The experiment was then
resumed with air pumped at the same ﬂow rate in order to push as much of the sample as
possible through the chamber. All the experiments were conducted at room temperature.
4.1.4.3 Sampling
Samples of 1ml were taken at various points throughout the experiment in order to meas-
ure the parasitaemia. One sample was taken of the `initial' sample, before ﬁltration. Two
or three samples were then taken from the `ﬁltered' sample: one of the ﬁrst ml to exit
the separation chamber, one when the volume within the syringe chamber had been re-
duced by half, and one once the syringe was empty. In some experiments, a sample of the
`ﬁltered' sample was also taken after air had been used to push as much of the sample as
possible through the chamber.
Once the sample had been ﬁltered, the chamber was removed from the magnetic
assembly and reconnected to the empty syringe. The chamber was then vigorously ﬂushed
with air in order to remove any sample remaining in the chamber, typically about 1ml.
This recovered sample constituted the ﬁnal sample of an experiment, and was used to
investigate the cells that had been captured within the chamber. Thus every experiment
had four or ﬁve 1ml samples:
1. One from the initial unﬁltered sample, as provided at the beginning of the experi-
ment. This was generally used as the `initial sample' for two experiments, since two
experiments were conducted with the 40ml of cultured cells.
2. The ﬁrst ml to emerge from the separation chamber after the start of the experiment.
3. After the syringe was empty - 20ml had been pumped, but only 5-8ml had typically
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been ﬁltered with the rest of the sample in the chamber or tubing.
4. One after as much of the sample as possible had been passed through the separation
chamber, which had been ﬂushed with air at the same ﬂow rate as the experiment.
5. One from the sample remaining in the separation chamber at the end of the exper-
iment.
For each of these, one microscope slide was prepared as described in section 4.1.2, and
the parasitaemia established by a trained microscopist. The microscopy was carried out
by Alexandra Marcela and Briegel de Las Salas, from the Grupo Malaria.
4.1.5 Donated P. vivax
In order to test whether the haemoﬁlter functioned on malaria patient blood, samples
voluntarily donated by P. vivax patients were passed through the device and their initial
parasitaemia compared to their parasitaemia after ﬁltration. Furthermore, in order to
see whether the device had any undesirable eﬀect on blood components, complete blood
counts were performed on the samples before and after being passed through the hae-
moﬁlter. The samples were taken from donors infected with P. vivax in the El Bagre
municipality in the north-east of Antioquia, Colombia, an area with relatively high in-
cidence. Patients presenting with symptoms at the malaria diagnostic post were ﬁrst
diagnosed using thick blood smears. If positive, they were invited to volunteer to take
part in the study.
In four of the experiments, the samples were chilled on ice and shipped to the Uni-
versidad de Antioquia in Medellin, where the experiments were performed. As such, the
time between taking of the samples and performing the experiment varied considerably
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between each sample, from eight hours up to 24. While the experiments were performed
at room temperature, the blood samples were still chilled. Temperature aﬀects the rhe-
ology of the blood, importantly aﬀecting the viscosity of blood, a key contributor to the
drag force felt by cells (see Eq. 1.2)[225]. The temperature can also aﬀect the function of
platelets and other cells[226].
Ethics approval for this research was provided by the Human Ethics Committee of
the Universidad de Antioquia and can be seen in Appendix C (internal document num-
ber BE-IIM). The patients were fully informed of the purpose of the study, and each
signed a patient consent form, the template for which is in Appendix D, while the patient
registration form is in Appendix E. The inclusion criteria for the patients were:
 Exclusive infection with P. vivax
 At least 18 years of age
 Diagnosed with non-complicated malaria, using clinical evaluation methods recom-
mended by the WHO
The exclusion criteria were:
 Pregnant women
 Recognised concomitant pathologies
 Anaemia
The blood was collected by experienced researchers from the Grupo Malaria of the Uni-
versidad de Antioquia, in 2.5ml vacutainer blood tubes containing heparin; ﬁve tubes
(12.5ml) were taken per patient. The samples were chilled in ice and immediately shipped
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by air to the Universidad de Antioquia in Medellín, where they were ﬁltered through the
device at various ﬂow rates (1-4ml/min). Samples pre and post ﬁltration were immediately
sent to the university's haematology laboratory for full blood count analysis.
4.2 Flow rate analysis
The chambers used in the experiments had a cross-sectional surface area of 21× 18mm =
378mm2. The surface areas of the clinical versions described in section 3.2.4 are:
 Infant: 40× 25mm = 1, 000mm2. 2.7 times small-scale version.
 Small: 75× 40mm = 3, 000mm2. 7.9 times small-scale version.
 Medium: 100× 50mm = 5, 000mm2. 13.2 times small-scale version.
 Adult: 160× 50mm = 8, 000mm2. 21.2 times small-scale version.
These provide the multipliers that can be used to calculate the ﬂow rates that could be
used within the clinical scale device. If an experiment is conducted at 2ml/min in the
scaled-down chamber, for example, a ﬂow rate of 42.4ml/min in the adult version would
generate the same linear ﬂow rate, and thus the same drag force. Since the magnetic
forces are the same, this indicates the throughput that would theoretically produce the
same result in vivo.
As discussed in section 3.1.2, signiﬁcantly more than TBV needs to be ﬁltered in order
to achieve a high total parasitaemia reduction. For example, taking a TBV of 5l for an
adult and assuming a separation eﬃciency of 90%, 12.8l of blood need to be processed in
order to remove 90% of infected cells from a patient, a total treatment time of just over
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two hours if ﬁltering at 100ml/min. Using this same model, the total treatment times for
diﬀerent ﬂow rates were calculated for an infant, child, youth and adult. The assumptions
were:
 Initial parasitaemia: 2%
 Separation eﬃciency of device: 90%
 Infant TBV: 500ml (weight 6.5kg)
 Child TBV: 1,500ml (weight 20kg)
 Youth TBV: 3,200ml (weight 40kg)
 Adult TBV: 5,000ml (weight 65kg)
The calculated total volumes to be processed to achieve a 90% reduction in total parasit-
aemia were:
 Infant: 1,275ml
 Child: 3,830ml
 Youth: 8,180ml
 Adult: 12,785ml
It is interesting to note that the total volume that needs to be processed is equal to
approximately 2.5x TBV for all patients. This number should be taken as the `ﬁltration
ratio' and used to calculated the total volume that will need to be processed to treat any
given patient.
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Figure 4.6: Time required to achieve a 90% reduction in parasitaemia for diﬀerent
patient TBV, assuming 2% initial parasitaemia and 90% device separation eﬃciency
The total time needed to reduce the total parasitaemia by 90% for diﬀerent ﬂow rates
is shown in Fig. 4.6. Because of the dimensions of the separation chambers, the ﬂow
rates used in the small, medium and adult versions can be respectively three, ﬁve and
eight times the ﬂow rate used in the infant version. This means that if the experiments
indicate that a 90% separation is possible using a ﬂow rate of, for example, 3ml/min,
the ﬂow rate used in the clinical versions could be 8ml/min, 24ml/min, 40ml/min and
64ml/min for the infant, small, medium and adult versions respectively. Using our model
patients, these correspond to total treatment times of:
 Infant: 2 hours 40 mins
 Child: 2 hours 40 mins
 Youth: 3 hours 15 mins
 Adult: 3 hours 10 mins
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All of these are respectable treatment times, although the ultimate target should be to
reduce them as much as possible.
These data were used to help choose the ﬂow rates to be used in the scaled-down
experiments. While the ﬁrst priority was to demonstrate that the separation chamber
was successful in capturing malaria infected erythrocytes, the second goal was to check
whether its performance was maintained at higher ﬂow rates. The ﬁrst experiments were
therefore carried out at 1-2ml/min, followed by further experiments at up to 4ml/min.
4.3 Results - cultured P. falciparum
The 24 experiments using cultured P. falciparum were conducted with ﬂow rates ranging
from 0.2ml/min to 4 ml/min. The initial samples had varying parasitaemias and diﬀerent
combinations of ring-stage and mature infected erythrocytes. The results are summarised
in Table 4.1 and Fig. 4.7; the two bars for each experiment represent the initial and ﬁltered
samples after a single pass through the magnetic haemoﬁlter. Across all experiments, there
was an average 44.4% reduction in the parasitaemia with a standard deviation of 32.0%,
with separation eﬃciencies ranging from -34.7% (i.e. an observed increase in parasitaemia)
to 81.8%. Fig. 4.8 shows the separation of only ring stage infected cells, while Fig. 4.9
shows the separation of only mature stage infected cells.
It is diﬃcult to draw a conclusion from the data in Fig. 4.7. While 87.5% (21 out
of 24) showed an overall reduction in the parasitaemia, the overall separation eﬃciency
varied signiﬁcantly and showed no evident link to the ﬂow rate. One immediate conclusion,
however, is that the three experiments in which no reduction in parasitaemia was observed
all saw slight (35%, 7% and 8%) increases in the number of ring stage cells, but decreases
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Table 4.1: Summary of results from 24 experiments with cultured P. falciparum
in the parasitaemia of trophozoites and schizonts. This supports the hypothesis that
the device is only eﬀective at removing mature infected cells which contain suﬃcient
haemozoin. To investigate this further, the separation of rings and of mature cells were
analysed separately.
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Figure 4.7: Parasitaemia of initial and ﬁnal samples and the percentage reduction
(capture eﬃciency) in parasitaemia for a single pass through the magnetic haemoﬁlter
for all 24 experiments conducted with cultured P. falciparum (n.b. capture eﬃciency
not included if below 0)
4.3.1 Separation of ring-stage parasites
Fig. 4.8 presents the variation in parasitaemia of only the ring-stage infected cells, with
experiments in which the initial ring-stage parasitaemia was at or close to 0% excluded.
It shows the unpredictability of the separation of ring-stage cells - some show signiﬁcant
reductions, while others remain ﬂat or even show small increases. The average separation
eﬃciency was 31.1%, but with a high standard deviation of 35.8%.
Ring-stage cells contain only small quantities of haemozoin, so should theoretically
not be captured by the magnetic haemoﬁlter. However, about 24 hours after infection,
some parasites still appear as rings but can contain 75% of the haemozoin that a schizont
contains at cell rupture[5]. It is therefore possible that some of the cells in the `ring-stage'
populations contain suﬃcient haemozoin to be captured by the device. Indeed, out of 19
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Figure 4.8: Parasitaemia of ring-stage cells, before and after for a single pass through
the magnetic haemoﬁlter
Figure 4.9: Mature stage parasitaemia of samples before and after for a single pass
through the magnetic haemoﬁlter, and separation eﬃciency of mature infected cells
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experiments presented in Fig. 4.8, 11 (58%) saw a decrease in ring-stage parasitaemia of
over 50%, including six (32%) over 75%, clearly indicating that some ring-stage cells were
captured by the haemoﬁlter.
However, there is no clear link between ring-stage separation eﬃciency and ﬂow rate,
and no discernible relationship with the initial ring-stage parasitaemia. This supports the
conclusion that the device is capturing `late-stage' rings, or early stage trophozoites - the
separation eﬃciency in this case would be determined by the proportion of ring-stage cells
that contain suﬃcient haemozoin, which could vary signiﬁcantly from one experiment to
another.
This conclusion is further supported by photographs of the samples. Fig. 4.10b shows
a typical sample after ﬁltration, and contains almost exclusively early-stage rings. The
ring-stage parasitaemia of this particular slide was found to be 2.53%, and was one of the
slides in an experiment run at 1ml/min, with a calculated ring-stage separation eﬃciency
of 55%. The immediate conclusion when comparing it to Fig. 4.10a is that the mature
cells have been very successfully captured, but a closer look shows the presence of larger
rings in the process of becoming mature trophozoites. There is only one of these in
Fig. 4.10b, suggesting that these cells are being captured, accounting for the decrease in
ring-stage parasitaemia seen in some of the experiments.
Only ﬁve experiments (26%) showed a negligible (between -25% and 25%) change
in ring-stage parasitaemia. While it was predicted that most of the experiments would
fall into this category, the conclusion that the device also captured `late-stage' ring-stage
parasites accounts for this small number - only about a quarter of the initial samples
didn't contain any late-stage rings. Indeed, it is worth noting that three out of these ﬁve
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are from initial samples that contained no trophozoites or schizonts, and were likely to
contain almost exclusively early-stage rings.
Four experiments (21%) showed an overall increase in the ring-stage parasitaemia
between the initial and ﬁltered samples. Since all the separation chambers used were
clean, it was highly unlikely that new infected cells be added to the sample during the
procedure. This increase, which peaked at a 32% increase (from 1.08% to 1.43%) in an
experiment with a ﬂow rate of 1ml/min, could therefore be due to:
 False positive capture of uninfected erythrocytes. If the separation chambers were
retaining more uninfected than ring-stage infected erythrocytes, then an increase in
the ring-stage parasitaemia would be expected. However, this seems unlikely. Even
if uninfected cells were susceptible to magnetic capture, which is not impossible,
there is no reason why a ring-stage infected cell would be less likely to be captured
than an uninfected cell. Furthermore, if this was the case, one would expect regular
increases in the parasitaemia throughout the experiments, rather than in only 21%.
 Experimental errors. This could include, for example, coincidental problems in
the sampling procedure, or during preparation of the slides, favouring either higher
infection rates for the ﬁltered samples, or lower infection rates for the initial samples.
 Uncertainties. As discussed in section 4.5.1, there are presumptions in the Giemsa
method for establishing parasitaemia which could account for the increase in ring-
stage parasitaemia - in fact, no cells have been captured, and the diﬀerence between
the initial and ﬁltered samples is within the margin of error. This is likely to be the
case for those experiments where the increase is small (7% and 8%), but perhaps
could not account for the experiment with an increase of 32%.
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In conclusion, the results indicate that early stage rings are not captured by the device.
However, the large number of experiments with reductions in the ring-stage parasitaemia
indicate that at least some of these infected cells are being captured, most likely those
that are beginning or about to begin their transformation into mature trophozoites.
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(a) Initial sample (b) Filtered sample (c) Recovered from chamber
Figure 4.10: Giemsa stained blood smears at 100x magniﬁcation
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4.3.2 Separation of mature parasites
In contrast to the ring-stages, all of the experiments in which the initial sample contained
mature stage infected erythrocytes showed a reduction in the mature stage parasitaemia,
as demonstrated in Fig. 4.9. The separation eﬃciency ranged from 19% to 88%, with an
average of 61.4% and standard deviation of 20.6%. 65% (13 out of 20) of the experiments
had separation eﬃciencies of over 60%, while 30% (six) had eﬃciencies above 80%. Five
experiments (25%) had separation eﬃciencies of less than 50% and only one (5%) less
than 25%.
The data clearly indicate that the separation chamber successfully captured mature
stage infected cells. This conclusion is further supported by comparing images of a ﬁltered
sample, which contains almost exclusively rings, and a sample recovered from a separation
chamber after an experiment (see Fig. 4.10). The initial and recovered samples clearly
contain a signiﬁcant number of infected cells, while the ﬁltered sample contains almost
exclusively ring-stage cells.
4.3.2.1 Relationship between separation eﬃciency and ﬂow rate
Initially, there does not seem to be a signiﬁcant link between the separation eﬃciency
and the ﬂow rate. This is particularly emphasised by Fig. 4.11. In this graph, the
data points are connected by lines as a visual aid only, as successive experiments are
not related. However, connecting the data points for the initial parasitaemia, ﬁltered
parasitaemia and separation eﬃciency makes it easier to see that there is a more apparent
link between the initial and ﬁnal paraistaemia, while the separation eﬃciency appears
unrelated to the other two data sets. There is not the anticipated decrease in separation
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Figure 4.11: Initial and ﬁltered parasitaemia and separation eﬃciency of mature stage
infected erythrocytes
eﬃciency as the ﬂow rate is increased. Two experiments in particular (at ﬂow rates of
3.5ml/min and 4ml/min) show oddly high separation eﬃciencies (81%) at high ﬂow rates.
Experiments conducted at the same ﬂow rates also do not show much consistency. The
three experiments performed at 1ml/min showed eﬃciencies of 61%, 81% and 88%, while
the three at 2ml/min showed eﬃciencies of 45%, 51% and 67%.
This suggests that either the role of the ﬂow rate is less important in this regime than
was anticipated, or there is another variable which aﬀects the separation more than the
ﬂow. One important factor could be the variation between two diﬀerent chambers. Since
these were manufactured by hand, a degree of heterogeneity was inevitable. In particular,
the mesh in some chambers could have accidentally been stacked in a way which allowed
escape channels up the side of the chamber, leading to poor separation performance.
However, further analysis suggests that there is a link between the separation eﬃ-
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Table 4.2: Contingency table showing
relationship between ﬂow rate and
separation eﬃciency of mature stage cells
Table 4.3: Average separation eﬃciency
of mature stage cells for diﬀerent ﬂow rate
ranges
ciencies and the ﬂow rate. Grouping the experiments into high and low ﬂow rates and
separation eﬃciencies shows that 80% of the experiments fall into the anticipated cat-
egories of high eﬃciency with low ﬂow, and low eﬃciency with high ﬂow (see Table 4.2).
Furthermore, all of the remaining 20% fall into the high ﬂow and high eﬃciency category,
with none in the low ﬂow and low eﬃciency. In other words, the experiments that had
unexpected separation eﬃciencies had unexpectedly high ones - an encouraging result
that suggests the ﬂow rate could be pushed up further.
In fact, grouping the results into ﬂow rate ranges - low, medium and high - and
calculating the average separation eﬃciency of each group demonstrates that there does
seem to be some correlation between ﬂow rate and separation eﬃciency (see Table 4.3).
The six experiments with ﬂow rates below 1.5ml/min had average separation eﬃciencies
of 74%, and were reasonably consistent with a standard deviation of only 8%. As the
ﬂow rate increases, both the average separation eﬃciency and the consistency of the
results decrease, with the eﬃciency dropping to below 50% for experiments with ﬂow
rates 2.5ml/min and above, with a standard deviation of 23%.
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4.3.2.2 Filtered parasitaemia
The parasitaemia of the ﬁltered sample is arguably more important than the separation
eﬃciency. After all, the goal of the device is to reduce a patient's parasitaemia as much
as possible in as short a time as possible. Fig. 4.12 shows the percentage of experiments
whose ﬁltered parasitaemias were below given values. It shows that the parasitaemia of
the ﬁltered sample was reduced to less than 1% in 65% of cases, and less than 0.5% in
40% of experiments. It is worth noting that the 13 experiments with ﬁltered parasitaemia
less than 1% are not the same as the 13 with separation eﬃciencies over 60%.
It would be more valuable for the device to reduce the mature parasitaemia to below
a critical value (e.g. 0.25%) regardless of the initial parasitaemia. For example, an initial
sample with parasitaemia of 1% reduced to 0.25% has a separation eﬃciency of 75%,
while a sample with initial parasitaemia of 5% that is reduced to 1% has an eﬃciency of
80%. Looking at the separation eﬃciency, the second experiment appears more successful,
whereas in reality the ﬁnal parasitaemia may have a more important impact in terms of
patient beneﬁt, so the ﬁrst experiment could be considered more successful. This eﬀect
can be seen in the results. One experiment with one of the highest separation eﬃciencies
at 76% had a ﬁnal mature stage parasitaemia of 1.5%, with the high eﬃciency largely
due to the high 6.3% initial parasitaemia. Meanwhile, one of the experiments with low
separation eﬃciency at 45% had one of the lowest ﬁltered parasitaemias at 0.2% - the low
eﬃciency was due to the small initial parasitaemia of 0.3%.
Looking at Fig. 4.11, the ﬁnal parasitaemia seems to bear no correlation with the ﬂow
rate, but does seem related to the initial parasitaemia. Indeed, the net diﬀerence between
initial and ﬁnal parasitaemia shows a strong correlation with the initial parasitaemia, as
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Figure 4.12: Cumulative frequency of experiments with ﬁltered parasitaemia below
given values
Figure 4.13: Net diﬀerence between initial and ﬁltered mature stage parasitaemia at
diﬀerent ﬂow rates
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Figure 4.14: Net reduction in mature parasitaemia vs. initial parasitaemia
can be seen in Fig. 4.13. With the exception of one experiment at 2.5ml/min, both the
net diﬀerence and the ﬁnal parasitaemia appear to track the initial parasitaemia. Fig.
4.14 shows the relationship between the initial parasitaemia and the net reduction in
parasitaemia for mature cells. The linear trend-line suggests a good correlation with a
coeﬃcient of determination of 0.935; with a gradient of 0.78, it suggests that the device
removes 78% of the infected cells.
4.3.2.3 Conclusion
While this data certainly suggests a signiﬁcant correlation between the initial parasitaemia
and its reduction, it is only one factor aﬀecting the performance of the device and the
linear trend-line should not be taken as a rule. Given the two conclusions that the
ﬂow rate aﬀects the separation eﬃciency, and the initial parasitaemia aﬀects the ﬁltered
parasitaemia, it could be assumed that the relationship between the initial and ﬁltered
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parasitaemias would be linear for a given ﬂow rate. Alternatively, for a given initial
parasitaemia, one could expect a strong correlation between the separation eﬃciency and
the ﬂow rate.
The device is certainly able to capture a signiﬁcant proportion of the mature troph-
ozoites and schizonts that pass through it, but the data clearly indicates that both the
initial parasitaemia and the ﬂow rate are important factors in determining the success of
the ﬁltration. In a clinical environment, the device's ability to reduce a patient's parasite
burden - and the time it takes to do so - will depend primarily on these two factors. Ini-
tial parasitaemia will vary considerably and cannot be controlled. Testing of the clinical
version described in section 3.2.4 should therefore focus on ﬂow rate optimisation, bearing
in mind that the optimal value may depend on the patient's current parasitaemia, and
the best scenario may therefore be to vary the ﬂow rate as the treatment progresses and
the patient's parasitaemia is reduced.
4.4 Results - donated P. vivax
4.4.1 Reduction in parasitaemia
Through the collaboration with the Universidad de Antioquia in Colombia, it was possible
to obtain samples of blood from six patients infected with P. vivax, as described in section
4.1.5. The intention was to check whether the device successfully extracted infected
cells from the blood of patients, conﬁrming that the results reported in section 4.3 were
repeatable when (1) the infected cells were in whole blood, rather than just medium, and
(2) with P. vivax as well as P. falciparum.
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Table 4.4: Initial parasitaemia, ﬁltered parasitaemia and resultant separation eﬃciency of donated P. vivax samples
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Figure 4.15: Initial and ﬁltered parasitaemia for samples donated by P. vivax patients
The blood samples were ﬂowed through the haemoﬁlter using the method described
in section 4.1 and the same apparatus as the P. falciparum experiments from section 4.3.
The change in parasitaemia resulting from a single pass of the samples through the device
are preseted in Table 4.4 and Fig. 4.15. All of the experiments were conducted at room
temperature, although the temperature of the samples was not monitored. For patients
1-4, the samples were collected in El Bagre and shipped on ice to Medellin, where the
experiments were performed in the laboratories of the Grupo Malaria at the Universidad
de Antioquia. For patients 5 and 6, however, the experiments were performed on site at
the hospital in El Bagre by Briegel de las Salas from the Grupo Malaria. The temperatures
of the samples for the ﬁrst four patients may therefore have been diﬀerent than those of
patients 5 and 6.
Unfortunately, the patient's parasitaemias were too low to draw a signiﬁcant conclu-
sion from the results - initial parasitaemia ranged from 0.03% to 0.30%, most of which
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was constituted of ring-stage cells. Low parasitaemias are common in P. vivax patients,
particularly in uncomplicated cases, so it was unsurprising that it was not possible to
obtain donated samples with high levels of infected cells, particularly considering the fact
that "uncomplicated malaria" was one of the inclusion criteria for volunteers.
The measured values were all close to or lower than the margin of error of the Giemsa
staining method of establishing the parasitaemia, preventing a meaningful conclusion
from being drawn. Ideally, the parasitaemia of these samples would have been checked
using a highly sensitive technique such as RT-PCR, but no such equipment was avail-
able. However, the results do indicate that infected cells are captured, with a decrease in
parasitaemia observed in all experiments except patient 2.
In this case, an increase in parasitaemia was observed, but this result is particularly
unreliable, ﬁrstly because of the very low initial parasitaemia, and secondly because the
Giemsa staining of the microscope slide containing the initial sample was unsuccessful.
The sample underwent almost complete haemolysis and it was not possible to read any
data from the slide. As a result, it was not possible to establish the initial parasitaemia
for patient 2 in the same manner as the other samples. While the number of parasites
per microlitre was established when the sample was taken from the patient, this was not
established for the ﬁltered sample.
4.4.2 Preliminary safety tests
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Table 4.5: Summarised complete blood count results for P. vivax patient's blood ﬂowed through the magnetic haemoﬁlter
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Figure 4.16: Complete blood count results (white blood cells, red blood cells and
haematocrit) for P. vivax patients' blood before and after being passed through the
haemoﬁlter
The samples did, however, allow for testing of whether the haemoﬁlter causes any
harm to other blood components. Complete blood counts of the blood samples before
and after ﬁltration through the device were performed; the results can be seen in Table
4.5 and Fig. 4.16; the complete, raw results can be seen in Appendix A. In addition to the
complete blood counts, all of the samples were observed using light microscopy to check
for any cell lysis or other observable damage.
The most signiﬁcant variations were observed in the RBC counts. These may be
expected to decrease slightly, due to the capture of infected erythrocytes, but this eﬀect
should be very small owing to the very low parasitaemias present in the sample. Some
patients saw signiﬁcant RBC decreases much higher than would be expected; there was
no apparent link between the samples which saw a decrease and either the ﬂow rate
or the temperature (i.e. patients 1-4 vs. patients 5 and 6). It is also surprising that
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some patients saw increases in their RBC counts, and these remain unexplained. One
possible explanation is error or inaccuracy of the full blood count tests, although this
seems unlikely to account for changes in the values of up to 15% (in patient 5). It is
possible that there is some false positive capture of RBC for some patients, which could
explain the large decreases, and this will need to be further investigated.
At the slowest ﬂow rate of 1ml/min, there is a slight but repeated reduction in white
blood cells. This is likely due to slight sedimentation of these heavier cells - indeed, in the
experiments with cultured P. falciparum, signiﬁcant sedimentation of the cells in medium
was observed at the lowest ﬂow rates, so it is natural to assume some eﬀect with the white
blood cells. This could be reversed by having the separation chamber inlet at the top and
outlet at the bottom.
While little diﬀerence between before and after ﬁltration was observed, many of the
samples exhibited the signs of infection that would be expected, including in particular
low platelet and high neutrophil counts; the former was observed in all patients (range: 36-
138×103/µl). Importantly, the haemoglobin did not decrease signiﬁcantly or consistently,
indicating that there is, as expected, no capture of haemoglobin. None of the samples
showed any visual signs of cell lysis when observed under a microscope.
Signiﬁcant variations between the initial and ﬁltered samples were observed in the
white blood cell population proportions. For example, Patients 1 and 6 saw a signiﬁcant
increase in their proportion of lymphocytes, from 20% to 25% and from 11% to 24%
respectively. Patient 1, the only patient with a signiﬁcant initial basophil proportion,
also saw a huge decrease in basophils, from 2.3% to 0.2%. Patient 2 meanwhile saw a
signiﬁcant increase in monocytes, from 6% to 10%. As isolated cases, these are not of
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Table 4.6: Complete blood count results for Patient 2, showing the diﬀerence between
before ﬁltration, after ﬁltration, and the blood captured in the haemoﬁlter
signiﬁcant concern, but should be monitored during future development of the device.
In addition to the initial and ﬁltered samples, the blood that was captured within
the device was analysed for Patient 2 - these results can be seen in Table 4.6. While
the ﬁltered sample is not signiﬁcantly diﬀerent from the initial sample (bar the increase
in monocyte proportion, mentioned above), the sample captured in the chamber has a
signiﬁcantly higher red blood cell count, haemoglobin and haematocrit, with signiﬁcantly
lower WBC and platelet counts. This indicates a puriﬁcation of red blood cells, which
may be indicative of false positive capture of RBC. The higher haemoglobin content may
be due to the capture of deoxygenated haemoglobin, which is slightly paramagnetic (see
section 1.2.8).
4.5 Error analysis
4.5.1 Giemsa staining uncertainties
The Giemsa staining method is a rapid and established method of diagnosing malaria and
establishing its severity, but its reliability has been questioned[227]. However, it has lim-
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itations in terms of accurately quantifying parasitaemia for the purposes of this project,
in which we are investigating potentially small changes in the parasitaemia. It is crucial,
for example, for the microscopist to choose a ﬁeld of view with a good distribution, corres-
ponding to 303 cells per view, and this is typically only estimated rapidly. Furthermore,
small parasitaemias (i.e. <1%) correspond to a very small number of counted infected
cells - if one infected cell per viewing ﬁeld is counted, that corresponds to a parasitaemia
of 0.33% - presenting increased uncertainty, particularly for the ﬁltered samples in which
the parasitaemia is predicted to be reasonably low.
We can demonstrate these inaccuracies with two hypothetical samples. The ﬁrst mi-
croscopist chooses an area of the slide with an average of 321 cells per ﬁeld of view. They
count a total of 30 cells, of which 7 are schizonts. The calculated total parasitaemia is
30×3/100 = 0.90% and the schizont parasitaemia is 7×3/100 = 0.21%. Due to the num-
ber of healthy cells being 6% higher than is assumed when using eq. 4.1 (321/303 = 1.06),
the `real' parasitaemias should be total infected cells divided by total cells, times 100. This
gives a total parasitaemia of (30× 100)/(321× 11) = 0.85% and a `real' schizont parasit-
aemia of (7× 100)/(321× 11) = 0.20%, 5.5% and 4.8% lower than the calculated values
respectively.
The second microscopist chooses an area with an average 285 cells per ﬁeld of view
(6% lower than the assumed 303). They also count a total of 30 cells with 7 schizonts.
The results are identical with a total parasitaemia of 0.90% and schizont parasitaemia of
0.21%. However, the `real' parasitaemia here should be (30 × 100)/(285 × 11) = 0.97%
and `real' schizont parasitaemia (7× 100)/(285× 11) = 0.22%.
In this scenario, we have two samples which appear identical in terms of the calculated
157
parasitaemias. However, the 6% error each side in the estimation of the cell distribution,
which is imperceptible to the microscopist, indicates that there is actually a 14% diﬀerence
in the total parasitaemia - 0.85% compared to 0.97% - and a 10% diﬀerence in the schizont
parasitaemia - 20% compared to 22%.
We can use these numbers to indicate the eﬀect that the uncertainties have on the
separation eﬃciency (i.e. percentage of infected removed by the device). Assuming the
calculated initial schizont parasitaemia was 0.90%, and the ﬁnal parasitaemia was 0.21%,
we calculate that 76.7% of the schizonts were removed. However, using the `real' para-
sitaemias from above, we could actually have an initial parasitaemia of 0.85% and a
ﬁnal parasitaemia of 0.22% a separation eﬃciency of 74%. We could also have an initial
parasitaemia of 1.06% and ﬁnal parasitaemia of 0.20%, a separation eﬃciency of 81%.
This hypothetical scenario is conservative in terms of the potential error as it con-
siders only the uncertainty in the average number of cells per ﬁeld of view, ignoring other
contributors to error, particularly the observed number of infected cells - the same mi-
croscopist can look at the same sample twice and count only 5 schizonts the ﬁrst time,
and 12 the second. Clearly, this can have a signiﬁcant eﬀect on the results, particularly
when looking at separation eﬃciency or dealing with low parasitaemias. Based on these
considerations, it is reasonable to assume that the error in establishing parasitaemia using
the Giemsa staining method could be as high as 10%.
4.5.2 Conﬁdence of result
In order to conﬁrm the validity of the results from section 4.3, a paired student t-test
was performed on the mature cell results. The null-hypothesis for this analysis was "the
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Table 4.7: Results from paired t-test
magnetic haemoﬁlter has no eﬀect on the mature cell parasitaemia", or in other words
there is no diﬀerence between the parasitaemia before and after ﬁltration across all 20
experiments. The data sets compared were the 20 `initial' and `ﬁltered' parasitaemia of
mature infected erythrocytes, shown above in Table 4.1. The analysis was performed
using KaleidaGraph 4.5 (Synergy Software, USA). The results from the analysis can be
seen in Table 4.7.
The results demonstrate that the haemoﬁlter was successful in reducing parasitaemia
with a very high conﬁdence (p=0.0002). The correlation between the initial and ﬁltered
samples was calcuated to be 0.76, also with very high conﬁdence. This is very similar to
the average separation eﬃciency of 78%, found by comparing the initial parasitaemia to
the ﬁnal parasitaemia, plotting a linear trendline and calculating the gradient (see Fig.
4.14) here the conﬁdence was high too, with an R2 value of 0.935.
The high conﬁdence of the conclusion is not surprising. Even allowing for a pessimistic
error of 10% in the parasitaemias, all of the experiments still showed a reduction in
parasitaemia, with only two experiments showing a `minimum' reduction in parasitaemia
of less than 10%, and only three less than 30% (see Table 4.8). Meanwhile, the `maximum'
parasitaemia reductions were as high as 90%.
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Table 4.8: Minimum and maximum mature cell parasitaemia of initial and ﬁltered
samples, allowing for a 10% error, and resulting minimum and maximum separation
eﬃciencies
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4.6 Conclusions
The experiments evaluating the haemoﬁlter indicate ﬁrstly that the magnetic haemoﬁlter
is able to separate malaria-infected erythrocytes from uninfected cells. The results detailed
in section 4.3 are very promising in that that was a reduction in the parasitaemia of
trophozoites and schizonts in every experiment and at all ﬂow rates. Considering the
uncertainties in establishing the parasitaemia using the Giemsa staining method, the
maximum expected change in the calculated separation eﬃciencies would be less than
10%, while the experiment with the smallest reduction in parasitaemia was 19%. In other
words, the worst performing experiment still showed a reduction in parasitaemia. Looking
at Fig. 4.9, this experiment could even be considered an outlier, most likely due to poorly
stacked mesh within the separation chamber.
Some experiments did show a reduction in ring-stage parasitaemia, including one par-
ticularly signiﬁcant reduction from 4.8% to 2.2%. This was unexpected - theoretically,
ring-stage cells do not contain the paramagnetic haemozoin required to give the cells a
magnetic susceptibility and enable their capture. However, it can be diﬃcult to diﬀeren-
tiate between early and late ring-stages, and the latter can contain signiﬁcant quantities
of haemozoin (see Fig. 1.5 and section 1.2.8). Some experiments may have contained a
large quantity of late ring-stage parasites containing suﬃcient haemozoin to be captured,
particularly at low ﬂow rates. Other experiments, meanwhile, may have contained mostly
early ring-stage cells, explaining the lack of capture. The experiments in which small in-
creases were observed are most likely due to uncertainties in parasitaemia quantiﬁcation;
the only other possible explanation would be a false capture of healthy RBC, but there
was no data to indicate this was occuring.
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Figure 4.17: Mature stage parasitaemia of samples before and after ﬁltration,
including error bars assuming an error of 10% in estimating the parasitaemia using the
Giemsa staining method, and separation eﬃciency of mature infected cells
The separation eﬃciencies achieved were reasonably high, although did not meet the
hoped for target of 90%. However, allowing for a 10% error in the parasitaemia, some of
the separation eﬃciencies could approach 100% (see Fig. 4.17). Initially, there was also
no apparent link between the separation eﬃciency and the ﬂow rate within the values
used, contrary to what was expected. However, simplifying the data by dividing it into
low and high ﬂow rate and separation eﬃciencies indicates that there is a link between
the two, with 80% of the experiments falling into the expected categories (low ﬂow and
high eﬃciency, or high ﬂow and low eﬃciency). The 20% that didn't had high ﬂow and
high eﬃciency; in other words, when the experiments did not perform as expected, it was
in a positive way.
Because new separation chambers were used for each experiment, to prevent cross-
contamination, it is possible that the variation in separation eﬃeciency is due to some
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chambers being manufactured to a higher standard than others. The insertion of the
mesh was done by hand, and small gaps could easily allow for the formation of escape
channels - paths through which cells can pass without being captured. If the experiments
which showed signiﬁcantly lower ﬂow rates than others performed at the same ﬂow rate
are removed from Table 4.8, namely experiments 10, 14, 16 and 17, the average eﬃciency
rises to 71%±6%.
It was not possible to reliably conclude that the device successfully reduced the para-
sitaemia of donated P. vivax samples after a single pass, due to the very low initial
parasitaemias of the samples. Furthermore, while there was an apparent reduction in
parasitaemia in ﬁve out of the six experiments, there are insuﬃcient data points for a
conclusion to be made with any conﬁdence. That being said, the reduction seen in most
experiments (and the fact that the only case in which a reduction was not observed was
when the data for the initial sample was particularly low and unreliable due to unsuccess-
ful Giemsa staining) is indicative that the device might work on whole blood samples as
well as on cultured samples.
The experiments using blood samples donated by P. vivax patients, combined with
light microscopy observations of the samples, indicated that the device was not causing
any harm to blood cells - there were no signs of signiﬁcant haemolysis. However, there
were some signiﬁcant changes in the cell counts which may be indicative of false positive
capture of uninfected red blood cells. The very slight reduction in WBC seen at lower ﬂow
rates was almost certainly down to sedimentation as the direction of ﬂow was from the
bottom of the chamber to the top. The full blood counts should be taken as preliminary
safety data which are positive in the sense that there does not seem to be any drastic
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Figure 4.18: Theoretical parasitaemia reduction for four model patients with high ﬂow
rate (3ml/min; separation eﬃciency 53%; dotted lines) and low ﬂow rate (1.5ml/min;
separation eﬃciency 72%; solid lines)
eﬀect caused by the device, but insuﬃcient to conclude that the device as it is currenty
designed is safe for use in humans.
A further limitation to the P. vivax experiments is that the temperature of the samples
was not monitored during the experiments. Ideally experiments looking at the perform-
ance and safety of the device should be performed at body temperature, since the rheology
of the blood and function of certain cells varies with temperature (see section 4.1.5). This
fact contributes further to the conclusion that the safety data collected is only very pre-
liminary and more experiments are required before any meaninful conclusion as to the
safety of the haemoﬁlter can be made.
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4.6.1 Flow rates
The data did not provide a conclusive link between the ﬂow rate and the separation
eﬃciency, although experiments performed at lower ﬂow rates were more successful on
average. This could be due to outliers, or simply because the ﬂow rates used were not
within a range in which the variations had an observable eﬀect. However, in order to
calculate estimated treatment times based on this data, average separation eﬃciencies at
`low' and `high' ﬂow rates can be taken. Eliminating the lowest and highest separation
eﬃciencies for each group, the averages were:
 Low ﬂow rate (1.5ml/min): 72%
 High ﬂow rate (3ml/min): 53%
Fig. 4.18 shows the theoretical parasitaemia reduction rates that could be achieved in four
diﬀerent model patients using these ﬂow rates and separation eﬃciencies in the clinical
versions of the device described in section 3.2.4. It shows that, despite the lower eﬃciency,
the higher ﬂow rate yields better parasite reduction with faster treatment times. With
the results achieved in these experiments, a child's or infant's parasitaemia level could be
reduced by 50% in only 80 minutes. A 90% reduction would be achievable in 4.5 hours.
For youths and adults, the treatment times are longer because of higher TBV - 1 hour 45
mins for a 50% reduction, and over ﬁve hours for 90%.
These results demonstrate that the device's performance is reasonably close to what
would be clinically acceptable. While a reduction in treatment time (i.e. faster reduction
of parasitaemia) would be desirable, the ability to halve a child's parasitaemia in less than
an hour and a half could already provide signiﬁcant clinical beneﬁts.
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4.6.2 Summary
The results were very positive and certainly indicate that the device as designed could be a
positive medical device, achieving material parasite reduction in acceptable times. Indeed,
as initial results, they are particularly promising - there is still scope for optimisation in
terms of design which could improve separation eﬃciencies and allow for higher ﬂow rates.
The ferromagnetic mesh within the chamber, for example, has not been investigated, and
diﬀerent gauges or materials could provide improved performance.
The full blood count results were also good, indicating that the haemoﬁltration process
does not cause any harm to cells through shear or stress. However, the possibility of
accidental capture of both RBC and WBC by the device needs to be studied further.
Further toxicology studies and blood analyses could be performed to investigate any
long term toxicity, particularly of the clinical versions of the device. The potential false
capture of other blood components such as trace metals, though unlikely, should also be
investigated.
Further investigation into the device's performance at higher ﬂow rates and, import-
antly, on patient samples are required. The eﬀect of the ﬂow rate on the separation
eﬃciency has not be quantiﬁed, and is crucial to the optimisation of the haemoﬁlter's
performance. Tests on patient blood are important to see how the results are aﬀected by
ﬁltering whole blood rather than cultured samples. Results are likely to be less good, due
to the higher viscosity of whole blood when compared to RPMI medium.
As discussed in section 3.6, anticoagulant will need to be added to the system during
each procedure with heparin the most likely candidate. In these experiments, both Ethyl-
ene Diamine Tetra Acetic Acid (EDTA) and heparin were used as anticoagulants, and the
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dosages used were determined by the fact that the samples needed to be shipped from
El Bagre to Medellin, rather than to be representative of the dosage that would be used
when treating a human patient. As such, the eﬀective use of anti-coagulant and risk of
clotting, particularly within the separation chamber, will need to be carefully investigated
when developing the medical device.
Finally, in order to justify the potential applications detailed in Chapter 2, the ability
of the haeomﬁlter to separate MNP and magnetically labelled cells and other agents from
whole blood would need to be demonstrated with similar experiments to those presented
in this Chapter. This would justify the argument that the device is a platform, easily
adaptable to any new application.
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Chapter 5
Commercial Evaluation of Device
5.1 Introduction
In this Chapter, the commercial evaluation that has been undertaken is outlined. The
aim was to establish whether commercialisation of the haemoﬁlter as a medical device to
treat malaria is commercially viable, addressing the following questions:
1. Does the haemoﬁlter meet an unmet need?
2. Can it be proﬁtable?
3. What is the size of the market?
4. What is the go-to-market strategy?
5. How much investment is required to get to market?
Each of these questions has a number of sub-questions, and to answer these both primary
and secondary research was conducted. The malaria treatment market and industry were
analysed, mainly through a literary review, and experts were consulted, including malaria
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clinicians and researchers, medical device entrepreneurs, nephrologists, business and start-
up experts, medical device manufacturers and industry regulators, amongst others.
The method devised to ascertain whether the project is commercially viable was:
1. Establish where the device ﬁts into the current treatment pathway. Discuss with
clinicians how and when they would use the treatment, and which patients stand
to beneﬁt most. From their answers, identify the best niche in which to start using
the device, considering the best target market to drive rapid adoption.
2. Identify the ﬁrst country in which the device would be sold. Analyse data of the
number of patients in that country who ﬁt into the identiﬁed niche, where they go
to get treatment, and how much it currently costs the customer (i.e. patient or
health service).
3. Look at whether the device could provide an economic beneﬁt as well as a clinical
beneﬁt, by reducing inpatient time for example, and estimate the cost per death
averted using the device. This provides an estimate for how much the customer
would be willing to pay for the treatment.
4. Estimate the cost of a single treatment to the patient or health service, and compare
it to what they currently pay. The main task here is to estimate how much a single
set of consumables would cost, once the manufacturing and distributing processes
are established.
5. Combine the results from 2 and 3 to establish whether or not the company could
make a margin on each treatment, and if so how large, and as a result how big the
total addressable market is.
169
6. Create a go-to-market strategy to reach the customer niche, detailing what is re-
quired to make the ﬁrst commercial sale (e.g. regulatory approval), and outlining
any speciﬁc device capabilities or speciﬁcations (e.g. able to treat both adults and
children).
7. Construct a ﬁnancial plan, estimating the total costs of getting to market, the time it
will take, and the total investment required to get there. Identify potential funding
sources and put together a timeline including both development and investment
strategy.
Finally, successful commercialisation of medical devices often depends largely on the re-
commendations of respected members of the healthcare community. During this process,
proﬁles were made of the individuals who will be essential to the project's success. These
include members of the board or team of the potential commercialising vehicle, as well
as key opinions leaders in the principal target markets, who will need to be champions of
the technology and enhance its credibility.
5.2 The clinical need
In order to establish how the haemoﬁlter would ﬁt into the current treatment pathway,
malaria experts, both clinicians and researchers, were asked what eﬀects they thought the
haemoﬁlter might have on a patient, whether used in isolation or in combination with
existing therapies. Based on these discussions, patients who stood to beneﬁt from the
treatment were broken down into three categories - untreatable, hospitalised severe and
non-severe - with diﬀerent value propositions for each group.
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5.2.1 Untreatable patients
Patients in this group are deﬁned as those for whom there is currently no eﬀective phar-
maceutical treatment. For these patients, the haemoﬁlter could be used independently of
drugs, with the goal of reducing and maintaining the parasitaemia at a low level so as to
prevent the manifestation of symptoms. As the device does not remove early ring-stage
infected erythrocytes (see section 4.3.1), two treatments would be required initially, per-
formed 18-36 hours apart, at which point the infected cells that escape capture during the
initial treatment have matured into trophozoites and schizonts, but have not yet ruptured
to release merozoites. The patient could then be discharged from hospital, but should be
regularly monitored, and possibly still given a course of anti-malarial tablets.
Ideally, a second round of treatments would take place when the parasitaemia rises
above a pre-deﬁned critical value and before symptoms reoccur. Realistically however,
it is likely that patients would only return to be treated once symptoms manifest again,
and constant monitoring of the parasitaemia would be economically and logistically chal-
lenging. Trials would need to be conducted to ascertain the average time between ﬁrst
treatment and patient relapse, which could vary signiﬁcantly for diﬀerent patients and
malaria species. The ideal scenario would be to keep a patient alive and symptom free
indeﬁnitely with regular treatments. Eventually, particularly for young children, it is pos-
sible that the controlled presence of a small number of parasites could act like a vaccine,
helping the patient's immune system to build up an immunity and successfully ﬁght the
parasite without further intervention.
Patients in this category include those with drug resistant strains, such as those cur-
rently emerging in the Mekong Delta (see section 1.2.7). These currently have very limited
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treatment options and, in the absence of a better option, are usually prescribed an anti-
malarial drug course regardless of its eﬀectiveness. These patients could beneﬁt substan-
tially from treatment with the haemoﬁlter, regardless of the severity of their condition.
Furthermore, drug resistance arguably gets more coverage in the press than any other
malaria related news, and the ability to oﬀer an alternative treatment to these patients
could create signiﬁcant buzz around the device, helping to drive adoption.
5.2.2 Hospitalised patients
The majority of malaria patients who are admitted to hospital in endemic countries,
whether in public or private units, are complicated or severe cases, or at risk of becoming
so. Other patients are simply given a course of anti-malarial tablets and sent home. The
deﬁnition of complicated and/or severe varies from country to country, but the WHO has
a deﬁnition of severe, which is typically used to categorise patients. However, using this
method, most patients admitted would not be considered severe - one study in found that
only 17% of malaria patients admitted to a hospital were `severe' according the WHO
deﬁnition, while all would be considered `complicated'[228].
When a patient presents at hospital with malaria-like symptoms (e.g. fever), malaria is
typically conﬁrmed within about 30 minutes using Giemsa stained blood smears, whereby
the patient is admitted and immediately given anti-malarial medication, usually either
quinine or artesunates intravenously. Their chances of survival, which varies considerably
between countries, depends largely on their parasitaemia upon admission[229, 230]. In
this scenario, the haemoﬁlter would be used as soon as possible, in order to reduce the
patient's initial parasitaemia and increase the chances of recovery.
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The immune response that causes malarial symptoms is caused by rupturing infected
cells, which result in circulating debris within the bloodstream (see section 1.2.4). In
the case where a patient with high parasitaemia is treated with intravenous drugs, these
symptoms can worsen immediately after drug administration, as the immune system re-
sponds to the debris created by the large number of cells killed. In some cases, this
response can be so severe as to cause death. Using the haemoﬁlter to remove the infected
cells, particularly mature trophozoites and schizonts, would reduce or even eliminate these
side-eﬀects.
Using the haemoﬁlter alongside existing drugs to treat hospitalised patients could not
only decrease mortality in severe cases, but also reduce average inpatient time. The time
between administration of treatment and patient discharge from hospital, and indeed
symptom elimination, is linked to the initial parasitaemia. Reducing this using the hae-
moﬁlter could therefore help patients to recover faster, enabling hospitals to discharge
them in a shorter amount of time.
5.2.3 Non-severe patients
The haemoﬁlter could have a beneﬁt for all malaria patients when combined with the
anti-malarial tablet courses, such as Coartem, typically given to acute non-complicated
patients. Currently, complete recovery using typical drug courses frequently takes over a
week (see Appendix B). Symptom elimination time is linked to the length of time between
infection and beginning the drug course, or in other words is linked to the parasitaemia
when the course is started. Furthermore, as with severe patients, the courses can cause
side eﬀects similar to malaria symptoms, such as head-aches and vomiting[231]. Treating
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a patient with the haemoﬁlter on the day they start the drug course could therefore
reduce the time to symptom elimination by increasing the drug's eﬃcacy and reducing
its side-eﬀects.
Anti-malarial tablet courses are often heavily subsidised by the state, so the cost
to the patient is generally low or negligible. Furthermore, many patients in endemic
countries acquire the drugs from pharmacies where there can be a wide choice, including
very cheap (although less eﬀective) options. Haemoﬁltration cannot compete on cost with
these treatments, and it is unlikely that the health systems of endemic countries, or indeed
any other sponsor such as a charity, would subsidise a treatment that does not save lives,
but simply quickens recovery. Therefore, patients in this group would be those in private
healthcare, with health insurance or paying for their own treatment.
5.3 Beachhead market
5.3.1 Patient segment
Each of the three patient segments detailed in section 5.2 stands to beneﬁt from the
treatment. From a commercial perspective, each has its advantages and diﬃculties, but
one needs to be selected as the niche segment on which to focus initially. The best group
in which to start is not necessarily the one with the largest total addressable market,
but rather the one which would best facilitate getting to market and best drive adoption
to the other groups. Furthermore, the development of the haemoﬁlter into a product is
likely to heavily depend on grants, be they business, engineering, research or medical (see
section 5.6). The patient segment focus should therefore be the one that provides the
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best chances of winning a wide range of supporting grants; most grants that would be
targeted focus either on human impact or commercial potential.
The group that best fulﬁls these criteria is the hospitalised severe group, which strikes
the right balance of human impact - it is the group in which most lives stand to be saved
- and commercial potential - there is a large and growing hospitalised malaria patient
population, driven by urbanisation and rising middle classes in endemic countries. Since
clinical trials would have to be performed in hospitals in any case, it is easiest to perform
clinical trials on this group, as they are all concentrated in one place. It is also the best
group from which to drive adoption, as the clinical trials will demonstrate not only if
there is reduced mortality but also if there is reduced recovery time and, importantly,
the size of these reductions. The treatment could be available in both public and private
hospitals.
Non-severe patients in private healthcare will only pay for a treatment which is proven
to provide the beneﬁts they are paying for with no risks of complications, and their pain is
much smaller than severe patients. The value proposition to the former is to return to work
faster, while to the latter it is to increase their chances of surviving the disease. Non-severe
patients seeking haemoﬁltration through private healthcare would also be harder to reach,
as they often attend small clinics rather than large hospitals. It is also a bad segment to
focus on initially because haemoﬁltration would be perceived as a treatment for the rich,
attracting negative publicity and making it more diﬃcult to raise development money
from grants. However, once the beneﬁts of haemoﬁltration have been demonstrated, and
it has generated some noise and excitement, this segment could be the most proﬁtable in
the long term.
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Billing the haemoﬁlter as a treatment for patients who are currently untreatable,
particularly drug resistant patients or pregnant women, could be a very useful marketing
tool. Drug resistance in particular gets a lot of media attention. Proposing a drug-free
treatment in an era of emerging drug resistance (as discussed in section 1.2.7) could also
increase the liklihood of being awarded grants to develop the device. However, it is a
challenging segment from a commercial perspective, ﬁrstly because there is a relatively
small number of untreatable patients, and secondly because they are widely dispersed.
Particularly in cases of drug resistance, the patients can in fact be very diﬃcult to locate
and identify. The ability to `treat the untreatable' should therefore be a core part of
the marketing of the device, but not the main initial focus of product development and
market penetration.
In conclusion, hospitalised severe cases are the best segment to focus on initially,
enabling the haemoﬁlter to get a foothold in the market, demonstrating its beneﬁts and
driving wider adoption. The segment of non-severe patients in private healthcare is likely
to be the most proﬁtable in the long term due to the large numbers and high potential
margins. Growth and expansion should therefore be focussed on this segment. Meanwhile,
`treating the untreable' should remain a mantra of the commercialisation vehicle in order
to increase awareness of the device, but should not, at least initially, be a primary focus
of commercialisation, as the segment is likely to prove the most challenging and least
proﬁtable.
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5.3.2 Starting country
Having selected a niche patient segment, 7 countries with the high malaria burdens -
Brazil, The Democratic Republic of Congo, India, Indonesia, Kenya, Nigeria and Thailand
- were analysed in order to select the one in which to focus initially (see table 5.1). The
ideal country would have:
1. A large number of patients and deaths, in order to have a large addressable market
and be able to achieve the maximum human impact.
2. A large number of hospitals, since the initial focus will be on hospitalised patients,
and the treatment may well be limited to tertiary healthcare facilities for some time
after launch.
3. A well funded public healthcare system. Patients in endemic countries are often
from poor backgrounds and rely on the public healthcare system to provide their
treatment. That system will therefore be a major driver of adoption and, in many
cases, a very important customer.
4. A large private healthcare market, helping to drive adoption and growth. Many
patients in the initial target segment will be in private hospitals which are less
price-sensitive and often more eﬃcient than public units, facilitating sales.
5. A mixture of P. vivax and P. falciparum. As discussed in section 1.2.4.3, the treat-
ment may be more eﬀective on P. vivax than on P. falciparum, due to cytoadherence.
However, the impact on survivability could be greater on P. falciparum patients, as
the mortality rates are much higher. As such, the country in which the device is
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ﬁrst used should ideally have a mixture of both strains, so that the diﬀerent eﬀects
on each can easily be tested.
The conclusion from the analysis was that the best country in which to start is India. It has
a large number of malaria cases, which are widely agreed to be largely underestimated
by the WHO - some estimate that malaria may account for up to 3.6% of deaths in
India[17, 18]. Furthermore, despite healthcare funding varying in diﬀerent states, malaria
patients in India are more likely than in most endemic countries to be able to reach a
hospital with relative ease. While the national healthcare system remains underfunded
and faces challenges in its goal of delivering good quality healthcare to all Indians, there
are increasing numbers of high quality units throughout the country, reﬂecting India's
status as a large emerging economy with commendable healthcare ambitions. The private
healthcare market is also large and growing. It accounted for 63% of hospital beds in
India in 2010, up from 49% in 2002, creating over 70% of India's new hospital beds
in that period[232, 233]. Finally, there is approximately a ﬁfty-ﬁfty split between P.
falciparum and P. vivax in India[4].
5.3.3 Size of beachhead market
Comparing India to the other countries in Table 5.1 indicates that the best beachhead
market is hospitalised patients in India, the majority of whom will be severe patients.
However, the number of patients in this segment is unclear, with no oﬃcial statistics for
the number of hospitalised malaria patients available. While India does have a system
for reporting on the burden of malaria in the country, it, along with the WHO, is widely
criticised as being inaccurate[16, 17, 18, 235, 236]. Indeed, even Dr Neena Valetcha,
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Table 5.1: Analysis of countries with high malaria burdens[4, 234, 233]
director of the National Institute for Malaria Research in India, who was contacted during
the market research process, said that she was unable to provide an estimate, and that
"no one knows".
In order to estimate the number of malaria patients admitted to hospital in India each
year, six diﬀerent methods were used, combining statistics and estimates from diﬀerent
sources. The results, shown in Table 5.2, demonstrate the diﬃculty in achieving a reliable
estimate. The results for the total number of hospitalised severe patients range from
16,300 to 205,000, with an average of 96,000 and standard deviation of 69,000. The
results for the total number of hospitalised patients, range from ca. 100,000 to ca. 1.2
million, with an average of 566,000 and a standard deviation of 406,000. These were
calculated assuming that 17% of patients in hospital are severe, a number taken from
Singh et al.[228].
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Table 5.2: Estimating number of hospitalised patients in India[4, 17, 229, 228, 237, 234]
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5.3.4 Expansion
Once the haemoﬁlter is established in the beachhead market, growth should be targeted at
non-severe patients in private healthcare units in India, and hospitalised patients in other
endemic countries, with Nigeria the best country to focus on second. Indonesia could
also be a lucrative market, while Thailand and Cambodia (not included in the analysis
in Table 5.1 due to its low comparitive burden) should not be neglected as the countries
in which drug resistance is emerging (see section 1.2.7). Moving forward, growth is likely
to come from large cities in endemic countries, particularly in Africa.
There may also be a signiﬁcant market in non-endemic countries to treat imported
cases, where hospitals are under more pressure to oﬀer the best available treatments and
margins can be signiﬁcantly higher than those achievable in emerging markets. There
were 1,500 imported cases in the UK in 2013, and the WHO estimated that there were
6,250 cases in Europe in 2010, although some claim the real ﬁgure could be as high as
36,000[238, 239, 235]. In the USA, the Center for Disease Control reported 2,000 cases in
2011, an increase of 14%[240].
5.4 Pricing and margin
5.4.1 Value propositions
The value propositions to patients are simple, ranging from the haemoﬁlter being the only
treatment option, to increasing the chances and speed of recovery. However, there also
needs to be a strong value proposition for the hospitals or healthcare systems who will
be purchasing the instrument and disposables from the company or its distributor. The
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value propositions vary between private and public units, but include:
1. The chance to save lives
2. Reduced inpatient time, freeing up beds
3. Able to treat patients who would otherwise be untreatable
4. Demonstrate that the hospital is innovative and oﬀers the latest treatments
5. Higher average proﬁt per malaria patient
6. Reduced average cost of treating a patient
7. Reduced cost per death averted
Which of these value propositions are most important will vary from hospital to hospital,
and depend largely on whether the hospital is in the public or private sector. For example,
a hospital in the private sector probably cares more about increasing proﬁts, so would be
most interested in increasing the number of patients and the average proﬁt per patient
rather than freeing up beds or reducing cost per death averted. A public hospital, on the
other hand, has no interest in proﬁts, but would likely be more attracted by the possibility
of reducing the average inpatient time and cost of treating a patient.
5.4.2 Cost beneﬁts of haemoﬁlter
If the haemoﬁlter delivers on the promised patient beneﬁts - decreased mortality and
recovery time - value propositions one through ﬁve are likely. However, numbers six
and seven require further investigation. In order to see if the haemoﬁlter could deliver
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Table 5.3: Average cost of treating a severe patient in India[229]
cost reductions to hospitals, the current cost of treating a severe patient in India was
investigated.
According to Lubell et al., in 2009 the average cost of treatment with artesunates is
$70.30, or ¿43.60 ($1 = ¿0.62). With a mortality rate of 21.4%, the cost per death averted
was ¿55.50. The average inpatient time of patients in Lubell's study was 4.6 days. The
average inpatient care cost in India is $10.25 per day, yielding a total average inpatient
care cost of $47.30 (¿29.34). The artesunates, which are administered intravenously
several times a day, cost on average $4.68 per day, resulting in a total drug cost of $21.60
(¿13.40)[229]. These costs are summarised in Table 5.3.
These ﬁgures clearly demonstrate that reducing the average time in hospital could
have a signiﬁcant eﬀect on the average cost of treating a patient and the cost per death
averted. Reducing the average inpatient time to two days, for example, could provide
a cost saving of ¿25 (Fig. 5.1). The impact that reducing both inpatient time and the
average mortality rate has on the cost per death averted is shown in Fig 5.2. Reducing
the inpatient time to two days and the mortality to 10% would reduce the cost per death
averted by ¿34.50 to ¿21. This excludes the cost of haemoﬁltration, but provides an
indication of how the treatment could be priced if it provides the anticipated beneﬁts.
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Table 5.4: Bill of materials for consumables
With an inpatient time of two days, a mortality rate of 10%, and a haemoﬁltration cost
of ¿25, the average total cost of treating a patient would not change, but the cost per
death averted would decrease by ¿9.50. If the price of the haemoﬁtler was such that its
use would provide an overall cost saving, it would be much easier to sell to hospitals and
healthcare systems, helping to drive adoption.
5.4.3 Manufacturing cost of consumables
In order to investigate the price at which the haemoﬁlter would be sold, the manufacturing
cost of the consumables required for each treatment was estimated. The parts required
for each set of consumables are (Fig. 5.3):
 2x male Luer connectors: used to connect the device to the catheter
 2x female Luer connectors: used to connect the saline drip bag and heparin syringe
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Figure 5.1: Cost savings achieved by reducing average inpatient time
Figure 5.2: Cost per life saved for diﬀerent mortalities and inpatient times
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Figure 5.3: Sketch of blood circuit showing parts required for the consumables
 2x pinch clamps
 2x tee junctions: used to interface the saline bag and heparin syringe with the circuit
 1x 3ml syringe: included to ensure that the syringe with which the heparin is injected
is always the correct type (in terms of dimensions and interface)
 4ft of 1.6mm inner diameter, 3.2mm outer diameter silicone or polyethylene tubing
 Separation chamber casing
 Ferromagnetic (SS430) stainless steel mesh
Note that no speciﬁc part is required for air detection within the blood circuit - the
transparent tubing can be simply passed through a detector on the instrument.
Suppliers for each of these parts were approached for quotes to estimate the total cost
of the materials required to manufacture 1,000 sets of consumables. These were combined
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Table 5.5: Comparison of manufacturing cost of consumables in UK and India[241]
in order to construct a complete bill of materials (BOM) (Table 5.4). The BOM for
each set was found to be ¿4.40. It is important to bear in mind that this is not volume
optimised, and that the price would drop signiﬁcantly when manufacturing hundreds of
thousands or millions of sets.
The BOM does not include the cutting of the mesh, assembly, or sterilisation, which
are all factored into the estimated labour time even though they could be outsourced. To
estimate the total manufacturing cost, this total labour time was estimated and combined
with average hourly wages as well as import tax and shipping costs to get an estimated
cost per consumable. The cost of manufacturing in the UK and in India were compared,
highlighting the size of cost saving that can be achieved by manufacturing in India (Table
5.5) - at ¿6.52, the cost of manufacturing in India is less than 25% of the cost of manufac-
turing in the UK, which was estimated at ¿27.40. This is primarily due to the diﬀerence
in labour costs, but also due to India's 38% import tax.
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Figure 5.4: Gross proﬁt earned vs. percentage of beachhead market reached
5.4.4 Margin and proﬁt
Section 5.4.3 estimates a manufacturing cost of about ¿6.50 per consumable, while section
5.4.2 demonstrates that it could be sold to a hospital at a total cost of about ¿25. This
implies a proﬁt of ¿18.50 that the company would need to share with the distributor.
The distributor would likely want a margin at least equivalent to the company's, giving
a proﬁt of ¿9 per treatment. This represents a margin of 58%.
Combined with the estimate from section 5.3.3, Fig. 5.4 shows the gross proﬁt earned
versus the percentage of the beachhead market that is reached. If the company had
estimated ﬁxed costs of ¿500k, it would need to sell to 10% of the hospitalised patients
in India in order to break even.
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5.4.5 Revenue model
Section 5.4.4 demonstrates that it is possible to earn a margin on the disposables that
are required for each treatment. This is crucial, as the haemoﬁlter will be commercialised
using a `razors-and-blades' model, where most of the proﬁts come from the consumables
and not the instrument[242]. This model is widely used in several industries, for example
desktop printers, where companies such as HP make little or no proﬁt from the printer
itself, but earn high margins on the ink cartridges which are required for, and only com-
patible with, their printers. A highly relevant comparison to the haemoﬁlter are dialysis
machines, which reguarly use a similar revenue model in which they lease the instrument
to hospitals who then purchase the tube sets and cartridges required for each treatment.
5.5 Route to market
5.5.1 Milestones
As the haemoﬁlter is a medical device, a number of hoops need to be jumped through
before a product is ready to be sold to the market:
1. Safety trials : before approval is given to conduct clinical trials (in the UK, approval
is given by the Medicines and Healthcare products Regulatory Agency (MHRA)),
safety trials need to be conducted on healthy subjects in order to demonstrate that
the device does not cause any harm. Typically, an animal safety trial is required
ﬁrst, followed by a human safety trial. The latter would be conducted on volunteers
(who would be compensated) in collaboration with a hospital or vetinary college
with haemoﬁltration or extra-corporeal dialysis experience.
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2. Clinical trials : in order to obtain regulatory approval and have a product that can
be sold, its clinical beneﬁts need to be demonstrated in one or several clinical trials.
For the haemoﬁlter, these will be conducted on patients that ﬁt into the beachhead
market segment (i.e. hospitalised in India). The indication criteria for inclusion in
the trial will have to be very well deﬁned, including details such as parasitaemia
cut-oﬀ points, age, severity, etc.
3. Regulatory approval : in the EU, CE marking is required; in the USA, Food and
Drug Administration (FDA) approval is required. Most countries have their own
regulatory body which needs to certify the device before it can be sold. While they
are not essential, having CE marking and/or FDA approval greatly facilitates the
regulatory pathway in new markets. Getting these can be an expensive process, not
least because of the required testing to prove biocompatibility and non-toxicity.
These constitute the main milestones that a company commercialising the technology
would have to achieve, and each has its own subset of tasks that will need to be carried
out. Product development should be streamlined as much as possible in order to achieve
the three milestones quickly and in a cost-eﬀective manner. However, it is also important
to ensure that the right questions are answered at each step. For example, the prototypes
used to demonstrate product safety must be internally identical to what would be used
on a patient in a clincal setting, as any change to the dimensions or ferromagnetic matrix
could cause unanticipated eﬀects. Therefore, before the safety trials can be conducted,
the device design and speciﬁcations need to be ﬁnalised, and further biocompatibility and
toxicity tests performed.
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5.5.2 Product development
5.5.2.1 Cost estimates
Product development, achieving the milestones above, will be the most expensive aspect of
commercialisation. In order to estimate the costs of developing a CE marked instrument
and consumables, a medical device prototyping company, EG Technology (Cambridge,
UK), was approached and asked for both top-down and bottom-up estimates of the total
cost. The top-down estimate was ¿2 million, while the bottom-up estimate was ¿1.125
million, as detailed in Table 5.6. It should be noted that these estimates exclude any
unforeseen problems or changes.
5.5.2.2 Development strategy
As the milestones will need to be achieved in order to generate any revenue, all expendit-
ure on product development will need to come from investment into the company. The
estimates from EG Technology underline the need to streamline the product development
process in order to reduce the size of investment needed to get to market. Table 5.6 shows
that, of the ¿1.125 million, about ¿800,000 is needed to develop the instrument, while
around ¿325,000 is needed for the consumables.
The instrument is expensive as it includes all the safety mechanisms, needs to consist
of medically approved parts, required custom electrons and software, etc. However, in
the safety and clinical trials, it is the consumables that are being tested (along with the
external magnets), and not the instrument, which is essentially a blood pump. The trials
could be conducted using medically approved commercial blood pumps with the necessary
safety controls (e.g. pressure monitors) already included. The trials therefore only require
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Table 5.6: Cost estimates for product development (from EG Technologies,
Cambridge, UK)
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prototypes of the consumables, which could be manufactured in-house, for lower than the
price quoted by EG Technology.
5.5.2.3 Prototypes of consumables
The consumables, and more speciﬁcally the separation chambers, constitute the most
important part of the device. The ﬁnal design, based on the work described in section
3.2.4, would be checked by dialysis experts, conﬁrming that characteristics such as the
ﬂow rates that will be used are appropriate. There will be several diﬀerent sizes produced
so that patients from infants through to adults could be treated, and each size will incur
its own tooling costs. They will all undergo the same assay tests as the donated P. vivax
samples from section 4.4, and any further tests that may be required (e.g. detection of
trace metals), before being used in safety and then clinical trials.
The separation chambers would need to be manufactured using medically approved
plastic, probably using injection moulding. Moulds would need to be tooled for each
chamber size, and each of these would incur a signiﬁcant cost - one can cost tens of thou-
sands of pounds. However, once the tools are made, the chambers could be manufactured
by a professional medical device manufacturer relatively cheaply.
The stainless steel mesh would need to be cut to size and loaded into each chamber,
as described in section 3.5. This is a time-consuming process and, to be both rapid and
precise, would require specialised machinery. As such, it would probably be more cost
eﬀective to outsource the mesh cutting, avoiding the capital expenditure that would be
required to purchase the equipment and hire the staﬀ required for in-house cutting.
While the manufacture of the separation chamber cases and the cutting of the mesh
would be outsourced, the ﬁrst prototypes could be assembled in-house. The required
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parts, described in Table 5.4, would be purchased from a medical equipment supplier
(e.g. The West Group, UK), and the circuits described in Fig. 5.3 assembled. The parts
would be sterilised in an autoclave in advance of assembly, which would take place under
sterilised conditions. Each consumable would need to be packed into sterilised packaging
ready for use in the trials.
5.5.2.4 Development of the instrument
The instrument consists of the following parts:
 Magnetic assembly
 Peristaltic pump to drive the circuit
 Syringe pump for heparin
 Pressure monitor
 Air bubble detector
 UI
 Display panel with information on current ﬁltration
In order to minimise product development costs and focus investment on getting clinical
data, commercial equipment will be used where possible, including for example the syringe
pump used during this project (see section 4.1.3) and a blood pump such as the Graseby
Model 500 Volumetric Infusion Pump (Graseby, Watford, UK), a variable speed peristaltic
pump with an occlusion pressure monitor and an air bubble detector included. One
of these pumps has generously been donated by Smiths Medical (Watford, UK). The
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magnetic assembly, meanwhile, would be the same model used throughout this project
(see section 3.3).
In the longer term, it would be desirable to develop an instrument intended for use
solely with the consumables, incorporating all the above parts and required features into
one piece of equipment. As mentioned in section 5.5.2.1, this would incur signiﬁcant costs
and would require a large investment round which would be sought at the earliest after
the safety trials have been completed.
5.5.3 Intellectual property and competition
While there is no magnetic haemoﬁlter currently on the market, there is signiﬁcant prior
art which may limit the scope of any patent that is ﬁled, if indeed a patent could be
ﬁled. As discussed in Chapter 2, HGMS is a well-established technology that has existed
for over 100 years. There are several biological applications already commercialised, and
some patents covering the area of magnetic haemoﬁltration, including one that proposes
using it as a method to treat malaria[106, 131, 132, 243, 244, 136, 245, 200, 139, 202].
While the prior art does not necessarily rule out the ﬁling of a patent - the magnetic
haemoﬁlter described in this project is signiﬁcantly diﬀerent to other technologies in its
design and implementation - this creates a challenging IP environment. There are several
strategies that could be adopted and diﬀerent avenues of IP protection available despite
these challenges. There is, for example, signiﬁcant know-how and protectable design rights
associated with the technology. The company commercialising the ﬁlter could also `black
box' the technology, maintaining its operation as a trade secret.
However, regardless of the chosen IP strategy, the device, by its nature, will remain
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easy to reverse engineer, opening up the possibility of counterfeits appearing on the mar-
ket. This is likely to be particularly problematic in malaria endemic countries, in which
it is typically more challenging for a foreign company to protect its innovations and tech-
nologies. One advantage is the high barriers to entry that need to be overcome in the
healthcare industry - competing products will need regulatory approval, which may dis-
courage counterfeits and their use.
One method of remaining competitive is to build a strong brand around the company
and the product. People need to know and trust the product, so that they are suspicious
of, and reluctant to try, alternatives. As such, marketing will be very important for the
company commercialising the haemoﬁlter.
5.6 Funding
5.6.1 Funding rounds
Several investment rounds will be required to get to market. Each round has speciﬁc
targets to achieve, with the aim of eliminating risks suﬃciently to enable the next stage
of funding. The targets for each round are:
1. Seed round: ready for clinical trials
(a) Working prototypes of consumables with the ability to manufacture more
(b) Safety trials completed with permission for clinical trials
2. `A' round: ﬁrst customer
(a) Clinical data proving reduction in mortality
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(b) Working prototypes of instrument
(c) CE marking
(d) First customer
3. `B' round: proﬁtability
(a) Clinical trials proving beneﬁts for non-severe patients
(b) Grow into other markets
(c) Product optimisation
(d) Company proﬁtable
The seed and A rounds could consist of both private capital, for example from angel
investors, and grants, for example the innovateUK biomedical catalyst or the EU SME
instrument. It is estimated that ¿500,000 would be needed to achieve the goal of being
ready to conduct the ﬁrst large clinical trials. This includes development of prototype
consumables, benchtop biocompatibility tests, animal and human safety trials, salaries for
two staﬀ members, legal costs and operating costs (e.g. oﬃce, telecoms, website building).
The `A' round provides the investment needed to get the ﬁrst customer, with most of
the funds being spent on clinical trials and product development, getting to CE marking
and a saleable product. It is estimated that ¿2.5 million would be required to get the ﬁrst
paying customers. Of this, ¿2 million would be spent on product development and trials,
while ¿500,000 would be spent on salaries and operating costs. As with the seed round,
this investment could be a mixture of private capital, probably from a venture capital
fund, and grants. Partnerships with companies, institutions, charities or governments
could also be a valuable source of funding. The cost of the clinical trials, for example,
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could be shared between the company, the Indian government, and a charity like the Bill
and Melinda Gates Foundation.
At this stage, it is not possible to provide a reliable estimate for how much would be
needed at the B round, since it depends on the results of the clinical trials and what the
objectives of the company are at that time. However, since the goal would be to grow
the company new markets as quickly as possible, it is likely that a large investment round
would be required. This could come either from venture capital or as part of a trade sale,
and could be a logical exit point for the founders.
5.6.2 Estimated spending
Table 5.7 shows the estimated spending on various items up to the B round investment.
These were assembled after discussions with business experts, prototyping companies,
and healthcare companies. The product development costs include designing, tooling and
testing, amongst other activities as described in section 5.5.2. They do not include the cost
of manufacturing or assembling prototypes, which were estimated to cost on average ¿100
each for the consumables, and ¿20,000 each for the instruments, including sterilisation
and packaging. The total was based on an estimated number of prototypes that would
be needed for benchtop testing, optimisation and the safety and clinical trials.
The costs of safety trials were estimated after talking to experts in the area. It was
estimated that the animal safety trials, with seven pigs, would cost ¿30,000, while the
human safety trials, with 10 healthy subjects, would cost ¿50,000. The clinical trials,
involving at least 50 patients, were estimated to cost ¿400,000. This is the same as the
cost of clinical trials quoted by a European healthcare company at a similar stage, and
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may in fact be smaller if the trials are carried out in India.
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Table 5.7: Estimated company expenditure until B round
Table 5.8: Company employees up to B round (grey shading indicates two employees)
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The salary costs assume a gradually increasing team size, from one employee initially,
to nine by Q3 2016 onwards, as can be seen in Table 5.8. The staﬀ required and their
salaries were estimated after consultancy with business experts, including prior and cur-
rent CEOs of medical device start-ups. The operating costs include all the costs associated
with running the business (oﬃce, telecoms, website maintenance) as well as the cost of
business trips and conferences. The ﬁgures also include legal fees incurred due to IP
protection, contracts and deals.
5.6.3 Required investment
The Gantt chart in Fig. 5.5 summarises the conclusions regarding activities and funding.
The analysis in Table 5.7 shows that the company will need approximately ¿450k in the
seed round, and a further ¿2.35 million in the A round. Allowing for some contingency,
and assuming that some unforeseen delays will be encountered, the total funding required
to get to the B round (i.e. the ﬁrst customer) is estimated to be ¿3 million, consisting of
a ¿500k seed round and ¿2.5 million B round.
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Figure 5.5: Gantt chart outlining commercialisation plan
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5.7 Conclusion
This section presents an analysis of the commercial viability of the magnetic haemoﬁlter
as a treatment for malaria, as well as a suggestion for how a company might undertake
commercialisation. The analysis successfully identiﬁed a number of customer segments
(i.e. patients who could beneﬁt from the treatment), and, after considering several en-
demic countries with very high burdens, concluded that the best beachhead market is
hospitalised patients in India. This market segment promises high human impact, enables
relatively hassle-free clinical trials, drives adoption, and is quite large, with an estimated
TAM of over half a million patients. There is signiﬁcant potential for growth, with a large
number of endemic countries to grow into - half the world's population is in an endemic
region - and large and growing private healthcare markets in many of those countries.
The analysis suggests that it will be possible for a company to earn a healthy margin
on each treatment, by both saving patients' lives and reducing hospitals' costs. However,
this analysis is based on the current cost of treating a severe patient in India. The cost in
other endemic countries may be signiﬁcantly lower, and the healthcare system less able to
aﬀord the treatment. Any proﬁtable commercial activities in these countries would have
to focus on the private healthcare market. Here, there is still a strong value proposition,
even for non-severe patients, if the haemoﬁlter is able to signiﬁcantly decrease recovery
time.
The route to market has been identiﬁed, a roadmap has been outlined and costs
of getting to market have been estimated. The results from this analysis resulted in the
conclusion to focus development and funds on the consumables initially, and to eventually
adopt a `razor-and-blades' model. It also demonstrated that product development and
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prototypes would account for almost half of the total expenditure, with salaries accounting
for a further quarter. The conclusion from this analysis was the two funding rounds would
be needed to get to market, consisting of a seed round of ¿500k and an A round of ¿2.5
million. Both of these would be sourced from a mixture of private capital and public
grants, with the target of using this investment to get the ﬁrst customer by mid-2017. At
that point, a further investment round would be required, which might provide a logical
exit point for the company's founders.
In conclusion, the commercialisation of the haemoﬁlter is a viable venture and worth
pursuing. However, despite the commercial potential, it is clear from the manufacturing
costs estimated in section 5.4.3 that many of the patients who need this treatment will
be unable to aﬀord it, and many healthcare systems are likely to be unable to provide it.
Any company commercialising this technology therefore needs to carefully consider the
ethical implications of the business, as the ultimate goal has to be to enable access to as
many people as possible and achieve the maximum possible human impact. One solution
to this would be to partner with the organisations who currently provide funding for much
of the malaria treatment and prevention in the world, such as the Bill and Melinda Gates
Foundation and the Global Fund to Fight AIDS, Tuberculosis and Malaria. The company
could provide instruments and consumables to these organisations at-cost.
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Chapter 6
Discussion and Conclusions
6.1 Magnetic haemoﬁlter performance
In this project, the centuries old principles of HGMS have been used to design a novel
magnetic haemoﬁlter medical device, capable of removing magnetic material directly from
a patient's bloodstream. The design is successful in terms of fulﬁlling the initial require-
ments set out at the start of the design process (see section 3.1.1):
 High eﬃciency : although not consistently reaching the target eﬃciency of 90%,
the device successfully lowered the parasitaemia in all experiments with an average
separation eﬃciency of about 65%. Variations in the performance were principally
due to diﬀerent initial parasitaemias, which seemed to have a greater eﬀect on the
ﬁltered parasitaemia than the ﬂow rate. Eﬃciencies of close to 90% were achieved in
several experiments, and eﬃciencies of 70-80% were common. The objective should
still be to increase these values, but the intial results are very promising and indicate
that high separation eﬃciencies are possible.
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 High selectivity : the experiments conducted with donated P. vivax indicate that
there was no false positive capture of uninfected cells. However, this requires further
investigation, particularly by analysing the contents of the separation chambers after
ﬁltration to ensure that there is no consistent false positive capture. This was only
done to a limited degree in this study.
 High throughput : the ﬂow rates used in the experiments are orders of magnitude
higher than any that have been previously reported in the literature (see section
2.2.1). Scaled up to the clinical-scale designs, the ﬂow rates used enable acceptable
treatment times of only a few hours. As with the eﬃciency, the target should always
be to increase the throughput, but these intial results are very promising, and even
before optimisation are already suﬃcient for a clinical device.
 Able to incorporate diﬀerent chamber types : the four chamber sizes, intended for
infants, children, youths and adults, all integrate easily into the same magnetic
assembly, producing consistent magnetic forces across a range of ﬂow rates. The
design is highly ﬂexible, allowing modules to be added or removed for diﬀerent
applications, and could be used on chambers with volumes varying from <1ml to
>250ml. Furthermore, the magnetic force can easily be increased by reducing the
separation between the magnetic assemblies, creating a much higher magnetic ﬁeld
in the chamber area to provide even more ﬂexibility.
 Controlled, consistent and variable ﬂow rates : the chamber and assembly design
easily allow for diﬀerent ﬂow rates, and bespoke chambers capable of much smaller
ﬂow rates could be designed to integrate with the magnetic assembly. In the exper-
iments, the ﬂow was provided by a syringe pump, but in a clinical device would be
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provided by a highly accurate peristaltic pump. Future testing of the device should
employ an appropriate pump to ensure that the results are repeatable.
 No harm caused to other blood components : the full blood counts performed on
samples of blood donated by patient infected with P. vivax demonstrate that the
device does not cause any harm to other blood components. Light microscopy
analysis did not reveal any haemolysis, further supporting this conclusion.
 Intuitive and easy-to-use: the device has been designed to be `plug-and-play', with
very little user input required. An appropriate UI will need to be designed, but the
device will be useable by anyone who can insert a cathetar. In principle this would
be a procedure that could be carried out by any trained nurse, although in practice,
more senior staﬀ supervision will be required, especially as the treatment ﬁrst enters
the market.
 Cheap to manufacture: both the consumables and the magnetic assembly have been
designed to be simple and cheap. The consumables will have amanufacturing cost of
less than ¿5 each, and even if each treatment costs over ¿20, the haemoﬁlter could
still reduce the total cost-per-death-averted (see section 5.4.2).
The design is therefore deemed ﬁt for purpose, performing beyond expectations in these
ﬁrst tests. While further improvement would be desirable, and a lot of development work
is still required to turn the bench-top prototype into a viable clinical product, the work
presented here clearly demonstrates the potential of the design and can be taken as the
ﬁrst step towards a novel medical device for the drug-free treatment of malaria.
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6.2 Potential as a medical device
The results in this thesis indicate that the magnetic haemoﬁlter has signiﬁcant potential
as a novel medical device. It has been shown to be both technically and commercially
viable, both of which are essential for the success of any medical device. Designed from
the start with end-users in mind, the haemoﬁlter is simple, ﬂexible and cost-eﬀective.
The consumables and magnetic assembly have low manufacturing costs and can easily be
modiﬁed to enable diﬀerent separation chambers and ﬂow rates to be used. The instument
is easy-to-use, would have a long lifetime, and will be compatible with any number of
diﬀerent blood circuits and separation chambers intended for diﬀerent applications.
6.2.1 Malaria
The focus within this thesis has been on the potential use of the haemoﬁlter as a medical
device to treat malaria patients. This potential has been demonstrated through the
testing and results presented in Chapter 4, which shows that the haemoﬁlter is capable
of capturing malaria-infected erythrocytes, and could achieve signiﬁcant reductions in
patient's parasite burdens in a short time period. The device would be the world's ﬁrst
medical device for the treatment of malaria, as well as the ﬁrst drug-free treatment. It
could be used in combination with other treatments or as a standalone therapy, and has
the potential to deliver signiﬁcant beneﬁts to a wide range of patients, improving recovery
and saving lives.
However, it should be noted that a lot of work is still required before the goal of using
the haemoﬁlter as a drug-free method for treating malaria (and indeed other conditions)
can be achieved. The results are positive, but inconsistent (the target of 90% eﬃciency
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was not achieved), and a medical device would need to be able to rapidly, reliably and
repeatedly reduce a patient's parasitaemia every time it is used. Furthermore, questions
remain as to the safety of the device, notably the potential for false positive capture of
healthy cells, causing haemolysis and activation of leukocytes. Some signiﬁcant engineer-
ing challenges have also not beed addressed, speciﬁcally methods for priming the blood
circuits, ensuring that no air bubbles are formed or returned to the patient and no blood
clots are formed. The potential for saturation of the ﬁlter has also not been investigated,
due to the small samples volumes used in the experiments.
The commercial evaluation presented in Chapter 5 outlines how the haemoﬁlter could
be commercialised as a medical device to treat malaria. It shows that there is a market
for such a device, particularly thanks to its unique selling point of being the only drug-
free treatment. Commercialisation will require signiﬁcant investment to enable product
development and clinical trials, but the haemoﬁlter will be, relatively speaking, cheap to
get to market (compared to a new drug, for example). The haemoﬁlter has the potential
to have a signiﬁcant human and economic impact, helping to reduce the overall malaria
burden and cost. It could prove an invaluable new tool in the ﬁght against current and
future drug resistance.
However, the device's potential needs to be viewed in the light of not only the technical
challenges that still need to be faced, but also the commercial and logistical hurdles that
will need to be overcome to get the device into the hands of those who could eﬀectively
use it. Malaria patients are often in diﬃcult to reach areas and challenging environments,
with limited medical facilities and often no electricity. Being a relatively complicated
treatment (compared to tablets), the haemoﬁlter will face signiﬁcant adoption challenges,
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particularly as, at ﬁrst, it will only be possible to use it in a hospital environment.
Furthermore, which the costs have been kept low, they will still represent a barrier to
adoption in many malaria endemic countries where neither patients nor the healthcare
systems may be able to aﬀord the treatment. Any company commercialising the haemo-
ﬁlter will need to face these diﬃculties, and will certainly require the assistance of the
global anti malaria community, working with and getting support from organisations such
as the Global Fund, WHO and Bill and Melinda Gates Foundation.
6.2.2 Other applications
Despite the focus on malaria, the haemoﬁlter has been designed to be used in a wide
variety of clinical applications through the use of magnetic labelling. Chapter 2 gives an
idea of the type and number of potential applications and wealth of research in the area.
It is currently impossible to identify which of these techniques will prove most successful
in the long-term, but it is possible, if not likely, that magnetic haemoﬁltration will become
a commonplace treatment for a variety of ailments in the near future. Should some of
these applications come to light, the clinical and commercial potential of the haemoﬁlter
would increase drastically.
Those applications will all require a high performance magnetic haemoﬁlter capable
of removing the magnetically labelled targets with high eﬃciency and, more importantly,
high throughput. The magnetic haemoﬁlter presented in this thesis is unique in terms
of the potential ﬂow rates achievable in the scaled-up versions, providing the possibility
of ﬁltering several times a patient's TBV in a small time period. Its performance in
capturing malaria infected cells is hugely promising when considering other applications
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- they are very weakly magnetic compared to the MNP and magnetic beads used in
magnetic labelling techniques. The haemoﬁlter should therefore be able to achieve better
magnetic particle separation eﬃciencies at much higher ﬂow rates, potentially reducing
total treatment times to minutes.
While the device unquestionably holds the potential to treat a wide variety of diseases
and conditions, each will have its own signiﬁcant challenges in terms of development. The
biggest will actually be in the development of the magnetic particles, which will need
to able to survive in the bloodstream and be eﬀective at labelling the targets whilst not
labelling any other blood components. They will need to go through a stringent and
expensive regulatory approval process, and clinical trials will be required for each new
application.
6.3 Future work
6.3.1 Optimisation
There are many further tests that could be conducted to improve the design and optimise
the performance of the haemoﬁlter. These include:
 Further investigations into the relationship between the ﬂow rate and separation
eﬃciency, especially using whole blood from patients.
 Increased understanding of which infected cell stages are captured, and improved
capture of late ring-stage cells.
 Performance variation across diﬀerent samples, for example with varied initial para-
sitaemia or diﬀerent malaria species.
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 Optimisation of the ferromagnetic mesh in terms of materials and dimensions.
 Increased homogeneity of ﬂow rates, particularly for the larger clinical versions.
The overall goal should be to maximise ﬁrst the separation eﬃciency and then the ﬂow
rate, as demonstrated by the analysis in this thesis. Beyond that, investigations into
whether the device can capture gametocytes as well as infected erythrocytes could prove
very interesting. Their successful capture would imply that the device could have an eﬀect
on malaria transmission rates, although this would require its own study. Establishing
whether the capture of circulating gametocytes in hospitalised patients has an impact on
the spread of drug resistance, for example, would be a challenging research project.
The safety of the device, most importantly any potential aﬀect on blood components,
needs to be established beyond doubt. This includes ensuring that there is no false positive
capture of uninfected cells. While the experiments detailed in section 4.4 are a good start
in terms of testing safety, more work is required, notably continuous ﬂow experiments
conducted with the blood at body temperature. These would consist of a relatively large
sample of blood (e.g. 500ml) continuously circulated through the haemoﬁlter, with regular
monitoring to check for any harmful or undesirable eﬀect. It will be particularly important
to monitor for false positive capture, haemolysis and activation of WBC.
Furthermore, the protocol for using the magnetic haemoﬁlter as a medical device needs
to be well-deﬁned, with appropriate minimisation of any risks associated with its use. One
key issue is the priming of the device, ensuring that no air bubbles are formed within the
blood circuit. The current design of the chamber makes guaranteed elimination of all
air within it during priming a signiﬁcant challenge, and this will need to be considered
throughout the product development. One solution may be to ship the chambers and
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circuits `pre-primed' with saline, although this could have implications in terms of shelf-
life and maintaining integrity during shipping.
Another important consideration is the use of anticoagulant and its dosage, ensuring
that any coagulation within the separation chamber can be avoided while utilising dosages
which remain safe for the patient.
6.3.2 Medical device development
For the magnetic haemoﬁlter to become a successful medical device, a lot of further
development is required. In any country, a medical device needs approval from the relevant
regulators before it can be sold, probably with CE marking (EU) and/or FDA approval
(USA). Often devices imported into other countries need to be granted approval in the
country in which they are going to be sold (e.g. India). This is typically granted on the
back of approval from the manufacturer's country. As such, for this device, CE marking
is the ultimate goal.
In order to get regulatory approval, the device must be shown to be both safe and
eﬀective. This is done through benchtop toxicology studies, followed by safety trials on
healthy subjects and ﬁnally clinical trials, when the device is shown to deliver some clinical
beneﬁt. The magnetic haemoﬁlter will need to go through this process for each of the
separation chambers, culminating in a clinical trial on malaria patients with suﬃcient
participants to demonstrate that it increases survivability.
The clinical trials will need to answer a number of questions regarding the clinical
beneﬁts of the device. The most important are questions surrounding the device's eﬀect
on survival rates in cases of severe malaria:
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 Does the device reduce mortality?
 How much does a patient's parasitaemia need to be reduced by to have a clinical
beneﬁt?
 If the device is used in combination with antimalarial drugs, are these administered
before, during or after treatment with the haemoﬁlter?
 How important is it to reduce parasitaemia quickly?
 Should patients in the ICU be treated constantly with the device, or just given a
one-oﬀ treatment for a few hours upon arrival?
Other questions surround clinical beneﬁts beyond reducing mortality, such as whether it
can be used to treat drug resistant or other untreatable patients:
 Can the device deliver sustained clinical beneﬁts without being used in combination
with drugs?
 How often do drug resistant patients need to be treated with the haemoﬁlter?
 Can the haemoﬁlter trigger remission or help the patient build up a natural im-
munity?
Finally, the clinical beneﬁts of magnetic haemoﬁltration combined with drug treatments
for non-severe patients should be studied:
 Are symptoms eliminated more rapidly?
 Can drug dosages be reduced?
 Are side-eﬀects eliminated?
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All of these (and probably more) questions will need to be addressed at various clinical
trials in order to demonstrate the device's eﬀectiveness as a treatment for malaria. In
order to progress down this road, the clinical-scale versions of the device will need to be
manufactured and tested, along with an appropriate instrument comprising the magnetic
assembly, peristaltic pump, UI, safety controls etc. These will all need to pass the required
standards for medical devices and be part of appropriate trials.
Moving into the longer term, new versions of the device appropriate for use in more
challenging environments (i.e. outside of a hospital setting) should be developed. These
will need to build on and learn from observations regarding the safety of the device during
hospital use. There will be risks when using the device, including infection of the patient
through the device or cathetar, the formation of clots that can cause brain aneurysms,
or an embolism caused by air bubbles within the blood circuit returning to the patient.
In a hospital setting, the risk of these complications can be minimised and if they occur
appropriate action can be taken quickly in order to minimise the danger to the patient.
Outside of a hospital however, they could be fatal. A `portable' version of the device will
therefore need to be designed ensuring that these and other complications are rare and
minimised, and that there is an established strategy for tackling them when/if they occur.
6.3.3 Other applications
The review in Chapter 2 highlights the wide potential clinical applications of magnetic
haemoﬁltration. These range from the treatment of sepsis and viral infections, to blood
detoxiﬁcation and prevention of cancer metastasis. These applications still require a lot
of investigation before becoming new clinical techniques, particularly in the development
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and testing of the MNP or magnetic beads that enable them. Each of these will need its
own clinical trials and regulatory approval.
The haemoﬁlter has been designed to be ﬂexible, allowing for a wide variety of ﬂow
rates and separation chamber dimensions and volumes. It should be possible to combine
it with any promising new magnetic labelling techniques that emerge. However, it will
be important to collaborate with other researchers as early as possible so as to tailor
the device to their particular application. In particular, in applications where success-
ful recovery from the separation chamber is more important than net removal from the
bloodstream, such as the targeting of stem cells for transplantation or CTC for diagnosis
of metastasis, recovery methods and post-processing protocols (e.g. centrifugation) will
need to be established.
One of the ﬁrst tasks will be to test the performance of the haemoﬁlter in removing
magnetic particles of various sizes from blood. In many of the potential applications, such
as blood detoxiﬁcation, the targets are much smaller in size than cells, so the eﬀect of
the drag force on a magnetic particle will be essentially the same whether it is bound to
targets or not. The objectives of these experiments should be to:
1. achieve very high separation eﬃciencies : for some applications, particularly those
where the magnetic labelling will take place within the extra-corporeal loop, it will
be crucial to remove essentially 100% of the particles to prevent their circulation in
the bloodstream.
2. achieve very high ﬂow rates : demonstrate that the device could ﬁlter several times
TBV in short time periods (e.g. less than 30 mins).
3. test the removal of diﬀerent targets : use magnetic particles bound to speciﬁc targets
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(e.g. toxins or cells) and demonstrate their removal from whole blood. Experiments
regarding the magnetic labelling (testing binding eﬃciencies, binding times, spe-
ciﬁcity, blood halﬂife etc.) should be done separately. These experiments could
be performed in collabortion with the research groups developing the magnetic
particles.
Each new application will need to follow a similar development pathway to the malaria
application - benchtop testing, evaluation of the clinical usefulness and commercial eval-
uation - before clinical trials are performed and regulatory approval sought. If magnetic
haemoﬁltration is to achieve its potential, it is likely that several commercial and research
organisations will perform this work on lots of diﬀerent projects simultaneously.
6.4 Final words
The aim during this PhD was to design and test a magnetic haemoﬁlter which could be
used to remove magnetic agents directly from a patient's bloodstream, with a focus on
evaluation of the device as a potential drug-free treatment for malaria. In this thesis, a
proposed design for a high throughput, high power magnetic separator incorporated into
an extra-corporeal loop is presented. The performance of the design was modelled and a
scaled down version of the device, in which the relevant forces were the same as in clinical
versions, was tested and shown to successfully and consistently remove malaria infected
erythrocytes from blood samples.
The device has been designed to be cheap to manufacture and easy to use. It has the
potential to deliver signiﬁcant clinical beneﬁts to a wide variety of malaria patients, saving
lives in serious cases, providing a treatment option for currently untreatable patients, and
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speeding up recovery in uncomplicated cases, while improving the eﬃcacy and eliminating
the side-eﬀects of pharmaceutical drugs. The experiments performed show that it is
eﬀective but safe, and does not negatively aﬀect other blood components. The commercial
evaluation indicates that there is a gap in the market for such a device, and a large
potential client base.
This work is merely the ﬁrst step in the development of the magnetic haemoﬁlter as
a platform technology with a wide variety of clinical applications - a lot of work is still
required if the device is ever going to be used to treat patients. The purpose of this thesis
is to demonstrate the rich clinical potential of magnetic haemoﬁltration technology, which
could provide valuable solutions and improvements in a huge number of areas. Despite
many research groups working on the magnetic separation of biomaterials, this is the ﬁrst
piece of work presenting the development of a platform magnetic haemoﬁlter able to unify
these applications with a single medical device.
The objective of the haemoﬁlter in this thesis is to treat patients and save lives. But
beyond that, the work presented in this thesis forms the basis of the prediction that a whole
new healthcare industry is on the cusp of being created, one that promises revolutionising
new treatments and diagnostic techniques. It is a call for researchers to tap into the huge
potential created by magnetic labelling technologies. It is a proposal to bring magnetism
to the forefront of healthcare, providing a much needed alternative to the pharmaceutical
treatments that have dominated for so long.
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Appendix A
Haemogram results
The document below shows the raw data from the complete blood counts discussed in
section 4.4. Note that the patient numbering is diﬀerent, as speciﬁed below:
 GF1 →Patient 1 initial
 GF2 →Patient 1 ﬁltered
 71 →Patient 2 initial
 73 →Patient 2 ﬁltered
 75 →Patient 2 recovered from chamber
 86 →Patient 3 initial
 88 →Patient 3 ﬁltered
 99 →Patient 4 initial
 102 →Patient 4 ﬁltered
 Wilmer Raigosa Restrepo (1) →Patient 5 initial
 Wilmer Raigosa Restrepo (2) →Patient 5 ﬁltered
 Jaider Romero Meza (1) →Patient 6 initial
 Jaider Romero Meza (1) →Patient 6 ﬁltered
The last four analyses were performed in the laboratories on site at El Bagre, and not at
the Universidad de Antioquia, accounting for the diﬀerent formatting and data provided.
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Appendix B
Survey of malaria patients
B.1 Summary
 Respondents : 45
 Questions : 14
 Date of survey : August 2014
 Method : Online, using Survey Money (https://www.surveymonkey.com/s/MalariaPatients)
B.2 Questions
1. Are you answering for yourself or on behalf of someone else?
2. Are you/they male or female?
3. At what age did you/they most recently have malaria?
4. In which country did you/they most recently:
(a) Contract malaria?
(b) Get treated?
5. What type of malaria did you/they have?
6. Was this your/their ﬁrst case of malaria?
7. In total, for how long did you/they feel unwell?
8. Please tick all symptoms that you/they had (please specify others)
9. Did you/they take any time oﬀ work/school (please specify how many days)?
10. How long after the ﬁrst symptoms did you/they get treatment?
11. After getting treatment, when were you able to resume normal activities (like return
to work or school)?
253
12. Where did you/they go to get treatment?
13. Please describe the treatment in as much detail as possible.
14. In total, approximately how much did you/they pay for the treatment (please input
amount and currency)?
B.3 Responses
254
Q
1
Q
2
Q
3
Q
4 
(a
)
Q
4 
(b
)
Q
5
Q
6
Q
7
Q
8
Q
9
Q
1
0
Q
1
1
Q
12
Q
13
Q
14
#1
M
ys
el
f
M
21
-2
9
To
go
To
go
D
o
n
't
 k
n
o
w
N
o
, 7
 o
r 
8 
ti
m
es
>7
 d
ay
s
Fe
ve
r,
 h
ea
d
ac
h
e,
 d
iz
zi
n
es
s,
 c
o
ld
 
sw
ea
ts
Ye
s,
 1
 w
ee
k
1-
2
 d
ay
s
>7
 d
ay
s
P
ri
va
te
 
cl
in
ic
2
/3
 s
es
si
o
n
s 
w
it
h
 IV
 d
ri
p
D
N
A
#2
M
ys
el
f
M
21
-2
9
To
go
To
go
D
o
n
't
 k
n
o
w
N
o
, 8
 t
im
es
>7
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
, 
b
re
at
h
in
g 
d
if
fi
cu
lt
ie
s,
 e
xh
au
st
io
n
Ye
s,
 1
 w
ee
k
<2
4 
h
o
u
rs
3-
4
 d
ay
s
P
ri
va
te
 
cl
in
ic
D
ai
ly
 IV
 d
ri
p
$1
10
 (
£7
2)
#3
M
ys
el
f
F
13
-1
7
To
go
G
er
m
an
y
D
o
n
't
 k
n
o
w
Ye
s
>7
 d
ay
s
Fe
ve
r,
 v
o
m
it
in
g
Ye
s,
 5
 d
ay
s
<2
4 
h
o
u
rs
>7
 d
ay
s
P
u
b
lic
 c
lin
ic
D
N
A
In
su
ra
n
ce
#4
M
ys
el
f
F
6-
1
2
N
ig
er
ia
N
ig
er
ia
Fa
lc
ip
ar
u
m
N
o
, 1
0 
ti
m
es
3-
4
 d
ay
s
Fe
ve
r,
 v
o
m
it
in
g,
 h
ig
h
 t
em
p
e
ra
tu
re
, 
lo
ss
 o
f 
ap
p
et
it
e,
 b
o
d
y 
ac
h
e
5 
d
ay
s
3-
4
 d
ay
s
4-
7
 d
ay
s
P
ri
va
te
 
cl
in
ic
In
je
ct
io
n
s 
(n
o
va
jin
e,
 n
al
o
xo
n
e,
 c
h
lo
ro
q
u
in
e)
, 
w
it
h
 p
ar
ac
et
am
o
l a
n
d
 s
u
p
p
le
m
en
ts
50
0 
N
ai
ra
 
(£
1.
80
)
#5
M
ys
el
f
F
6-
1
2
C
ô
te
 d
'Iv
o
ir
e
C
ô
te
 d
'Iv
o
ir
e
D
o
n
't
 k
n
o
w
N
o
, 2
 t
im
es
3-
4
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
N
o
<2
4 
h
o
u
rs
1-
2
 d
ay
s
A
t 
h
o
m
e
Fl
av
o
q
u
in
e 
an
d
 a
sp
ir
in
D
N
A
#6
M
ys
el
f
F
5 
o
r 
yo
u
n
ge
r
To
go
To
go
D
o
n
't
 k
n
o
w
N
o
, 2
-3
 
ti
m
es
/y
e
ar
3-
4
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
, b
re
at
h
in
g 
d
if
fi
cu
lt
ie
s
Ye
s,
 1
 d
ay
<2
4 
h
o
u
rs
3-
4
 d
ay
s
D
N
A
A
fr
ic
an
 h
er
b
s 
fr
o
m
 T
o
go
D
N
A
#7
So
m
eo
n
e 
el
se
F
21
-2
9
To
go
To
go
D
o
n
't
 k
n
o
w
Ye
s
>7
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
, 
b
re
at
h
in
g 
d
if
fi
cu
lt
ie
s,
 h
ae
m
at
u
ri
a
Ye
s,
 2
 
w
ee
ks
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
#8
M
ys
el
f
F
6-
1
2
To
go
To
go
D
o
n
't
 k
n
o
w
N
o
, 1
0 
ti
m
es
3-
4
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
Ye
s,
 1
 w
ee
k
1-
2
 d
ay
s
3-
4
 d
ay
s
P
ri
va
te
 
h
o
sp
it
al
IV
 a
n
d
 m
al
ar
ia
 p
ill
s
C
FA
 5
0
,0
00
 
(£
60
)
#9
So
m
eo
n
e 
el
se
F
13
-1
7
Ta
n
za
n
ia
Ta
n
za
n
ia
V
iv
ax
N
o
, m
an
y 
ti
m
es
3-
4
 d
ay
s
Fe
ve
r
N
o
3-
4
 d
ay
s
3-
4
 d
ay
s
P
u
b
lic
 
h
o
sp
it
al
M
al
af
in
D
N
A
#1
0
M
ys
el
f
M
30
-3
9
To
go
To
go
Fa
lc
ip
ar
u
m
N
o
, m
an
y 
ti
m
es
5-
7
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
, b
it
te
r 
ta
st
e,
 
sh
iv
er
in
g
Ye
s,
 3
 d
ay
s
<2
4 
h
o
u
rs
1-
2
 d
ay
s
P
ri
va
te
 
h
o
sp
it
al
Q
u
in
im
ax
 o
r 
ar
te
su
n
at
e
C
FA
 1
0
,0
00
 
(£
12
)
#1
1
M
ys
el
f
M
18
-2
0
N
ig
er
ia
N
ig
er
ia
Fa
lc
ip
ar
u
m
N
o
, 5
 o
r 
m
o
re
3-
4
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
Ye
s,
 D
N
A
1-
2
 d
ay
s
1-
2
 d
ay
s
P
ri
va
te
 
cl
in
ic
R
eg
u
la
r 
in
je
ct
io
n
s
35
0 
N
ai
ra
 
(£
1.
25
)
#1
2
M
ys
el
f
F
21
-2
9
To
go
To
go
D
o
n
't
 k
n
o
w
N
o
, t
w
ic
e
5-
7
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
, j
o
in
t 
p
ai
n
Ye
s,
 4
 d
ay
s
1-
2
 d
ay
s
1-
2
 d
ay
s
P
ri
va
te
 
cl
in
ic
Ta
b
le
ts
P
ro
-b
o
n
o
#1
3
M
ys
el
f
F
21
-2
9
To
go
To
go
Fa
lc
ip
ar
u
m
N
o
, m
an
y 
ti
m
es
5-
7
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
Ye
s,
 7
 d
ay
s
1-
2
 d
ay
s
4-
7
 d
ay
s
P
ri
va
te
 
cl
in
ic
Lu
fa
n
te
r 
ca
c 
1
00
0
C
FA
 5
,0
0
0 
(£
6)
#1
4
M
ys
el
f
F
5 
o
r 
yo
u
n
ge
r
Ta
n
za
n
ia
Ta
n
za
n
ia
D
o
n
't
 k
n
o
w
Ye
s
1-
2
 d
ay
s
Fe
ve
r
N
o
1-
2
 d
ay
s
1-
2
 d
ay
s
Fa
th
er
 is
 
d
o
ct
o
r
Ta
b
le
ts
N
o
th
in
g
#1
5
M
ys
el
f
M
21
-2
9
So
u
th
 S
u
d
an
So
u
th
 S
u
d
an
V
iv
ax
N
o
, t
w
ic
e
>7
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
Ye
s,
 1
 
m
o
n
th
4-
7
 d
ay
s
4-
7
 d
ay
s
P
ri
va
te
 
cl
in
ic
A
rt
es
u
n
at
e
In
su
ra
n
ce
#1
6
M
ys
el
f
F
13
-1
7
B
en
in
B
en
in
D
o
n
't
 k
n
o
w
N
o
, 5
-6
 
ti
m
es
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
#1
7
M
ys
el
f
F
21
-2
9
Za
m
b
ia
Za
m
b
ia
Fa
lc
ip
ar
u
m
Ye
s
3-
4
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
, f
ai
n
ti
n
g,
 t
ir
ed
n
es
s
Ye
s,
 4
 d
ay
s
1-
2
 d
ay
s
3-
4
 d
ay
s
P
u
b
lic
 
h
o
sp
it
al
Ta
b
le
ts
N
o
th
in
g
#1
8
M
ys
el
f
M
13
-1
7
To
go
To
go
Fa
lc
ip
ar
u
m
N
o
, 3
-4
 
ti
m
es
5-
7
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
Ye
s,
 D
N
A
3-
4
 d
ay
s
3-
4
 d
ay
s
P
ri
va
te
 
cl
in
ic
P
er
fu
si
o
n
, c
o
ar
te
m
, m
al
o
xi
n
e
D
N
A
#1
9
M
ys
el
f
F
40
-4
9
G
h
an
a
G
h
an
a
D
o
n
't
 k
n
o
w
N
o
, m
an
y 
ti
m
es
5-
7
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
, a
n
ae
m
ia
Ye
s,
 t
w
o
 
w
ee
ks
 t
o
ta
l
<2
4 
h
o
u
rs
3-
4
 d
ay
s
Se
lf
-t
re
at
A
rt
es
u
n
at
e,
 A
C
T,
 d
o
xy
cy
cl
in
e,
 ir
o
n
 
su
p
p
le
m
en
ts
£2
 o
n
 
av
er
ag
e
#2
0
M
ys
el
f
M
40
-4
9
N
ig
er
ia
N
ig
er
ia
Fa
lc
ip
ar
u
m
N
o
, 2
5 
ti
m
es
5-
7
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
, h
ig
h
 t
em
p
e
ra
tu
re
, 
lo
ss
 o
f 
ap
p
et
it
e,
 s
h
iv
er
in
g
Ye
s,
 1
 w
ee
k
3-
4
 d
ay
s
>7
 d
ay
s
P
ri
va
te
 
h
o
sp
it
al
C
h
lo
ro
q
u
in
e 
in
je
ct
io
n
, p
ar
ac
et
am
o
l, 
as
p
ir
in
, 
n
at
u
ra
l h
er
b
s 
(d
o
n
o
ya
ro
/n
ee
m
 t
re
e
)
10
0 
N
ai
ra
 
(£
0.
35
)
#2
1
M
ys
el
f
F
13
-1
7
B
en
in
Fr
an
ce
D
o
n
't
 k
n
o
w
N
o
, 3
 t
im
es
>7
 d
ay
s
V
o
m
it
in
g,
 f
ev
er
Ye
s,
 2
 
w
ee
ks
<2
4 
h
o
u
rs
>7
 d
ay
s
P
u
b
lic
 
h
o
sp
it
al
Ta
b
le
ts
D
N
A
#2
2
M
ys
el
f
F
21
-2
9
Se
n
eg
al
Se
n
eg
al
D
o
n
't
 k
n
o
w
Ye
s
3-
4
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
, s
ki
n
 a
ch
e
Ye
s,
 5
 d
ay
s
<2
4 
h
o
u
rs
4-
7
 d
ay
s
P
ri
va
te
 
h
o
sp
it
al
Ta
b
le
ts
D
N
A
#2
3
M
ys
el
f
M
21
-2
9
In
d
ia
U
K
D
o
n
't
 k
n
o
w
N
o
, m
an
y 
ti
m
es
>7
 d
ay
s
V
o
m
it
in
g,
 f
ev
er
Ye
s,
 7
-1
0 
d
ay
s
1-
2
 d
ay
s
>7
 d
ay
s
P
u
b
lic
 
h
o
sp
it
al
N
o
th
in
g
N
o
th
in
g 
(N
H
S)
#2
4
M
ys
el
f
M
40
-4
9
N
ig
er
ia
N
ig
er
ia
D
o
n
't
 k
n
o
w
Ye
s
>7
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
, h
yp
er
te
n
si
o
n
, 
co
u
gh
in
g,
 c
h
es
t 
p
ai
n
s
Ye
s,
 3
 d
ay
s
1-
2
 d
ay
s
3-
4
 d
ay
s
P
ri
va
te
 
h
o
sp
it
al
Ta
b
le
ts
, I
V
 d
ri
p
, p
ai
n
ki
lle
rs
8,
00
0 
N
ai
ra
 
(£
28
.5
0
)
#2
5
M
ys
el
f
F
21
-2
9
Ta
n
za
n
ia
Ta
n
za
n
ia
D
o
n
't
 k
n
o
w
N
o
, 3
 t
im
es
3-
4
 d
ay
s
H
ea
d
ac
h
e,
 d
iz
zi
n
es
s,
 jo
in
t 
ac
h
e
Ye
s,
 1
 d
ay
1-
2
 d
ay
s
1-
2
 d
ay
s
P
u
b
lic
 
h
o
sp
it
al
D
N
A
D
N
A
#2
6
M
ys
el
f
M
40
-4
9
Th
e
 G
am
b
ia
Th
e
 G
am
b
ia
O
th
er
N
o
, >
1
0 
ti
m
es
5-
7
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
Ye
s,
 3
 d
ay
s
1-
2
 d
ay
s
1-
2
 d
ay
s
P
ri
va
te
 
cl
in
ic
N
iv
aq
u
in
e
$3
0 
(£
19
.6
5)
#2
7
M
ys
el
f
M
30
-3
9
K
en
ya
K
en
ya
D
o
n
't
 k
n
o
w
N
o
, 4
 t
im
es
5-
7
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
, j
o
in
t 
p
ai
n
Ye
s,
 D
N
A
1-
2
 d
ay
s
1-
2
 d
ay
s
P
ri
va
te
 
cl
in
ic
A
n
ti
b
io
ti
cs
In
su
ra
n
ce
#2
8
M
ys
el
f
F
21
-2
9
N
ig
er
ia
N
ig
er
ia
D
o
n
't
 k
n
o
w
N
o
, 4
 t
im
es
1-
2
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
N
o
1-
2
 d
ay
s
24
 h
o
u
rs
P
h
ar
m
ac
y
Ta
b
le
ts
20
0 
N
ai
ra
 
(£
0.
70
)
#2
9
M
ys
el
f
M
21
-2
9
M
al
aw
i
M
al
aw
i
Fa
lc
ip
ar
u
m
Ye
s
>7
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
, f
at
ig
u
e,
 s
ei
zu
re
s
Ye
s,
 3
 
w
ee
ks
4-
7
 d
ay
s
>7
 d
ay
s
P
ri
va
te
 
h
o
sp
it
al
Q
u
in
in
e 
d
ri
p
, t
h
en
 t
ab
le
ts
£5
0
#3
0
M
ys
el
f
M
30
-3
9
N
ig
er
ia
N
ig
er
ia
Fa
lc
ip
ar
u
m
N
o
, 4
-6
 
ti
m
es
/y
e
ar
3-
4
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
, J
o
in
t 
p
ai
n
, 
q
u
ae
si
n
es
s,
 lo
ss
 o
f 
ap
p
et
it
e
Ye
s,
 2
 d
ay
s
<2
4 
h
o
u
rs
3-
4
 d
ay
s
P
h
ar
m
ac
y
A
rt
es
u
n
at
e
50
0 
N
ai
ra
 
(£
1.
80
)
#3
1
So
m
eo
n
e 
el
se
M
30
-3
9
M
o
za
m
b
iq
u
e
Sw
it
ze
rl
an
d
Fa
lc
ip
ar
u
m
Ye
s
3-
4
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
Ye
s,
 1
 w
ee
k
<2
4 
h
o
u
rs
3-
4
 d
ay
s
P
ri
va
te
 
h
o
sp
it
al
D
N
A
D
N
A
#3
2
M
ys
el
f
M
21
-2
9
A
n
go
la
A
n
go
la
Fa
lc
ip
ar
u
m
Ye
s
3-
4
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
, f
ai
n
ti
n
g
Ye
s,
 2
 d
ay
s
1-
2
 d
ay
s
3-
4
 d
ay
s
P
ri
va
te
 
cl
in
ic
C
o
ar
te
m
$5
00
 (
£3
28
)
#3
3
So
m
eo
n
e 
el
se
M
30
-3
9
U
SA
U
SA
D
o
n
't
 k
n
o
w
Ye
s
3-
4
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
N
o
1-
2
 d
ay
s
<2
4
 
h
o
u
rs
P
u
b
lic
 
h
o
sp
it
al
D
N
A
D
N
A
#3
4
So
m
eo
n
e 
el
se
M
5 
o
r 
yo
u
n
ge
r
N
ig
er
ia
N
ig
er
ia
D
o
n
't
 k
n
o
w
Ye
s
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
#3
5
M
ys
el
f
M
40
-4
9
N
ig
er
ia
N
ig
er
ia
D
o
n
't
 k
n
o
w
N
o
, 4
 
ti
m
es
/y
e
ar
5-
7
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
, m
u
sc
le
 p
ai
n
Ye
s,
 <
1
 
w
ee
k
<2
4 
h
o
u
rs
<2
4
 
h
o
u
rs
P
h
ar
m
ac
y
C
o
ar
te
m
€1
7 
(£
13
.3
0)
#3
6
M
ys
el
f
F
30
-3
9
P
ak
is
ta
n
P
ak
is
ta
n
D
o
n
't
 k
n
o
w
Ye
s
5-
7
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
Ye
s,
 3
 d
ay
s
<2
4 
h
o
u
rs
>7
 d
ay
s
P
ri
va
te
 
h
o
sp
it
al
Ta
b
le
ts
P
K
R
 2
0
0 
(£
1.
30
)
#3
7
M
ys
el
f
M
6-
1
2
N
ig
er
ia
D
N
A
V
iv
ax
Ye
s
5-
7
 d
ay
s
V
o
m
it
in
g,
 f
ev
er
N
o
3-
4
 d
ay
s
<2
4
 
h
o
u
rs
P
ri
va
te
 
h
o
sp
it
al
D
N
A
D
N
A
#3
8
M
ys
el
f
F
21
-2
9
In
d
ia
In
d
ia
O
th
er
Ye
s
5-
7
 d
ay
s
Fe
ve
r,
 s
h
iv
er
in
g
N
o
<2
4 
h
o
u
rs
<2
4
 
h
o
u
rs
P
ri
va
te
 
cl
in
ic
Q
u
in
in
e 
th
en
 o
th
er
IN
R
 5
,0
00
 
(£
51
.5
0
)
#3
9
M
ys
el
f
M
6-
1
2
In
d
ia
In
d
ia
D
o
n
't
 k
n
o
w
Ye
s
>7
 d
ay
s
Fe
ve
r,
 b
ro
n
ch
it
is
Ye
s,
 3
 
w
ee
ks
1-
2
 d
ay
s
>7
 d
ay
s
H
o
m
e
In
je
ct
io
n
s 
an
d
 t
ab
le
ts
D
N
A
#4
0
M
ys
el
f
M
5 
o
r 
yo
u
n
ge
r
N
ig
er
ia
D
N
A
Fa
lc
ip
ar
u
m
Ye
s
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
D
N
A
#4
1
M
ys
el
f
F
30
-3
9
C
ô
te
 d
'Iv
o
ir
e
G
er
m
an
y
Fa
lc
ip
ar
u
m
Ye
s
>7
 d
ay
s
Fe
ve
r
Ye
s,
 2
 
w
ee
ks
3-
4
 d
ay
s
>7
 d
ay
s
P
u
b
lic
 
h
o
sp
it
al
La
ri
am
N
o
th
in
g
#4
2
M
ys
el
f
M
6-
1
2
P
ap
u
a 
N
ew
 
G
u
in
ea
A
u
st
ra
lia
D
o
n
't
 k
n
o
w
Ye
s
>7
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
Ye
s,
 6
 
w
ee
ks
3-
4
 d
ay
s
>7
 d
ay
s
P
u
b
lic
 
h
o
sp
it
al
D
N
A
N
o
th
in
g
#4
3
M
ys
el
f
M
21
-2
9
G
h
an
a
G
h
an
a
V
iv
ax
Ye
s
>7
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
, s
ti
ff
 
jo
in
ts
Ye
s,
 1
0 
d
ay
s
1-
2
 d
ay
s
4-
7
 d
ay
s
P
u
b
lic
 c
lin
ic
D
N
A
G
H
S 
10
 (
£
2)
#4
4
M
ys
el
f
M
21
-2
9
In
d
ia
In
d
ia
V
iv
ax
N
o
, o
n
ce
3-
4
 d
ay
s
Fe
ve
r
Ye
s,
 2
 d
ay
s
<2
4 
h
o
u
rs
3-
4
 d
ay
s
P
ri
va
te
 
h
o
sp
it
al
Ta
b
le
ts
IN
R
 6
00
 
(£
6.
20
)
#4
5
So
m
eo
n
e 
el
se
M
30
-3
9
G
h
an
a
G
h
an
a
Fa
lc
ip
ar
u
m
N
o
, 3
 t
im
es
5-
7
 d
ay
s
H
ea
d
ac
h
e,
 v
o
m
it
in
g,
 f
ev
er
, 
w
ea
kn
es
s,
 s
h
ar
p
 p
ai
n
s
Ye
s,
 5
-1
0 
d
ay
s
1-
2
 d
ay
s
1-
2
 d
ay
s
H
o
sp
it
al
 a
t 
go
ld
 m
in
e
Q
u
in
in
e
$1
00
 (
£6
5)
#4
6
M
ys
el
f
F
30
-3
9
M
ad
ag
as
ca
r
M
ad
ag
as
ca
r
D
o
n
't
 k
n
o
w
N
o
, 4
 t
im
es
3-
4
 d
ay
s
H
ea
d
ac
h
e,
 f
ev
er
N
o
<2
4 
h
o
u
rs
<2
4
 
h
o
u
rs
P
u
b
lic
 
h
o
sp
it
al
A
n
ti
b
io
ti
cs
$2
50
 
(£
16
2
.5
0)
Appendix C
Ethics committee approval
257



Appendix D
Patient consent form
261





Appendix E
Patient registration form
267
 UNIVERSIDAD DE ANTIOQUIA / GRUPO MALARIA 
Studying magnetic separation of malaria infected red blood cells from patient´s bloodstream 
País Colombia Medellín, 
Antioquia 
Cesar Segura, Alberto Tobón Centros de investigación U de A 
 
Nombre de quien llena la hoja  Firma  Fecha  
 
1 
 Hoja 1: REGISTRO DEL PACIENTE 
Municipio __________ Iniciales* ______ Código Paciente (CC, TI, RC) : 
*Iniciales de los dos apellidos y del primer nombre.       
DATOS DEMOGRÁFICOS 
Edad:  ______ años Sexo    1 (    ) Masculino        2 (    ) Femenino Teléfono ______________ 
Etnia 1(   )Afro descendiente          2(   )Blanco             3(   )Indígena           4(   )Mestizo 
Actividad económica/ oficio 
1(  ) Ama de casa   2(  ) Agricultura   3(  ) Minería  4(  ) Pesca  5(  ) Oficina         
6(  ) Comercio      7(  ) Artesanía   8(  ) Estudiante  9(  ) Otro _______________ 
 
ANTECEDENTES 
Lugar de residencia (Barrio o vereda)_____________________________ 
1(   ) Urbano            2(   ) Rural   
Tiempo de  Residencia : ________ 
Lugar de procedencia (Dpto./Mpio/barrio o vereda)__________________  1 (   ) Urbano           2(   ) Rural 
Le ha dado malaria en el último 6 meses, además de esta: 1(  ) Si  2(  ) No. Fecha ultimo dx ____/____/____              
Por cual especie de Plasmodium? 1 (   ) P. falciparum       2 (   ) P. Vivax     3 (   )  No sabe 
Que tratamiento recibió en la última malaria? 
1 (  ) Cloroquina   2 (  ) Primaquina   3 (  ) Mefloquina 
4 (  ) Amodiaquina    5 (   ) Sulfadoxina/Pirimetamina 
6 (  ) Quinina  7 ( ) Artemeter/Lumefantrine  8 ( )Otro _________ 
Ha tomado algún medicamento en los últimos 30 días?   1(   ) Si       2 (    ) No   Cual?_____________________ 
Fiebre no diagnosticada en los últimos 3 meses:     1(   ) Si      2(   ) No   
 
INFORMACIÓN CONFIDENCIAL 
Nombre completo del paciente (sobrenombre)  
Nombre de uno de los padres, familiar o amigo 
(escribir parentesco) 
 
Teléfono, dirección de la casa y señales para  
ubicar la vivienda 
 
 
 
 
 
Hoja 2: REGISTRO DEL PACIENTE 
INGRESO 
Gota gruesa de ingreso  (microscopista). Dx____________ Recuento:________ /µL.  Anillos:_______ /µL 
Resultado RDT: __________________________ 
PCR: Se tomo la muestra (Si/No): _____ Resultado:______________________________________________ 
 
 
